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aa  Amino acid(s) 
ABC  Ammonium bicarbonate 
ACN  Acetonitrile 
AP  Affinity purification 
APS  Ammonium persulfate 
AQUA  Absolute quantification 
ATP  Adenosine 5’-triphosphate 
 
BBS  Bardet Biedl Syndrome 
bp  Base pairs 
BSA  Bovine serum albumin 
 
Cas9  CRISPR associated protein 9 
CC  Connecting cilium 
cDNA  Complementary DNA 
CHCl3  Chloroform 
CID  Collision induced dissociation 
CL Crosslinking 
CRISPR Clustered regularly interspaced 
palindromic repeats 
(C) C-terminal 
 
Da Dalton 
dATP 2’-deoxyadenosine 5’-triphosphate 
ddH2O  Ultra-pure water 
dH2O Deionized water 
DMEM  Dulbecco’s modified Eagle medium 
DMSO Dimethylsulfoxid 
DNA Deoxyribonucleic acid 
dNTP   2’-deoxynucleotide 5’-triphosphate 
dsDNA Double-stranded DNA 
DTT Dithiotreitol 
 
ECL Enhanced chemiluminescence 
E.coli Escherichia coli 
EDTA Ethylendiaminetetraacetic acid 
e.g. For example 
EP Equalizer Peptide 
EtEP Equimolarity through equalizer 
peptide 
EtOH Ethanol 
ESI Electrospray ionisation 
 
FA Formic acid 
FBS Fetal bovine serum 
FDR False discovery rate 
FT Flowthrough 
 
GOI Gene of interest 
 
h Hour 
HAc Acetic acid 
HCD  Higher energy collision induced 
dissociation 
HEK293 Human embryonic kidney 293 cells 
HEK293T Human embryonic kidney 293T cells 
HPLC High-performance liquid 
chromatography 
HPLC H2O Water (HPLC grade) 
HRP Horseradish peroxidise 
hTERT Human telomerase reverse 
transcriptase 
 
IFT Intraflagellar transport 
IFT-A Intraflagellar transport complex A 
IFT-B Intraflagellar transport complex B 
IP Immunoprecipitation 
IT Ion trap 
 
kb Kilobase 
kDa Kilodalton 
  
LB Luria-Bertani 
LC Liquid chromatography 
LC-MS/MS  Liquid chromatography-tandem mass 
spectrometry 
LCA Leber congenital amaurosis 
LCA5 Lebercilin 
LFQ Label-free quantification 
LTQ Linear trap quadrupole  
 
MeOH Methanol 
min Minute(s) 
Mr Molecular weight 
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MRM Multiple reaction monitoring 
MS Mass spectrometry 
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MS/MS Tandem mass spectrometry 
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m/z Mass to charge ratio 
 
NaCl Sodium chloride 
NHS ester N-hydroxysuccinimide ester 
NP-40 Nonidet P-40 
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p.a. Pro analysis (reagent-grade) 
PAGE Polyacrylamide gel electrophoresis 
PBS Phosphate-buffered saline 
PCR polymerase chain reaction 
PEI Polyethylenimine 
POI Protein of interest 
PPI Protein-protein interaction 
PRM Parallel reaction monitoring 
PVDF Polyvinylidene difluoride 
 
RNA  Ribonucleic acid 
RPE  Retinal pigmentary epithelium 
rpm  Round per minute 
RT Room temperature 
 
SDS Sodium dodecyl sulfate 
SDS-PAGE SDS-polyacrylamide gel 
electrophoresis 
SF-TAP Strep-FLAG-tandem affinity 
purification 
sec Second(s) 
SILAC  Stable isotope labelling in cell culture 
siRNA Short interfering RNA 
SRM  Selected reaction monitoring 
ssDNA Single stranded DNA 
StageTips Stop-and-go extraction tips 
 
TAP Tandem affinity purification 
TBS Tris-buffered saline 
TBST TBS-Tween 
TEMED  N,N,N’,N’-tetramethylethylene-
diamine 
TFA Trifluoroacetic acid 
tMS Targeted mass spectrometry 
Tris Tris(hydroxymethyl)aminomethane 
 
U Unit (enzymatic activity) 
UV/Vis Ultraviolet/visible  
 
v/v Volume per volume 
 
WB Washing buffer 
wt Wildtype 
w/v Weight per volume
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Summary 
Cilia are evolutionary conserved organelles which protrude from almost every polarized 
eukaryotic cell. These hair-like organelles are vital for human and animal development and 
physiology being associated with cell cycle and proliferation. Depending on its molecular 
structure cilia can be classified in motile and immotile cilia. Immotile cilia, also called primary 
cilia, are characterized by the lack of a central microtubule doublet and generally serve as 
sensory organelles. Based on the fact that cilia are present in cells and organs of the human 
body, malfunction of ciliary proteins and defects in cilia lead to a wide range of human diseases 
which are summarized under the term: ciliopathies. To understand the underlying mechanisms 
of ciliopathies, it is crucial to study processes within cilia. So far, no biosynthesis machinery is 
described within a cilium. To transport proteins from the cytoplasm to the tip of a cilium, which is 
essential for the ciliary assembly and its maintenance, the bidirectional intraflagellar transport 
(IFT) is necessary. This transport mechanism is driven by motor proteins and two multiprotein 
complexes IFT-A and IFT-B. IFT-A, consisting of six known complex components, is involved in 
retrograde transport of protein cargo from the ciliary tip back to the cell body. As described in 
previous studies, malfunction of IFT-A proteins leads to an accumulation of IFT-B particles in 
the ciliary tip which results in shortened and bulged cilia. Additionally, mutations within genes 
encoding IFT-A proteins are described to cause ciliopathies like Sensenbrenner syndrome 
which is characterized by ectodermal as well as skeletal anomalies. The presented study aims 
to investigate stoichiometric and structural properties of IFT-A, which is essential for the 
molecular function of IFT-A during intraflagellar transport and is assistant to unveil its role in 
IFT-A-related diseases. 
As basic prerequisite of this study, Flp-In monoclonal cell lines stably expressing N-terminally 
Strep-Flag (SF)-tagged baits were generated to circumvent the influence of artificial 
overexpression on stoichiometry of the protein complex. Three different baits were chosen: 
IFT122, an integral part of the IFT-A, TULP3 which is described to be associated with the IFT-A 
and LCA5 which represents an rather labile and transiently bound interaction partner of IFT-A. 
Using an integral part of the protein complex of interest (Flp-In (N)-SF-IFT122) led to a drastic 
change in complex composition. Due to the higher affinity of TULP3 to IFT-A compared to 
LCA5, higher amount of the IFT-A complex could be purified from Flp-In (N)-SF-TULP3 enabling 
a more robust determination of the stoichiometric and structural investigation. 
To determine complex stoichiometry performing absolute quantification, the establishment of a 
targeted mass spectrometry approach is crucial. Depending on the applied mass spectrometer, 
two different approaches were set up: Selected Reaction Monitoring (SRM) and Parallel 
12  Summary 
 
Reaction Monitoring (PRM). Another important step for the absolute quantification is the 
generation of a standard mix containing known amounts of representative peptides for the 
proteins of interest. To create an economic equimolar standard mix, the already described 
“Equimolarity through Equalizer Peptide” (EtEP) method was used. At the end, absolute 
quantification performing PRM on a Q-Exactive mass spectrometer in combination with an 
equimolar standard mixture was used to study complex stoichiometry of IFT-A. Data analysis 
was performed using the software Skyline. This study unveiled naturally occurring compositions 
of IFT-A which change during different stages of ciliogenesis and cilia disassembly. To 
investigate the impact of disease causing variants on the composition of IFT-A, CRISPR/Cas9 
system was used to generate targeted mutations within genes encoding two IFT-A proteins 
(IFT43 and WDR35) in Flp-In (N)-SF-TULP3 cells. One of the generated monoclonal cell lines, 
carrying a mutation in the gene encoding IFT43 (c.541_542insA/p.T181Nfs*2), showed 
significant changes within IFT-A complex composition that could explain the malfunction. 
The second part of this study aims to determine binding sites within IFT-A by chemical 
crosslinking in combination with mass spectrometry that serve as basis for structural models of 
IFT-A. For chemical crosslinking of purified IFT-A, the homobifunctional amine-reactive 
crosslinker dissuccinimidyl suberate (DSS) was used. This crosslinker contains two identical N-
hydroxysuccinimidyl groups which enable the formation of stable amide bonds with primary 
amines of N-termini and lysine residues of proteins. Based on a defined spacer length of DSS 
(11Å), distance information of cross-linked peptides can be achieved. To enrich low abundant 
cross-linked peptides before LC-MS/MS analysis, size exclusion chromatography (SEC) is a 
common used prefractionation method. However, SEC is time-, labour- and cost-intense. A 
facilitated method to reduce sample complexity prior to the analysis of cross-linked peptides is 
portrayed in this study. This economic method is based on preseparation using 3kDa CutOff 
spin columns. For the identification of linked peptides the computational software pipeline 
xQuest/xProphet was used. To illustrate identified links, free available software Xinet was used 
afterwards. Identified crosslinks as well as cross-linked positions within a protein sequence 
using both preseparation methods were comparable. Applying chemical crosslinking to purified 
IFT-A, well-known interaction domains within the complex components were confirmed. 
Furthermore, new crosslinking hotspots which are not described so far were identified in this 
study. 
With the data obtained in this study, the foundation of a structural model of the IFT-A can be 
generated by combining the determined complex stoichiometry with obtained structural 
information of the protein complex IFT-A. 
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Zusammenfassung 
Zilien sind evolutionär konservierte Zellfortsätze, die auf fast allen polarisierten, eukaryotischen 
Zellen vorhanden sind. Diese sogenannten „Antennen der Zelle“ sind unverzichtbar für die 
Entwicklung von Mensch und Tier, da sie zum einen wichtig für die Zellfortbewegung sind aber 
auch Signale aus der Umwelt aufnehmen können. Basierend auf ihrer molekularen Struktur 
können Zilien in zwei Subtypen eingeteilt werden: bewegliche und unbewegliche Zilien. 
Während bewegliche Zilien ein zentrales Mikrotubuli-Dublett besitzen, fehlt dieses in 
unbeweglichen Zilien, die auch primäre Zilien genannt werden. Diese primären Zilien dienen in 
der Regel als Mechano- und Chemosensoren. Aufgrund des Vorkommens von Zilien im 
gesamten menschlichen Körper führen defekte Zilien und Fehlfunktionen in involvierten 
Proteinen zu unterschiedlichsten Krankheitsbildern wie z.B. zystische Nieren und 
Netzhautdegeneration. Diese Krankheiten sind unter dem Begriff Ziliopathien 
zusammengefasst. Um den Mechanismus, der Ziliopathien zu Grunde liegt zu verstehen, 
müssen die Prozesse innerhalb eines Ziliums untersucht werden. Bisher wurde keine Struktur 
innerhalb eines Ziliums beschrieben, welche Proteine und andere Biomoleküle, die für die 
Herstellung und Instandhaltung von Zilien notwendig sind, bereitstellt. Allerdings ist der 
Intraflagellare Transportmechanismus (IFT) bekannt, der mit Hilfe von Motorproteinen und den 
zwei Proteinkomplexen IFT-A und IFT-B essentielle Proteine von dem Zytoplasma in die Spitze 
des Ziliums und wieder zurück transportiert. IFT-A besteht aus sechs Komponenten und ist für 
den retrograden Transport (vom Zilium zurück zur Zelle) wichtig. Vorangegangene Studien 
beschreiben eine Akkumulation von IFT-B Partikeln in der Spitze des Ziliums aufgrund eines 
Defektes in dem IFT-A Komplex. Dies führt zu verkürzten und gewölbten Zilien, welche zum 
Beispiel zu Deformationen im Skelett führen können. Solche Anomalien sind in 
unterschiedlichen Ziliopathien beschrieben, wie z.B. Sensenbrenner Syndrom. Um den Einfluss 
von IFT-A auf Ziliopathien zu untersuchen, soll in dieser Studie die Stöchiometrie des 
Proteinkomplexes in der natürlich vorkommenden Zusammensetzung als auch die Struktur von 
IFT-A untersucht werden. 
Grundlegend für diese Arbeit war die Generierung von stabilen Flp-In Zelllinien, um keinen 
Einfluss auf die natürlich vorkommende Zusammensetzung von IFT-A durch artifizielle 
Überexpression zu nehmen. Für die Generierung wurden drei Ankerproteine, sogenannte Baits 
ausgewählt, die in unterschiedlicher Weise mit IFT-A in Zusammenhang stehen: IFT122 ist ein 
Teil des IFT-A Komplexes, ein assoziiertes Protein TULP3 und LCA5, welches ein labiler und 
transienter Interaktionspartner von IFT-A ist. Der Einsatz eines internen Proteins als Bait (wie 
z.B. IFT122) führt zu einer deutlichen Veränderung der Komplexzusammensetzung. Im 
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Vergleich zu LCA5 besitzt TULP3 eine höhere Affinität zum IFT-A Komplex. Dies führt zu einer 
größeren Menge an aufgereinigtem IFT-A bei der Verwendung von Flp-In (N)-SF-TULP3, 
weswegen diese monoclonalen Zellen für die folgenden Experimente verwendet wurden. 
Um die Stöchiometrie eines Proteinkomplexes zu bestimmen, ist eine absolute Quantifizierung 
der einzelnen Komponenten des Proteinkomplexes notwendig. Für die absolute Quantifizierung 
mittels Massenspektrometrie wurden zwei unterschiedliche Methoden verwendet: Selected 
Reaction Monitoring (SRM) und Parallel Reaction Monitoring (PRM). Ein weiterer wichtiger 
Punkt für eine Absolute Quantifizierung ist die Auswahl von geeigneten und repräsentativen 
Standardpeptiden. Um einen kostengünstigen Standardmix mit equimolaren Mengen der 
ausgewählten, proteotypischen Peptide zu generieren wurde die Equimolarity through Equalizer 
Peptide (EtEP) Methode genutzt. Für die Bestimmung der Zusammensetzung von IFT-A wurde 
PRM auf einem QExactive Plus Massenspektrometer in Kombination mit einem equimolaren 
Standardmix zur Methode der Wahl. Die Datenanalyse erfolgte mit der freiverfügbaren Software 
Skyline. Diese Studie ermittelte die Stöchiometrie von natürlich vorkommendem IFT-A, welche 
während des Auf- und Abbau eines Ziliums variiert. Zusätzlich wurden durch CRISPR/Cas9 
ausgewählte IFT-A Proteine (IFT43 und WDR35) in Flp-In (N)-SF-TULP3 Zellen gezielt mutiert, 
um die Auswirkung von krankheitsassoziierten Mutationen auf die Stöchiometrie des IFT-A zu 
beschrieben. 
Der zweite Teil dieser Arbeit beschäftigt sich mit der Identifizierung von Bindestellen innerhalb 
des IFT-A mittels chemischen Crosslinking. Die Kombination von chemischem Crosslinking mit 
Massenspektrometrie legt den Grundstein zur Strukturaufklärung und Generierung eines 
Strukturmodels von IFT-A. Aufgereinigtes IFT-A wurde mit dem homobifunktionalem Crosslinker 
Disuccinimidylsuberat (DSS) inkubiert, um primäre Amine in N-Termini als auch in Lysinen 
innerhalb der Proteinsequenzen zu vernetzen. Dafür ist die Amin-Reaktivität der verwendeten 
N-hydroxysuccinimidyl-Gruppen verantwortlich. Durch die definierte Länge des eingesetzten 
Crosslinkers (11Å) können Nachbarschaftverhältnisse über vernetzte Peptide identifiziert 
werden. Für die Identifizierung der vernetzen Peptide mittels Massenspektrometrie ist eine 
vorangehende Anreicherung dieser Peptide notwendig. Size exclusion chromatography (SEC) 
ist in diesem Zusammenhang eine gern genutzte Methode, die allerdings sehr kostenintensiv, 
zeit- und arbeitsaufwendig ist. Deswegen ist in dieser Arbeit eine vereinfachte Methode zur 
Reduktion der Probenkomplexität mittels 3kDa CutOff spin columns parallel zur SEC verwendet 
worden und beschrieben. Für die Identifizierung der vernetzen Peptide wurde die Software-
Pipeline xQuest/xProphet verwendet. Die anschließende Visualisierung der Daten wurde mittels 
Xinet durchgeführt. Beide Anreicherungsmethoden erzielten vergleichbare Ergebnisse in der Art 
und der Positionen der identifizierten Crosslinks. Zusätzlich haben beide Methoden bisher 
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beschriebene Interaktions-Domänen bestätigt als auch neue, bisher unbeschriebene Crosslink-
Hotspots identifiziert. 
Mit Hilfe dieser Studie konnten sowohl bekannte Interaktionsdomänen innerhalb des IFT-A 
verifiziert, als auch neue unbekannte Bindestellen identifiziert werden. In Kombination mit der 
ermittelten Stöchiometrie des IFT-A legt diese Arbeit den Grundstein zur Generierung eines 
Strukturmodels dieses Proteinkomplexes, welches für die Aufklärung des Einflusses von IFT-A 
in Ziliopathien unabdingbar ist. 
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1 Introduction 
1.1 Cilia  
Cilia are complex and evolutionary conserved organelles which protrude from the surface of 
almost every polarized eukaryotic cell [1]. Based on its molecular structure, cilia are classified in 
motile and immotile cilia. Immotile, or primary cilia, serve as sensing organelles [1] and are 
specialized as cellular antennae for sensing the environment. They are involved in many 
different functions, for example in renal development as well as in neurosensory functions like 
hearing, smell and vision [1, 2]. The increase in surface area of a cell by building up a cilium is 
ideal to sense its extracellular environment [1, 3, 4]. 
1.1.1 Structure of a cilium 
The ciliary structure can be divided into different compartments: basal body, transition zone, 
axoneme, ciliary membrane and ciliary tip. 
 
Figure 1: Structure of a cilium 
A cil ium is composed of different compartments: Basal body, transit ion zone, cil iary 
membrane, axoneme and cil iary t ip. Different types of cil ia, ‘9+0‘ for primary cil ia and 
‘9+2‘ for motile cilia, are shown within the cross-sections. The axoneme of each cil ium is 
built by nine microtubule doublets with an additional centered microtubule doublet in case 
of motile cil ia (‘9+2‘). The basal body of a cil ium consists of nine microtubule tr iplets 
(‘9x3‘) in comparison to the doublets present in the axoneme. Y-shaped transit ion f ibres 
connect the basal body, the basis of each cil ium, to the cil ia membrane. Modified after [5]. 
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As illustrated in Figure 1, cilia arise from the basal body which originates from the mother 
centriole and represents a centriolar barrel [5]. Nearby this initiation point, docking sites for intra 
flagellar transport (IFT) particles are present. These are involved in the transport of protein 
cargo along the axoneme of a cilium, described in 1.1.4 [6, 7]. The transition zone is 
characterized by Y-shaped transition fibres which link the axoneme and the basal body to the 
ciliary membrane. This specialized region is thought to act as a barrier where only certain 
proteins may pass to enter the ciliary compartment [8]. The microtubule core of a cilium 
(axoneme) is composed of nine microtubule doublets, formed by heterodimers of tubulin A and 
B [9]. Motile cilia consist of nine outer and two central microtubules (‘9+2’ array of microtubules) 
in comparison to the ‘9+0’ array of microtubules in primary cilia which are in most cases 
immotile [10-12]. In contrast to the axoneme, the basal body consists of nine microtubular 
triplets (‘9x3’ array of microtubules). The two central microtubules of motile cilia combined with 
outer and inner dynein arms are necessary for directional ciliary movement [1, 13]. 
1.1.2 Ciliogenesis 
The generation of cilia, a process called ciliogenesis, proceeds in different stages [3].  
 
Figure 2: Ciliogenesis 
Ciliogenesis, the process of generating a cil ium, takes place in dif ferent steps. After the 
attachment of a cil iary vesicle to the distal end of a mother centriole, the axoneme is build 
up by microtubules. The elongation of the axoneme starts at its tip and the cil iary vesicle 
grows with it forming a ciliary sheath. This structure migrates to the plasma membrane 
where the ciliary sheath fuses to externalise the cil ium. For the completion of a funct ional 
cil ium, IFT as well as BBS proteins are necessary. 
As depicted in Figure 2, ciliogenesis in mammalian cells is initiated by the attachment of a 
mother centriole to the cell surface where it fuses with a ciliary vesicle. Subsequently, the 
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mother centriole differentiates into a basal body which is anchored to the plasma membrane. 
Through nucleation of microtubules the axoneme is built up and the transition zone is 
generated. During the elongation of the axoneme the ciliary vesicle fuses with a second vesicle 
forming the ciliary membrane. While the axoneme consists of doublet microtubules the basal 
body contains triplet microtubules [3, 13-15].  
Ciliogenesis is characterized by a variety of complex processes like the synthesis of 
macromolecules as well as assembly. Therefore, ciliogenesis must be regulated carefully. In 
dividing cells, ciliary disassembly has to take place before cell division because the basal body 
is crucial for the organization of the centrosome for the attachment of the spindle apparatus [14, 
16, 17]. As shown by Avasthi and Marshall [3], tubulin deacetylation, ciliary protein methylation 
as well as ubiquitination are involved in this disassembly of cilia. Centrioles are duplicated and 
transmitted to the daughter cells where they act as templates for the next generation of cilia. 
Other regulation mechanisms for ciliogenesis are cell confluence, fluid flow and cell spreading. 
To control ciliary length, a steady-state assembly is compensated by the permanent removal of 
microtubular subunits from the tip of cilia. Conversely, this process requires anterograde IFT to 
provide new axonemal subunits [1]. 
1.1.3 Photoreceptor: a modified sensory cilium 
One specific type of cilia is represented by photoreceptors, present in the retina. The retina is a 
light-sensitive tissue located at the back of the eye and represents an important part of the 
central nervous system. It is mainly formed by six types of neurons and one type of glia cells. 
The outermost neuronal cell layer of the retina is formed by photoreceptors which are light-
sensitive, transduce the light stimulus into an electrical signal and transmit the signal to the 
inner retinal neurons and through the optic nerve to the brain. There are two different types of 
photoreceptors present in the human retina: rods and cones. Rod photoreceptors are sensitive 
to dim light, whereas cones are specialized for high acuity daytime vision [18, 19]. Rods and 
cones have a distinct structure in common. They consist of an inner- and a light-sensitive outer 
segment [13, 20]. As depicted in Figure 3, the outer segment of photoreceptor cells represents 
a modified sensory cilium which originates from the basal body. The inner segment is linked to 
the outer segment of a photoreceptor through the innermost part of the axoneme, which is 
important as a structural backbone of the membrane disks. The connecting cilium represents 
the transition zone of this specialized cilia [21] and it plays a central role in photoreceptor 
function because it connects the metabolic machinery of the cell (inner segment) to the light-
sensitive outer segment [22]. The disks of the outer segment, unique to photoreceptors, create 
a maximally enlarged membrane surface area to harbour a large number of visual pigments. 
This maximises the visual efficiency. Considering that about 10% of all outer segment disks are 
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renewed every day, the maintenance of outer segments requires a precise control and an 
extremely high rate of ciliary transport. 
 
Figure 3: Structure of the human eye with photoreceptors 
The human eye is a complex optical system. It detects l ight and converts these physical 
stimuli into electro-chemical signals which are transmitted through the optical nerve into 
the visual cortex in the brain. The retina consists of different layers of neurons. The only 
l ight-sensit ive neurons present are the photoreceptors. There are two types of 
photoreceptors: rods and cones. While rods provide black and white vision, cones are 
essential for daytime vision and are sensit ive for colour. The connecting c il ium, located in 
the photoreceptor cells, connects the metabolic machinery ( inner segment) with the light-
sensit ive outer segment. The extensive surface area of the membrane disks leads to a 
maximum of photon capture and consequently in an effective visual transduction. 
1.1.4 Intraflagellar transport machinery 
Each particle which is essential for the assembly and the maintenance of cilia has to be 
delivered to the cilium because cilia do not contain any known biosynthesis machinery. Until 
now, little is known about the mechanisms how ciliary cargo is specifically targeted to the cilium. 
However, there is some evidence that the biogenesis of cilia is depending on vesicular and 
intraflagellar transport (IFT). Therefore, the fusion of carrier vesicles with the periciliary 
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membrane allows the ciliary cargo to be delivered [23-26]. For the bidirectional transport along 
the axoneme of a cilium, the elaborated and evolutionarily conserved IFT machinery is 
responsible (see Figure 4). 
 
Figure 4: Intraflagellar transport  
Intraflagellar transport (IFT) denotes the bidirectional movement along the axoneme of 
cil ia, essential for its assembly and maintenance. Each protein involved in ciliary 
assembly is transported from the cel l to the t ip of a cil ium. This anterograde IFT is driven 
by the subcomplex IFT-B in combination with kinesin motor proteins. Responsible for the 
delivery of protein cargo back from the ci l iary t ip to the basal body (anterograde) is the 
protein complex IFT-A along with dynein. Modified after [1].  
This IFT is driven by kinesin-2 and dynein motor proteins [27] and the cargo link is established 
by two distinct multiprotein complexes: IFT-A and IFT-B. IFT-B, consisting of 17 proteins and 
kinesin are important for the anterograde transport from the cell to the ciliary tip and are 
involved in the assembly and maintenance of cilia. In contrast, IFT-A which contains six known 
proteins, together with cytoplasmic dynein are essential for the retrograde transport of protein 
cargo from the ciliary tip back to the cell body [1, 13, 28]. To enable cargo binding, IFT proteins 
contain numerous protein-protein interaction motifs [3]. Whereas the molecular composition of 
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the IFT machinery is known, the mechanisms of ciliary assembly as well as the interaction of 
IFT proteins with correct protein cargo is still unknown, although there is some evidence that 
there are specific adaptors that link defined cargos to the IFT system [1]. 
1.1.5 Intraflagellar Transport Protein Complex A - IFT-A 
The IFT complex A (IFT-A), which is in the centre of this study, represents one of the two 
subcomplexes of the IFT machinery. IFT-A comprises six complex components IFT122, IFT140, 
IFT43, TTC21B, WDR19 and WDR35 and it was shown that three of them, WDR19, IFT122 and 
IFT140, are forming a core complex [29]. The whole protein complex IFT-A is essential for the 
retrograde transport of protein cargo from the ciliary tip to the cell body, a process that seems to 
be crucial for the protein turnover in the cell body but not necessarily of primary importance for 
ciliary assembly [1]. Due to their importance in axonemal transport, mutations in genes 
encoding IFT-A proteins may cause ciliopathies as described in more detail in 1.1.6. 
Tubby-like protein 3 (TULP3) has been described to interact with IFT-A and thereby promotes 
the ciliary localization of a subset of G protein-coupled receptors (GPCRs) [1]. Due to a 
conserved domain, located in the amino terminus, some proteins of the tubby family are able to 
bind to the core complex of IFT-A [29]. Based on this physical association of TULP3 to IFT-A, 
TULP3 can be used as bait for affinity purification (AP) of IFT-A and its interaction partners. 
1.1.6 IFT-A-related ciliopathies 
Cilia are present on almost any polarized cell of the human body. Therefore, defects in cilia and 
malfunction of ciliary proteins lead to a wide range of human diseases affecting many organ 
systems with multiple symptoms, including polycystic kidney disease, hydrocephalus and retinal 
degeneration [1, 2, 6]. According to their biological function, mutation-induced inactivation of 
IFT-B or kinesins leads to a defective biogenesis of cilia, whereas inactivation of IFT-A or 
cytoplasmic dynein results in defective ciliary function [13]. Due to its diverse occurance, any 
defect in cilia may cause a wide range of diseases such as Bardet-Biedl syndrome (BBS), 
Joubert syndrome (JBS) and retinitis pigmentosa (RP). These diseases are summarized under 
the term ciliopathies [2, 30]. 
Lack or malfunction of IFT-A proteins results in cilia deformation. Consequently, mutations in 
genes encoding IFT-A complex components cause different ciliopathies. Due to its involvement 
in retrograde ciliary transport, malfunction of IFT-A complex components leads to an 
accumulation of IFT-B particles in the ciliary tip and to the formation of shortened and bulged 
cilia. Based on this effect and in combination with the requirement of IFT-A proteins for 
mammalian sonic hedgehog (shh) signalling, mutations in genes encoding IFT-A proteins are a 
major cause of skeletal ciliopathies [27, 31-38]. Sensenbrenner syndrome for example, is 
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characterized by skeletal and ectodermal anomalies as well as chronic renal failure and liver 
fibrosis [39]. Another IFT-A-related ciliopathy is the rare autosomal recessive Mainzer-Saldino 
syndrome (MSS). This disease is caused by mutations in IFT140 and is characterized by 
phalangeal cone-shaped epiphyses, chronic renal failure and early-onset retinal dystrophy [40]. 
To ultimately understand the underlying mechanisms of these diseases it is crucial to determine 
the exact function of the involved protein complexes. A first step towards this is to determine the 
precise composition and the stoichiometry of the protein complex IFT-A. 
1.2 Mass spectrometry 
Mass spectrometry (MS) enables the determination of the mass of molecules within a sample. 
The mass spectrometer analyses ions under vacuum and it consists of three devices: ion 
source, mass analyser and detector. Ions are generated in and sorted via their mass to charge 
ratio (m/z) before they are detected [41]. The first application of mass spectrometry goes back 
to the early 20th century with steady progress for scientific applications, thenceforth [42, 43]. In 
1960’s the analysis of small volatile molecules performing mass spectrometry was achievable. 
Thereby, molecules were separated using gas chromatography. Separated fractions were 
bombarded with electrons to ionize the small molecules before analysis using mass 
spectrometry takes place. But this approach was not adaptable to larger non-volatile 
biomolecules. In the 1980’s other ion sources were developed which enabled the ionization of 
larger biomolecules for example matrix-assisted laser-desorption ionization (MALDI) or 
electrospray ionization (ESI) [44]. Nowadays, mass spectrometry is a central analytical 
technique for proteomic strategies and almost replaced other proteomic methods like 2D-gel 
electrophoresis. The quest to identify and quantify proteins and their interactions in complex 
samples resulted in many experimental strategies and mass spectrometric methods [45]. 
Advanced software tools and databases facilitate the analysis and interpretation of complex 
mass spectra. Although many applications require a steady increase in sensitivity and resolution 
of used mass spectrometer instruments, this also leads to the disadvantage of a simultaneous 
increase in background which leads to the identification of non-specific binding partners. There 
is a wide diversity in mass spectrometric based methods, however the main steps are the same. 
In often performed bottom–up approaches, proteins are fragmented into smaller peptides using 
proteases. The resulting peptide mixture is separated by liquid chromatography (LC) before 
peptide fractions are analysed by MS. The LC system can be directly coupled to the MS using 
electrospray ionization (ESI) source. Based on an initial full scan or on generated mass lists, 
precursor ions can be chosen for further fragmentation. The analysis of these fragments 
enables the detection of the amino acid sequence of the analysed peptide. Using different 
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software and databases the resulting data are assigned to the corresponding proteins for further 
evaluation. 
 
Figure 5: Workflow of a bottom-up mass spectrometry approach 
Samples for mass spectrometry approaches can be prepared from cell l ines as well as 
from various tissues with different methods. Extracted proteins are enzymatically cleaved 
into smaller peptides using a protease. Peptides are separated by liquid chromatography 
(LC) which, in case of electrospray ionization, is  directly coupled to the mass 
spectrometer. After peptides entered the mass spectrometer, a precursor scan (MS1 level) 
is performed and chosen precursors are further fragmented and sequenced (MS2 level). 
For data analysis, dif ferent computational tools tailored to the used approach can be used. 
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1.2.1 Structural mass spectrometry of protein complexes 
Malfunction of proteins, involved in critical cellular processes, may lead to disease. To 
understand the underlying molecular mechanism of diseases, such as ciliopathies, the 
knowledge about all involved proteins and especially how these are assembled into protein 
complexes as well as the complex stoichiometry is essential. To determine stoichiometry of 
involved proteins using mass spectrometry, absolute quantification is the method of choice.  
1.2.1.1 Absolute quantification and stoichiometry determination 
To determine the stoichiometry of a protein complex by mass spectrometry, the absolute 
quantification of representative peptides is crucial. Different methods are already described 
based on the addition of a known amount of standard proteins or peptides into the biological 
sample to be analysed. Thereby, it makes no difference whether the spiked-in representative 
peptides are synthesized with incorporated stable isotopes (AQUA peptides [46]) or the proteins 
within the biological sample are isotopically labelled for example using SILAC media. While 
targeted mass spectrometry is crucial for an absolute quantification of low and high abundant 
proteins, other quantitative proteomics approaches, for example 2D SDS-PAGE where gel 
spots were quantified using staining methods, are only useful for high abundant proteins [47]. 
Absolute quantification of peptides is a difficult but highly precise method to determine the 
composition and to calculate the stoichiometry of a protein complex of interest. Due to variability 
in ionization efficiency of selected peptides during electro spray ionization (ESI) and the 
following ion transfer and detection within the mass spectrometer, absolute quantification 
represents a challenging method for the analysis of protein complex stoichiometry [48]. The 
determined stoichiometry can be the basis for the determination of quantitative effects 
introduced through alterations in cellular state or by disease-associated mutations within a 
protein complex. The procedure of an absolute quantification approach can be separated into 
different steps, starting with the selection of representative peptides performing data-dependent 
shotgun analysis and ending with the quantification of each representative peptide using a 
defined amount of spiked-in standard peptide (described in more detail in chapter 3.2.5.1) [49]. 
1.2.1.2 Chemical crosslinking 
Protein complexes play a key role in cellular function. To understand the molecular mechanisms 
of cellular function, it is important to combine the information of protein-protein interaction 
studies and the knowledge of the comprehensive composition of protein complexes with 
structural information. Chemical crosslinking with subsequent LC-MS/MS analysis is a useful 
method to better characterize the structure of proteins and of protein complexes [50]. It 
represents a complementary approach to well-established high-resolution techniques like X-ray 
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crystallography, NMR spectroscopy and electron microscopy [51]. Chemical crosslinking 
combines the opportunity to investigate protein conformation and information about protein-
protein interactions with an additional benefit due to spacial proximity information given by the 
identification of two chemically cross-linked amino acids [50, 52]. A big advantage of all 
chemical crosslinking approaches is the potential to detect protein-protein binding sites in their 
native states. After enzymatic proteolysis cross-linked peptides are identified by mass 
spectrometry. Commonly used chemical crosslinkers are typically homobifunctional molecules 
with two lysine-reactive functional groups, like disuccinimide esters. To obtain a definite 
distance, aliphatic spacers are introduced between the reactive compounds. For LC-MS/MS 
analysis, peptides are fragmented using for example collision induced dissociation (CID) which 
leads to complex ion spectra. Therefore, a thorough computational analysis of MS data is 
essential. To facilitate the detection of cross-linked peptides by the generation of an isotopic 
signature, the applied crosslinker is used in two isotopic forms [51] as depicted in Figure 6. 
26  Introduction 
 
 
Figure 6: Identification of cross-linked peptides generating an isotopic signature 
First, isotopically shif ted pairs are identif ied on MS1 level. MS/MS spectra of isotopic pairs 
are compared and product ions are divided into common ions (highlighted in green) and 
cross-linked ions (highlighted in red). Common ions are identical in both spectra while 
cross-linked ions can be identif ied through the introduced mass shift. For the analysis, the 
generation of a focused database, comprising protein sequences of all proteins of interest, 
is essential. At the end, the software tool xQuest identif ies candidate cross-links f iltered 
by mass. This research was originally published in Molecular & Cellular Proteomics. 
Leitner, A., et al. Probing native protein structures by chemical cross- linking, mass 
spectrometry, and bioinformatics. Molecular & Cellular Proteomics. 2010; 9(8): p.1634-49. 
© the American Society for Biochemistry and Molecular Biology.  
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2 Aim of the study 
Cilia are found in almost every eukaryotic cell. Therefore, deformation of cilia or non-functional 
cilia result in a broad range of phenotypes including cystic kidney disease, polydactyly, 
hydrocephalus, retinal degeneration and many more. Diseases that are caused by malfunction 
of cilia are summarized under the term ciliopathies. 
The intraflagellar transport (IFT) machinery is important for the transport of protein cargo along 
the ciliary axoneme and can be divided into two protein subcomplexes: IFT-A and IFT-B. While 
IFT-B is involved in anterograde transport, IFT-A, consisting of six known proteins, is part of the 
retrograde transport machinery. This retrograde movement, which delivers protein cargo from 
the tip of a cilium back to its basal body is important for the maintenance and disassembly of 
cilia as well as for cellular signalling and recycling of components. According to previous 
knowledge, mutations in genes encoding some IFT-A complex components (WDR19, IFT43, 
IFT140) lead to syndromic (e.g. Sensenbrenner syndrome), as well as non-syndromic (e.g. 
nonsyndromic retinal dystrophy) forms of ciliopathies [33, 34, 40, 53]. To date, the function of 
the IFT-A complex on molecular level is only poorly understood. In contrast, there are many 
studies published dealing with the architecture of IFT-B and its involvement in ciliopathies [54-
57]. To understand the mechanisms underlying IFT-A-related ciliopathies and to improve the 
understanding of the cellular function of IFT-A, the determination of the stoichiometric 
composition of IFT-A as well as the investigation of its structural information are the focus of this 
present study. 
Objective 1: Absolute quantification of purified IFT-A in its native compositions 
To determine the native complex stoichiometry of IFT-A and to circumvent an effect of artificial 
over expression [58], the first aim of this study is the generation of monoclonal cell lines, stably 
expressing SF-TAP tagged IFT-A proteins, using the Flp-In system. The complete and intact 
purification of the whole IFT-A protein complex is a crucial step for a successful stoichiometry 
determination. Therefore, validation by SDS-PAGE with further silver staining and following 
quantitative mass spectrometry is obligatory. The stoichiometry determination of purified IFT-A 
in its native composition by absolute quantification combines a targeted mass spectrometry 
approach with representative standard peptides. To generate an economic equimolar standard 
mix, the “Equimolarity through Equalizer Peptide” (EtEP) is the method of choice in this study 
[59]. 
Based on its role in retrograde transport of protein cargo from the ciliary tip to the basal body, 
composition of IFT-A may change during the assembly and disassembly of cilia. Therefore, the 
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study of compositional changes in IFT-A stoichiometry during different ciliary stages is another 
important aim of this study. To investigate the composition of IFT-A in different cellular stages, 
hTERT-RPE1 cells, cultivated in different conditions, shall be used for the purification of IFT-A. 
Subsequently, the assembly of the IFT-A should be compared.  
Objective 2: Effect in complex composition of IFT-A generating disease-related mutations of 
single components of the IFT-A protein complex 
The last but not least step to understand the underlying molecular mechanism of IFT-A-related 
diseases is the analysis of induced changes in the complex stoichiometry. 
For the introduction of stoichiometry changes in the protein complex of interest, the genome of 
Flp-In monoclonal lines, expressing TAP-tagged TULP3, are subjected to gene editing using the 
CRISPR/Cas9 system. Thereby, cell lines carrying mutations either in the WDR19 or IFT43 
gene should be generated. To study the composition of IFT-A in disease-related mutations, the 
absolute quantification of purified IFT-A in validated and characterized mutant cell lines is 
another crucial step of this study. 
Objective 3: Structural investigation of the IFT-A complex as basis for the prediction of 
functional relevant domains 
Another aim of this study is the refinement of the stoichiometric investigations of IFT-A, 
achieved in this study, with structural information of this protein complex using chemical 
crosslinking. Therefore, dissuccinimidyl suberate (DSS), a homobifunctional chemical 
crosslinker, should be used to gain proximity information of protein components of IFT-A. This 
elaborate approach of chemical crosslinking of TAP-purified IFT-A has to be optimised 
regarding the amount of cells as well as crosslinker concentration.  
  
Material and Methods  29 
 
 
 
3 Material and Methods 
3.1 Material 
3.1.1 Equipment 
Analytical balance ABJ 120-4M Kern & Sohn GmbH, Balingen, Germany 
Autoclave DX-150 Systec, Wettenberg, Germany 
CO2-Incubator HeraCell 150i Heraeus, Hanau, Germany 
Compartment dryer T20 Heraeus, Hanau, Germany 
Developer Curix 60 Agfa, Mortsel, Belgium 
Freezer (-80°C) Forma 900 Series Thermo Fisher Scientific, Waltham, MA, USA 
Freezer Liebherr Comfort Liebherr, Bulle, Switzerland 
Gel documentation device Easy RH Herolab, Wiesloch, Germany 
Ice machine AF200 Scotsman, Vernon Hills, IL, USA 
Incubator INB 300  Memmert, Schwabach, Germany 
IntelliMixer NeoLab, Heidelberg, Germany 
Laboratory balance S72 Kern & Sohn GmbH, Balingen, Germany 
Laboratory hood model 854006.1 Wesemann, Syke, Germany 
Laminar flow HeraSafe HS 12 Heraeus, Hanau, Germany 
Laminar flow MSC 12 Thermo Fisher Scientific, Waltham, MA, USA 
Magnetic stirrer and heater MR Hei-Standard Heidolph, Schwabach, Germany 
Megafuge 16 Heraeus, Hanau, Germany 
Microscope PrimoVert Zeiss, Göttingen, Germany 
Microwave Siemens, München, Germany 
Multifuge X3R Heraeus, Hanau, Germany 
Neubauer counting chamber Marienfeld, Lauda-Königshofen, Germany 
pH meter PB-11 Sartorius, Göttingen, Germany 
Platform shaker Duomax 1030 Heidolph, Schwabach, Germany 
Power Supply Consort Consort, Turnhout, Belgium 
Power Supply PowerPak Basic Bio-Rad, Hercules, CA, USA 
Refrigerated Vapor Trap RVT400-230 Thermo Fisher Scientific, Waltham, MA, USA 
Refrigerator Liebherr, Bulle, Switzerland 
Roller Mixer RM5 Assistant, Sondheim, Germany 
Rotating incubator Infors HAT Ecotron, Bruckmühl, Germany 
Speedvac Concentrator SPD111V-230 Thermo Fisher Scientific, Waltham, MA, USA 
Table top centrifuge 5415D Eppendorf, Hamburg, Germany 
Table top centrifuge Fresco17, refrigerated Heraeus, Hanau, Germany 
Table top centrifuge Pico 21 Heraeus, Hanau, Germany 
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Thermoblock MBT 250 ETG, Illmenau, Germany 
Thermocycler Primus MWG-Biotech, Ebersberg, Germany 
Thermocycler Primus 96 Plus MWG-Biotech, Ebersberg, Germany 
Thermomixer Comfort Eppendorf, Hamburg, Germany 
Thermomixer Univortemp Universal Labortechnik, Leipzig, Germany 
Transluminator Fluo Link (312nm) Bachofer, Reutlingen, Germany 
Ultrapure water purification system Nanopure Thermo Fisher Scientific, Waltham, MA, USA 
Ultrasonic bath Sonorex Digitec Bandelin, Berlin, Germany 
UV/VIS Spectrometer T70 PG Instruments Limited, Lutterworth, UK 
Vacuum pump 2522Z-02 Welch, Niles, IL, USa 
Vortex Mixer NeoLab, Heidelberg, Germany 
Waterbath WNB 14 with shaker SV1422 Memmert, Schwabach, Germany 
3.1.2 Consumables and labware 
Accu-Jet® pro pipetting aid Brand, Wertheim, Germany 
Amersham Hyperfilm ECL GE Healthcare, Waukesha, WI, USA 
Baffeled flask 250/500ml  Neolab, Heidelberg, Germany 
Blue rack for 6/12 Tubes GLW Storing Systems, Würzburg, Germany 
Box for pipette tips Gilson, Middleton, WI, USA 
Cell culture dish, 6 well  BD Bioscienes, Franklin Lakes, NJ, USA 
Cell scraper  Sarstedt, Nümbrecht, Germany 
Centrifugation tubes 15/50ml  Greiner bio-one, Kremsmünster, Austria 
Comb 10/15 well for 0.75mm gels Bio-Rad, Hercules, CA, USA 
Cryo Tube Rack Nunc, Rochester, NY, USA 
Cryobox 0.5/1.5/2.0ml tubes Carl-Roth, Karlsruhe, Germany 
Culture tube 14ml BD Biosciences, Franklin Lakes, NJ, USA 
Cuvette 1.5ml  Sarstedt, Nümbrecht, Germany 
Drigalski spatula Carl-Roth, Karlsruhe, Germany 
Filter system 0.22µm  Corning, NY, USA 
Gel loading tips Carl-Roth, Karlsruhe, Germany 
Glas plate with 0.75mm spacer Bio-Rad, Hercules, CA, USA 
Gloves purple nitrile Kimberly-Clark, Irving, TX, USA 
Gloves soft nitrile Paul Hartmann, Heidenheim, Germany 
Graduated measuring glass Duran Group, Wertheim, Germany 
Hybond-P PVDF Transfer membrane GE Healthcare, Waukesha, WI, USA 
Hypercassette  GE Healthcare, Waukesha, WI, USA 
Hyperscreen GE Healthcare, Waukesha, WI, USA 
Icebath  Neolab, Heidelberg, Germany 
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Inlays for Cryobox for 0.5/1.7/2.0ml tubes Carl-Roth, Karlsruhe, Germany 
Inoculation loop Carl-Roth, Karlsruhe, Germany 
Laboratory bottles, 50-2000ml Neolab, Heidelberg, Germany 
MicroSpin Columns GE Healthcare, Waukesha, WI, USA 
Multiwell plate, 96wells Greiner bio-one, Kremsmünster, Austria 
Parafilm sealing foil Brand, Wertheim, Germany 
Pasteur capillary pipette VWR International, West Chester, PA, USA 
Pasteru Pipette PP VWR International, West Chester, PA, USA 
PCR rack Carl-Roth, Karlsruhe, Germany 
Petridish 90 x 14.2mm VWR International, West Chester, PA, USA 
pH indicator sticks Carl-Roth, Karlsruhe, Germany 
Pipettes 2/10/20/200/1000µl Gilson, Middleton, WI, USA 
Pipette tips 1-10/1-200/101-1000µl Sarstedt, Nümbrecht, Germany 
Pipettes (serological) 2/5/10/25/50ml BD Biosciences, Franklin Lakes, NJ, USA 
Polypropylen insert with bottom spring Sigma-Aldrich, St. Louis, MO, USA 
Reaction tube 0.2 Eppendorf, Hamburg, Germany 
Reaction tube (safe-lock) 0.5/1.5/5.0ml Eppendorf, Hamburg, Germany 
Reaction tube 15ml Sarstedt, Nümbrecht, Germany 
Reaction tube 50ml BD Biosciences, Franklin Lakes, NJ, USA 
Scalpell VWR International, West Chester, PA, USA 
Short plate Bio-Rad, Hercules, CA, USA 
Spin Columns, 3MWCO, 30MWCO GE Healthcare, Waukesha, WI, USA 
Stage Tips C-18, 200µl Thermo Fisher Scientific, Waltham, MA, USA 
Sterilfilter Millex 0.22 µm Merck, Darmstadt, Germany 
Tissue Dishes, 10cm, Nunclon Surface Nunc, Rochester, NY, USA 
Tissue Dishes, 14cm, Nunclon Surface Nunc, Rochester, NY, USA 
Whatman chromatography paper GE Healthcare, Waukesha, WI, USA 
3.1.3 Chemicals 
1,4-Dithiothreitol (DTT) Merck, Darmstadt, Germany 
2-Iodacetamide (IAA) Merck, Darmstadt, Germany 
2-Mercaptoethanol Sigma-Aldrich, St. Louis, MO, USA 
2-Propanol LC grade Merck, Darmstadt, Germany 
2-Propanol p.a. Merck, Darmstadt, Germany 
Acetonitrile LC-MS CHROMASOLV®, ≥99.9% Sigma-Aldrich, St. Louis, MO, USA 
Agar-Agar Carl-Roth, Karlsruhhe, Germany  
Agarose Lonza, Basel, Switzerland 
Ammonium Bicarbonate Sigma-Aldrich, St. Louis, MO, USA 
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Ammonium Persulfate Merck, Darmstadt, Germany 
Ampicillin Sodium Crystalline Carl-Roth, Karlsruhe, Germany 
Bis-Acrylamid/Acrylamid (37.5:1:30%) Serva Elektrophoresis, Heidelberg, Germany 
Bromphenolblue Sigma-Aldrich, St. Louis, MO, USA 
Chloramphenicol Carl-Roth, Karlsruhe, Germany 
Chloroform p.a. Merck, Darmstadt, Germany 
Dimethyl Sulfoxide Applichem, Darmstadt, Germany 
EDTA Disodium Salt Dihydrate Applichem, Darmstadt, Germany 
Ethanol p.a. Merck, Darmstadt, Germany 
Ethidiumbromide Applichem, Darmstadt, Germany 
Ficoll 400 Sigma-Aldrich, St. Louis, MO, USA 
Formaldehyde Solution (37%) Sigma-Aldrich, St. Louis, MO, USA 
Glacial Acetic Acid p.a. Merck, Darmstadt, Germany 
Glycerol Carl-Roth, Karlsruhe, Germany 
Glycin Carl-Roth, Karlsruhe, Germany 
HEPES Sigma-Aldrich, St. Louis, MO, USA 
Hydrochloric Acid p.a. Merck, Darmstadt, Germany 
Kanamycin Sulfate Carl-Roth, Karlsruhe, Germany 
Magnesium Chloride Sigma-Aldrich, St. Louis, MO, USA 
Methanol LC-MS grade Merck, Darmstadt, Germany 
Methanol LC-MS grade VWR International, West Chester, PA, USA 
Methanol p.a. Merck, Darmstadt, Germany 
Nonidet P40 Roche, Penzberg, Germany 
OrangeG Sigma-Aldrich, St. Louis, MO, USA 
Polyethylenimine, Linear (MW 25,000) Polysciences, Warrington, PA, USA 
Ponceau S Sigma-Aldrich, St. Louis, MO, USA 
Potassium Chloride p.a. Carl-Roth, Karlsruhe, Germany 
RapiGest SF Surfactant Waters, Milford, MA, USA 
Silver Nitrate  Merck, Darmstadt, Germany 
Sodium Chloride p.a. Merck, Darmstadt, Germany 
Sodium Dodecylsulfate, Pellet Sigma-Aldrich, St. Louis, MO, USA 
Sodium Dodecylsulfate, 20% Applichem, Darmstadt, Germany 
Sodium Hydroxide pellets p.a. Carl-Roth, Karlsruhe, Germany 
Sodium Thiosulfate Pentahydrate, supra pure Merck, Darmstadt, Germany 
TEMED p.a. Merck, Darmstadt, Germany 
Trifluoroacetic Acid, for protein seq. Merck, Darmstadt, Germany 
Tris(hydroxymethyl) Aminomethane (Tris ultrapure) Sigma-Aldrich, St. Louis, MO, USA 
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Trypsin from porcine pancreas, proteomics grade Sigma-Aldrich, St. Louis, MO, USA 
Tryptone/ Peptone from Casein Carl-Roth, Karlsruhe, Germany 
Tween® 20 Sigma-Aldrich, St. Louis, MO, USA 
Water, HPLC grade Merck, Darmstadt, Germany 
Water, HPLC grade VWR International, West Chester, PA, USA 
Water bath stabilizer, AKASOLV Aqua Care Carl-Roth, Karlsruhe, Germany 
Yeast Extract Carl-Roth, Karlsruhe, Germany 
3.1.4 Special reagents 
12C6, 14N2 - Lysine Silantes, München, Germany 
4.4.5.5.-D4 -L-Lysine Silantes, München, Germany 
13C6, 15N2 -L-Lysine Silantes, München, Germany 
12C6, 14N4 - Arginine Silantes, München, Germany 
13C6 - Arginine Silantes, München, Germany 
13C6, 15N4 -L-Arginine Silantes, München, Germany 
Adenosin 5’-Diphophate (ADP) Sigma-Aldrich, St. Louis, MO, USA 
AGFA Developer G153 Röntgen Bender, Baden-Baden, Germany 
AGFA Fixer G354 Röntgen Bender, Baden-Baden, Germany 
Anti-FLAG-M2-agarose Sigma-Aldrich, St. Louis, MO, USA 
Blotting Grade Blocker, nonfat dry Bio-Rad, Hercules, CA, USA 
Bovine Serum Albumin (BSA) PAA, Pasching, Austria 
Coomassie Brilliant Blue Merck, Darmstadt, Germany 
D-Desthiobiotin IBA, Göttingen, Germany 
Dialysed Fetal Bovine Serum (FBS) Sigma-Aldrich, St. Louis, MO, USA 
Didesoxyadenosine 5’-triphosphate (ATP) Sigma-Aldrich, St. Louis, MO, USA 
Disuccinimidyl Suberate (DSS) H12/ D12 Creative Molecules Inc  
dNTP Mix, 40µM  New England Biolabs, Ipswich, MA, USA 
Dulbecco’s Modified Eagle Medium Sigma-Aldrich, St. Louis, MO, USA 
Dulbecco’s PBS Sigma-Aldrich, St. Louis, MO, USA 
ECL plus Western Blotting Substrate  Thermo Fisher Scientific, Waltham, MA, USA 
ECL Western Blotting Substrate Thermo Fisher Scientific, Waltham, MA, USA 
Effectene transfection reagent Qiagen, Hilden, Germany 
Fetal Bovine Serum (FBS) Sigma-Aldrich, St. Louis, MO, USA 
Flag peptide Sigma-Aldrich, St. Louis, MO, USA 
GeneRulerTM1kb Plus DNA ladder Thermo Fisher Scientific, Waltham, MA, USA 
L-Glutamine, 200mM Life Technologies, Carlsbad, CA, USA 
Hygromycin B (50mg/ml) Invitrogen, Carlsbad, CA, USA 
PageRuler Plus, 250kDa prestained Fermentas, Burlington, Canada 
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PageRuler, 170kDa prestained Fermentas, Burlington, Canada 
Penicillin/ Streptomycin Life Technologies, Carlsbad, CA, USA 
Phosphatase Inhibitor Cocktail 2 Sigma-Aldrich, St. Louis, MO, USA 
Phosphatase Inhibitor Cocktail 3 Sigma-Aldrich, St. Louis, MO, USA 
Proline Silantes, München, Germany 
Protease Inhibitor Cocktail Complete Roche, Penzberg, Germany 
Protein Assay Dye Reagent Bio-Rad, Hercules, CA, USA 
Protein G PLUS-Agarose Santa Cruz, Santa Cruz, CA, USA 
Protein A PLUS-Agarose Santa Cruz, Santa Cruz, CA, USA 
Puromycin Dihydrochloride GIBCOTM (sterile) 
(10mg/ml) 
Thermo Fisher Scientific, Waltham, MA, USA 
SILAC DMEM Thermo Fisher Scientific, Waltham, MA, USA 
Strep Tactin Superflow (50% suspension) IBA, Göttingen, Germany 
Strep-TAG Elution Buffer IBA, Göttingen, Germany 
Trypsin EDTA Life Technologies, Carlsbad, CA, USA 
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3.1.5 Buffers, solutions and media 
In this study, deionized water is described as dH2O and ddH2O refers to ultra-pure water. 
3.1.5.1 E.coli culture 
LB-Medium   1% (w/v) Tryptone/ Peptone from Casein 
   0.5% (w/v) Yeast Extract 
   1% (w/v) NaCl 
   adjust to pH 7.0 using NaOH 
   in dH2O 
 
LB-Agar   1% (w/v) Tryptone/ Peptone from Casein 
   0.5% (w/v) Yeast Extract 
   1% (w/v) NaCl 
   1% (w/v) Agar-Agar 
   in dH2O 
3.1.5.2 Mammalian cell culture 
Cryo Medium  90% FBS 
   10% DMSO 
 
Growth Medium   Dulbecco’s Modified Eagle Medium 
   10% FBS 
   0.5% Penicillin/ Streptomycin 
 
PEI Transfection Reagent  1mg/ml Polyethylenimine (PEI) 
   in dH2O   
 
SILAC Medium Light  SILAC DMEM 
   10% FBS (dialysed) 
   2% L-Glutamine 
   0.5% Penicillin/ Streptomycin 
   2mM Proline 
   0.55mM 12C6, 14N2 Lysine 
   0.4mM 12C6, 14N4 Arginine 
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SILAC Medium Medium  SILAC DMEM 
   10% FBS (dialysed) 
   2% L-Glutamine 
   0.5% Penicillin/ Streptomycin 
   2mM Proline 
   0.55mM 4.4.5.5- D4-L-Lysine 
   0.4mM 13C6 Arginine 
 
SILAC Medium Heavy  SILAC DMEM 
   10% FBS (dialysed) 
   2% L-Glutamine 
   0.5% Penicillin/ Streptomycin 
   2mM Proline 
   0.55mM 13C6, 15N2-L-Lysine 
   0.4mM 13C6, 15N4-L-Arginine 
 
Flp-In Growth Medium  Dulbecco’s Modified Eagle Medium 
   10% FBS 
   1% Penicillin/ Streptomycin 
2mM L-Glutamine 
100µg/ml Zeocin 
 
Flp-In Transfection Medium Dulbecco’s Modified Eagle Medium 
   10% FBS 
2mM L-Glutamine 
 
Flp-In Post-Transfection Medium Dulbecco’s Modified Eagle Medium 
   10% FBS 
2mM L-Glutamine 
1% Penicillin/ Streptomycin 
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Flp-In Selection Medium  Dulbecco’s Modified Eagle Medium 
   10% FBS 
2mM L-Glutamine 
1% Penicillin/ Streptomycin 
   100µg/ml Hygromycin 
 
CRISP Selection Medium  Dulbecco’s Modified Eagle Medium 
   10% FBS 
0.05% Penicillin/ Streptomycin 
   8µg/ml Puromycin 
3.1.5.3 Agarose Gels 
Orange G (6x)  250mg/ml Ficoll 400 
   0.5% (w/v) SDS 
   50mM EDTA 
   1 spatula tip Orange G 
   in ddH2O 
 
TAE-buffer (50x)  2M Tris 
   50mM EDTA 
   1M Acetic Acid  
   in dH2O 
3.1.5.4 SDS-PAGE, Coomassie staining and Western blot analysis 
Blocking Solution  5% Blotting Grade Blocker 
   in TBST (1x) 
 
Coomassie Staining Solution 0.4% (w/v) Coomassie Brilliant Blue 
   in dH2O 
 
Fixer Solution  50% MeOH 
   12% Acetic Acid 
   in dH2O 
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Laemmli buffer (5x)  250mM Tris-HCl pH 6.8 
   5% SDS 
   50% Glycerol 
   500mM 2-Mercaptoethanol 
   0.05% (w/v) Bromphenol Blue 
   in ddH2O 
 
Ponceau-Solution (10x)  0.1% (w/v) Ponceau S 
   50% Acetic Acid 
   in ddH2O   
 
Running buffer (10x)  2M Glycine 
   250mM Tris 
   1% (w/v) SDS 
   in dH2O 
 
Separation Gel   25% Tris-HCl pH 8.8 
   12% Acrylamide 
   0.1% SDS 
   0.2% TEMED 
   0.05% Ammonium Persulfate (APS) 
   in ddH2O 
 
Stacking Gel   14% Tris-HCl pH 6.8 
   4.2% Acrylamide 
   0.1% SDS 
   0.4% TEMED 
   0.1% Ammonium Persulfate (APS) 
   in ddH2O 
 
TBST (10x)   300mM Tris 
   1.5M NaCl 
   1% Tween® 20 
   in dH2O 
   adjust pH to 7.4 using HCl 
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Western buffer (10x)  1.92M Glycine 
   250mM Tris 
   in dH2O 
 
Western buffer (1x)  10% Western buffer  
   20% MeOH 
   In dH2O 
3.1.5.5 Silverstaining  
AgNO3-Solution  11.8mM Silver Nitrate (AgNO3) 
   0.075% Formaldehyde (37%) 
   in ddH2O 
 
Coomassie Fixer  50% MeOH 
   12% Acetic Acid 
   in ddH2O 
 
Developer   1M Sodium Carbonate (Na2CO3) 
   5% Na2S2O3-Solution 
   0.1% Formaldehyde (37%) 
   in ddH2O 
 
Fixer   50% MeOH 
   12% Acetic Acid 
   0.05% Formaldehyde (37%) 
   in ddH2O 
 
Na2S2O3-Solution  1.3mM Sodium Thiosulfate (Na2S2O3) 
   in ddH2O 
 
Preserver   20% EtOH 
   2% Glycerol 
   in ddH2O 
3.1.5.6 Affinity purification 
FLAG-Peptide (25x)  5mg/ml FLAG-Peptide 
   in TBS (1x) 
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Lysis Buffer    0.55% Nonidet P40 
   2% Protease Inhibitor Cocktail Complete (PIC) 
   1% Phosphatase Inhibitor Cocktail 2 
   1% Phosphatase Inhibitor Cocktail 3 
   in TBS (1x) 
   
Strep-Elution Buffer  10% Strep-TAG Elution Buffer 
   in H2O (HPLC grade) 
 
TBS (10x)   300mM Tris 
   1.5M NaCl 
   in dH2O 
   adjust pH to 7.4 using HCl 
 
Washing Buffer  0.12% Nonidet P40 
   1% Phosphatase Inhibitor Cocktail 2 
   1% Phosphatase Inhibitor Cocktail 2 
   in TBS (1x) 
3.1.5.7 Chemical crosslinking 
Crosslinking Buffer  50mM HEPES 
   150mM NaCl 
   5mM MgCl2 
   in ddH2O 
   adjust pH to 7.5 using NaOH 
 
Disuccinimidyl Suberate  12.5mM Disuccinimidyl Suberate (H12/D12) 
   in DMSO 
 
FLAG-peptide (25x)  5mg/ml FLAG-peptide 
   in Crosslinking Buffer  
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CL-Lysis Buffer   0.58% Nonidet P40 
   2% Protease Inhibitor Cocktail Complete 
   1% Phosphatase Inhibitor Cocktail 2 
   1% Phosphatase Inhibitor Cocktail 3 
   in Crosslinking Buffer 
 
CL-Strep-Elution Buffer (10x) 5.35mg/ml D-Desthiobiotin 
   in Crosslinking Buffer   
 
CL-Washing Buffer   0.12% Nonidet P40 
   1% Phosphatase Inhibitor Cocktail 2 
   1% Phosphatase Inhibitor Cocktail 3 
   in Crosslinking Buffer 
3.1.6 Kits 
Bio-Rad Protein Assay Kit Bio-Rad, Hercules, CA, USA 
EndoFree Plasmid Maxi Kit Qiagen, Hildem Germany 
Enhanced Chemiluminescence Kit, ECLplus GE Healthcare, Waukesha, WI, USA,  
Gel Extraction Kit Fermentas, Burlington, Canada 
GeneJetTM Plasid Miniprep Kit Fermentas, Burlington, Canada 
peqGold Tissue DNA Mini Kit Peqlab Biotechnologie GmbH. Erlangen, Germany 
PureYield Plasmid Midiprep Kit Promega, Fitchburg, WI, USA 
3.1.7 Enzymes 
BP Clonase II Enzyme MIX, with proteinase K Invitrogen, Carlsbad, CA, USA 
FastDigest BbsI/BpiI Thermo Fisher Scientific, Waltham, MA, USA 
HindIII New England Biolabs, Ipswich, MA, USA 
LR Clonase II Enzyme MIX, with proteinase K Invitrogen, Carlsbad, CA, USA 
Phusion High-Fidelity DNA Polymerase supplied 
with HF Reaction buffer (5x) and MgCl2 (50mM) 
Thermo Fisher Scientific, Waltham, MA, USA 
PlasmidSafe exonuclease supplied with 
PlasmidSafe buffer (10x) 
Epicentre, Madison, WI, USA 
T4 DNA Ligase supplied with Reaction buffer (10x) Roche, Penzberg, Germany 
T4 Polynucleotide Kinasesupplied with Reaction 
buffer (10x) 
Roche, Penzberg, Germany 
Taq DNA Polymerase supplied with Reaction 
buffer (10x) 
Fermentas, Burlington, Canada 
XhoI New England Biolabs, Ipswich, MA, USA 
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3.1.8 E.coli strains 
Library Efficient® DH5α Invitrogen, Carlsbad, CA, USA 
3.1.9 Oligonucleotides  
Table 1: Oligonucleotides for gene editing using CRISPR/Cas9 system  
Oligonucleotides were purchased from Eurofins Genomics. 
Oligo name Sequence 5’-3’ 
IFT43 sgRNA1_for caccgctgggaccatctgttcactg 
IFT43 sgRNA1_rev gaccctggtagacaagtgaccaaa 
IFT43 sgRNA2_for caccgcctccttctccgtctgcagt 
IFT43 sgRNA2_rev cggaggaagaggcagacgtcacaaa 
IFT43 HDR1 gctgggactgggaccacctgttcaccgaggtgtcctcagaggtcctcactgagtgggacccactgtagact
gagaaagaggaccctgcggggcaggccaggcacacctgag 
WDR19 sgRNA1_for caccgaaatactaactcgtgaatat 
WDR19 sgRNA1_rev ctttatgattgagcacttatacaaa 
WDR19 sgRNA2_for caccggaaaagagatatcttcaggc 
WDR19 sgRNA2_rev ccttttctctatagaagtccgcaaa 
WDR19 HDR1 gaaggagaaaagagatatcttcaggctggaaaattcttcttgctgtgtggccaatactaagaattctcacgc
gttagtatttgccaagaaaatatacactgactccgcaggaataattg 
WDR19 HDR2 cttgaaggagaaaagagatatcttcaggctggaaaattcttcttgctgtgtggccaatacttacgccttagcatt
tgccaagaaaatatacactgactccgcaggaataattgtagg 
Table 2: Sequencing and PCR Primers 
Primer name Sequence 5’-3’ Application 
attB1 gggacaagtttgtacaaaaaagcaggct Gateway Cloning 
attB2 ggggaccactttgtacaagaaagctgggt Gateway Cloning 
BGH polyA signal (P-13-074) ctgtgccttctagttgccag FlpIn System 
CMV_for cgcaaatgggcggtaggcgtg CRISPR/Cas9 System 
Hygromycin_rev (P-13-067) gcaaagtgccgataaacataac FlpIn System 
IFT43_genomfor ggcattcctgcaggtctcag CRISPR/Cas9 System 
IFT43_genomrev gaggagatggcacagaataagc CRISPR/Cas9 System 
IFT43_HDR1_for gacccactgtagactgagaaag CRISPR/Cas9 System 
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IFT43_HDRfail_for gacccactgcagacggag CRISPR/Cas9 System 
lacZ-Zeocin_rev (P-13-079) gggaacaaacggcggattga FlpIn System 
lacZ-Zeocin_rev (P-13-075) gttttcccagtcacgacgtt FlpIn System 
pcDNA3_for ctctggctaactagagaac CRISPR/Cas9 System 
SV40_for (P-13-066) aattagtcagcaaccaggtgtg FlpIn System 
SV40_for (P-13-070) tccgccccatggctgactaa FlpIn System 
WDR19_genomfor gaatgtcatcttccctacttgtctg CRISPR/Cas9 System 
WDR19_genomrev gccttaggccaaggggct CRISPR/Cas9 System 
WDR19_HDR1_for gccaatactaagaattctcacgcg CRISPR/Cas9 System 
WDR19_HDR2_for gccaatacttacgcgttagcatttg CRISPR/Cas9 System 
WDR19_HDRfail_for gccaatattcacgagttagtatttgc CRISPR/Cas9 System 
3.1.10 Plasmids 
Table 3: Vectors 
Vector name Vector type Tag Resistance 
Gateway® pDONRTM221 Donor Vector - Kanamycin 
Gateway® pENTR223 Entry Vector - Spectinomycin 
(C)SF-TAP pDEST Destination Vector (C)-SF-TAP Ampicillin, 
Chlormaphenicol, 
Neomycin 
(N)SF-TAP pDEST Destination Vector (N)-SF-TAP Ampicillin, 
Chlormaphenicol, 
Neomycin 
pcDNA5/FRT/TO Destination Vector - Hygromycin 
pSpCas9n(BB)-2A-Puro Destination Vector - Ampicillin, 
Puromycin 
3.1.11 Constructs 
Table 4: Constructs 
Construct name cDNA (human) Vector 
(C)-SF-TAP pDEST-IFT122 IFT122 (C)-SF-TAP pDEST 
(C)-SF-TAP pDEST-LCA5 LCA5 (C)-SF-TAP pDEST 
(C)-SF-TAP pDEST-TULP3 TULP3 (C)-SF-TAP pDEST 
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3.1.12 Antibodies 
Table 5: Primary Antibodies 
Antibody  Species Dilution Vendor 
Anti-FLAG® M2-Peroxidase 
(HRP) 
mouse (monoclonal) 1:1000 Sigma-Aldrich, St. Louis, MO, USA 
Anti-βGal Rabbit (polyclonal) 1:100000 Abcam, Cambridge, UK 
 
Table 6: Secondary Antibodies 
Antibody  Species Dilution Vendor 
Anti-rabbit IgG goat (polyclonal) 1:15000 Jackson Immunoresearch, West 
Grove, PA, USA 
3.1.13 Liquid chromatography and mass spectrometry 
Acclaim PepMap RSLC C18 (75µm x 25cm) Thermo Fisher Scientific, Waltham, MA, USA 
Ettan FPLC  GE Healtcare, Waukesha, WI, USA 
LTQ Orbitrap Velos Thermo Fisher Scientific, Waltham, MA, USA 
LTQ Orbitrap XL Thermo Fisher Scientific, Waltham, MA, USA 
Orbitrap Fusion Thermo Fisher Scientific, Waltham, MA, USA 
QExactive Plus Thermo Fisher Scientific, Waltham, MA, USA 
Qtrap 5500 AB Sciex, Framingham, MA, USA 
Superdex Peptide PC 3.2/30’’ column GE Healtcare, Waukesha, WI, USA 
Ultimate 3000 Nano-RSLC Thermo Fisher Scientific, Waltham, MA, USA 
µ-Precolumn Acclaim PepMap100 C18 (300µm i.d. 
x 5mm)  
Thermo Fisher Scientific, Waltham, MA, USA 
3.1.14 Software and databases 
3.1.14.1 Software 
Table 7: Software 
Adobe Illustrator CS5.1 Adobe Systems Inc., San Jose, CA, USA 
Adobe Photoshop CS5 Adobe Systems Inc., San Jose, CA, USA 
Chromeleon 2.1.4 Thermo Fisher Scientific, Waltham, MA, USA 
EndNote X6 Thomson Reuters, New York, NY, USA 
MaxQuant 1.5.3.30 MPI of Biochemistry, Martinsried, Germany 
MS Office 2010 (Word, Excel, PowerPoint) Microsoft, Redmond, WA, USA 
OriginPro 9.0 OriginLab Corporation, Northampton, MA, USA 
Perseus 1.5.2.6 MPI of Biochemistry, Martinsried, Germany 
Proteome Discoverer Daemon 2.0 Thermo Fisher Scientific, Waltham, MA, USA 
RawMeat Vast Scientific,  
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Scaffold 4.0 Proteome Software Inc., Portland, OR, USA 
Skyline 3.5 MacCoss Lab Software,  
Vector NTI Suite 9.0 Invitrogen, Carlsbad, CA, USA 
XCalibur 2.07 Thermo Fisher Scientific, Waltham, MA, USA 
Xinet Rappsilber Laboratory, Edinburgh, UK 
xQuest/xProphet ETH Zürich, Switzerland 
3.1.14.2 Databases 
Table 8: Databases 
Ensembl Genome Browser http://www.ensembl.org 
NCBI http://www.ncbi.nlm.nih.gov/ 
NCBI Blast http://www.ncbi.nlm.nih.gov/Blast.cgi 
NCBI Nucleotide http://www.ncbi.nlm.nih.gov/sites/entrez?db=nuccore 
NCBI Protein http://www.ncbi.nlm.nih.gov/sites/entrez?db=protein 
NCBI PubMed http://www.ncbi.nlm.nih.gov/sites/entrez 
Swiss-Prot http://www.expasy.ch/sprot/ 
UniProt http://uniprot.org/ 
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3.2 Methods 
3.2.1 Molecular biology 
3.2.1.1 Enzymatic DNA treatment 
The basis of molecular biology is the use of different enzymes to generate DNA constructs for 
specific needs. 
DNA restriction digestion 
An important tool in molecular biology is the use of restriction endonucleases. These enzymes 
recognise a specific basepair sequence and thereby create a targeted double-strand cut at or 
next to its specific recognition site. Depending on the applied enzyme, this cut results in blunt or 
sticky ends. For DNA restriction digestion, buffers and reaction conditions were chosen as 
recommended by NEB (http://www.neb.com). Digestion of 1µg of double-stranded DNA was 
performed using 20U of restriction endonuclease. 
To create corresponding ends, 5µg of the plasmid containing target cDNA as well as 5µg of the 
destination vector were incubated with the same restriction enzyme for 2h at 37°C. For double 
digestion, buffer conditions with best reactivity for both enzymes were chosen. If reaction 
conditions of selected endonucleases were not compatible, DNA restriction was performed 
sequentially. 
Annealing and phosphorylating of oligonucleotides 
Short double-stranded DNA (dsDNA) fragments can be generated through the annealing of 
complementary synthetic oligonucleotides. The annealing of single-stranded DNA (ssDNA) 
occurs through the formation of hydrogen bonds between complementary nucleobases A/T and 
G/C. This reaction leads to basepairs forming dsDNA. To enable subsequent ligation of blunt 
ended dsDNA into restricted plasmid vector, phosphorylation of the hydroxy group (-OH) at the 
5’ end is necessary.  
To phosphorylate and anneal single-stranded oligonucleotides, 1µl of each complementary 
fragment (100µM) was incubated with 1µl T4 polynucleotide kinase (T4 PNK) in 1xT4 PNK 
buffer in a total reaction volume of 10µl. Incubation was performed in a thermocycler. ssDNA 
was phosphorylated for 30min at 37°C, followed by a denaturation for 5min at 95°C and 
subsequently annealing of complementary oligonucleotides by cooling down slowly to 25°C with 
a decrease of 5°C/min as described previously [60]. 
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Ligation 
The ligation of a restriction enzyme digested DNA fragment with a vector backbone can be 
introduced by the formation of phosphodiester bonds between the 3’ hydroxy group and the 5’ 
phosphate group of both molecules. Ligation was enzymatically catalysed by T4 DNA Ligase 
and performed as described by Ran and colleagues [60]. 
3.2.1.2 E.coli culture and plating 
E.coli were cultivated in LB-medium. Depending on the antibiotic-resistance, encoded on the 
introduced plasmid, the LB-medium was supplemented with Ampicillin (100µg/ml), Kanamycin 
(50µg/ml), Chloramphenicol (30µg/ml) or Spectomycin (100µg/ml) for selection. E.coli were 
cultured in different volumes of LB-medium according to following experimental needs. 
3.2.1.3 Transformation and cryoconservation of E.coli 
For the uptake of pure DNA into E.coli, plasmid DNA constructs are transformed into the 
bacterium using a heat shock protocol. Thereby, competent bacteria are heated up to 42°C to 
permeabilise the cell wall which allows DNA to enter the cell. 
Transformation of DNA constructs into competent cells was performed using 50µl of library 
efficient DH5α and either 1µl of vector DNA (100ng/µl) or 5µl of ligation product. Incubation was 
performed for 1h on ice. Subsequently, cells were heat shocked for 45sec at 42°C before 
sample was cooled down on ice for 2min. After 250µl S.O.C. Medium was added, cells were 
incubated for 1h at 37°C under constant agitation for initial bacteria growth. For selection, 25-
100µl were spread on a pre-warmed LB-Agar plate containing the appropriate antibiotic. Plates 
were incubated overnight at 37°C. The next day, formed colonies were transferred to 5ml LB-
medium supplemented with the appropriate antibiotic and cultured for at least 5h. For 
cryoconservation of bacteria at -80°C, 500µl of bacteria suspension were mixed with 500µl 
sterile 80% glycerol. To cultivate bacteria strains again, a small amount of the frozen 
cryoconservation stock was transferred to LB-medium using an inoculation loop. To initiate 
growth, cells were cultured overnight at 37°C under constant agitation. For the purification of 
plasmid DNA, remaining bacterial culture was used.  
3.2.1.4 DNA isolation from E.coli 
To purify plasmid DNA from bacterial cultures, different kits were used. Depending on the 
culture volume, the GeneJetTM Plasmid Miniprep (for 5ml culture), PureYield Plasmid Midiprep 
(for 100ml culture) or EndoFree Plasmid Maxi Kit (for 100ml culture) was used according to the 
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manufacturer’s instructions. To determine the DNA concentration, the absorbance at 260nm 
and 280nm was measured using a UV/VIS photometer and calculated the following way: 
 
Additionally, calculation of the ratio of OD260/OD280 can be used to determine the purity of the 
plasmid DNA. Highly pure DNA preparations have ratios of 1.8 or higher. 
3.2.1.5 Polymerase chain reaction - PCR 
Polymerase chain reaction (PCR) is a fast and effective way for the in vitro amplification of DNA 
fragments. This reaction is divided into three steps (Denaturation, Annealing and Elongation) 
which are repeated for several cycles (30-35). At the very beginning, an initial denaturation of 
the dsDNA into ssDNA is performed for 2min at 96°C. Subsequently, every amplification cycle 
starts with a denaturation for 30sec at 98°C, followed by the binding of oligonucleotide primers 
to their complementary sequence, each on one strand, at a primer specific annealing 
temperature. The last step includes the DNA synthesis at 72°C. This elongation step is 
catalysed by a thermostable DNA polymerase (e.g. Phusion High-Fidelity DNA Polymerase or 
DreamTaq DNA Polymerase). After amplification cycles are completed, a final extension step is 
performed for 10min at 72°C. To terminate PCR, the temperature is decreased to 15°C. Based 
on different template length as well as primer melting temperatures, the following PCR program 
(see Table 9) is adjusted for every individual PCR. The elongation time is adjusted according to 
template length, whereas the annealing temperature is varied according to the melting 
temperature (Tm) of used primers. 
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Table 9: PCR program 
 
For the validation of Flp-In monoclonal lines using PCR, 60ng of genomic DNA was used and 
mixed with 1µl dNTP mix, 1.5µl MgCl2 (50mM), 2.5µl of both primers (10µM) and 0.5µl Phusion 
High-Fidelity DNA Polymerase (2U/µl) in a final volume of 50µl in 1x Phusion HF reaction buffer. 
To validate mutations generated using the CRISPR/Cas9 system, PCR was performed with 1µl 
of genomic DNA mixed with 0.2µl dNTPs (each 10mM), 0.3µl DreamTaq DNA Polymerase and 
1µl of each primer (10pM) in 1x GreenTaq Buffer with a total reaction volume of 20µl. Genomic 
DNA was extracted applying the peqGOLD Tissue DNA Mini Kit according to the manufacturer’s 
instructions. 
3.2.1.6 Cloning of plasmid expression vectors 
Cloning is a commonly used method to generate defined DNA constructs at the level of 
individual bacterial cells and to produce large amounts of plasmid DNA through cultivation of 
individual bacterial clones. 
Gateway cloning 
A high efficient and universal cloning method is the so called Gateway cloning, commercialized 
by Invitrogen. This approach is based on site specific recombination at defined sequences 
derived from the attachment (att) sites of bacteriophage lambda [61]. A big advantage of 
Gateway cloning in comparison to classical cloning is the opportunity to enable cloning at sites 
where no suitable restriction enzymes are available. Additionally, this method allows a simplified 
transfer of cDNA inserts between a variety of destination vectors for different purposes. After 
recombination of an attB-flanked PCR product with an attP-donor vector (BP-reaction), an attL-
including entry clone as well as an attR-containing by-product is formed. This reaction is 
catalysed by the BP ClonaseTM enzyme mix containing bacteriophage λ integrase and E.coli 
integration host factor. The reaction product is transformed into competent bacteria and 
selection is performed taking advantage of the kanamycin resistance of the created entry 
50  Material and Methods 
 
clones. The recombination of the attL sites of the entry vector with the attR site of the 
destination vector (LR reaction) is mediated by LR ClonaseTM enzyme mix (bacteriophage λ 
integrase, excisionase and E.coli integration host factor) and results in an attB site carrying 
expression clone and attP1 site containing by-product. The reaction is transformed into 
competent bacteria and clones selected with ampicillin. 
The gene of interest (GOI) was first generated performing PCR (see 3.2.1.5). To link attB sites 
to selected PCR fragments, another PCR was performed using attB primers (listed in Table 2). 
Thereafter, the BP-reaction was performed, incubating 3µl of attB-comprising PCR product with 
1µl of pDONOR vector (90ng/µl) and 1µl BP-clonase II mix for 4h at 25°C. 0.5µl proteinase K 
was added to terminate the reaction by incubating the mixture for 10min at 37°C. After 
transformation and kanamycin selection, plasmid DNA was isolated. For the LR-reaction, 1µl of 
DNA (100ng/µl) was incubated with 1µl pDEST vector (100ng/µl), supplemented with 2µl 
Miniprep elution buffer and 1µl LR-clonase II mix for 4h at 25°C. The LR-reaction was 
terminated adding 0.5µl proteinase K for 10min at 37°C. Thereafter, the complete LR-reaction 
product was transformed into E.coli followed by selection on ampicillin-containing plates. 
Cloning sgRNA into a vector backbone 
The CRISPR/Cas9 gene editing system (described in 3.2.2.6) relies on a target-specific single-
guided RNA (sgRNA) that together with the Cas9 protein forms a ribonucleoprotein complex 
capable to introduce a double-strand break into DNA at a defined sequence. The plasmid-borne 
CRISPR/Cas9 system used in this study requires an insertion of the template for the sgRNA 
into the parental plasmid vector. A fast and easy cloning procedure which combines DNA 
restriction and ligation was used for this purpose [60]. 
The annealing product (see 3.2.1.1) was diluted 1:200 in ddH2O and incubated with 100ng of 
the vector, 0.5µl T4 DNA Ligase, 1µl DTT (10mM), 1µl ATP (10mM) and 1µl FastDigest 
BbsI/BpiI in 20µl 1x DNA Ligase reaction buffer for 1h in a thermocycler with the following cycle: 
5min at 37°C followed by 5min at 21°C. To digest any residual linearized DNA, 1.1µl of ligation 
reaction was treated with 1µl PlasmidSafe exonuclease supplemented with 1.5µl ATP (10mM) 
in a total volume of 15µl of 1x PlasmidSafe buffer. 
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3.2.2 Mammalian cell culture 
3.2.2.1 Cryopreservation and thawing of cells 
To conserve mammalian cell stocks, cells of a confluent grown 10cm culture dish were washed 
with dPBS, detached with Trypsin/EDTA and dispersed in growth medium. After centrifugation 
for 3min at 500xg, the cell pellet was resuspended in 5ml cryo medium (see 3.1.5.2) and 
distributed into five cryopreservation tubes. A slow freezing protocol was performed to avoid 
intracellular freezing. First, the aliquots were incubated for 10min at 4°C followed by 2h at -20°C 
with further overnight incubation at -80°C. For long-term storage, cell stocks were transferred to 
liquid nitrogen.  
Frozen cell stocks were rapidly defrosted in a water bath at 37°C. To prevent DMSO-mediated 
cytotoxicity, cells were quickly resuspended in prewarmed growth medium and seeded in 
culture dishes. The following day, when cells have already adhered to the plate, growth medium 
was exchanged to remove remaining cryo medium and cell debris. 
3.2.2.2 Maintenance and growth of cells 
HEK293T cells and hTERT-RPE1 cells were cultured in a humidified atmosphere containing 5% 
CO2. They were grown at 37°C in Dulbecco’s Eagle Medium supplemented with 0.5% Penicillin/ 
Streptomycin and 10% FBS until they reached, after 3-4 days, 100% cell confluence. 
Afterwards, confluent cells were washed with 5ml prewarmed dPBS, detached by incubation 
with 2ml Trypsin/EDTA for 1-3min at RT and resuspended in prewarmed growth medium. To 
maintain cells in culture, they were regularly split on new culture dishes in a ratio of 1:10 (or 1:5 
for SILAC-labelled cells). 
Newly generated Flp-In monoclonal lines as well as manipulated Flp-In monoclonal lines were 
cultivated in Flp-In Selection Medium (see 3.1.5.2) in a humidified atmosphere containing 5% 
CO2. After 3-4 days, cells were washed with 5ml prewarmed dPBS and detached by incubation 
for 1-3min with 2ml Trypsin/EDTA solution. Afterwards, cells were resuspended in prewarmed 
Flp-In Selection Medium and plated on new dishes in a ratio of 1:5 (or 1:3 for SILAC-labelled 
cells). 
3.2.2.3 Stable isotope labelling of amino acids in cell culture - SILAC 
Stable isotope labelling of amino acids in cell culture (SILAC) is a common approach for 
metabolic labelling of mammalian cell lines. This approach is well-established for quantitative 
mass spectrometry and is based on the incorporation of stable isotopically labelled amino acids 
into the proteome of the cell. As shown in Figure 7, this method can be used to pool samples of 
different labels to compare the proteome of different cell conditions. For a SILAC approach, 
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growing cells are crucial and at least five cell cycles are required for a complete incorporation. A 
complete incorporation of isotopically labelled and essential (semi-essential) amino acids results 
in a defined mass shift as depicted in Figure 7. Typically, lysine and arginine are used as 
labelled amino acids resulting in at least one incorporated isotopically labelled amino acid at the 
end of each tryptic peptide [41]. 
For SILAC labelling, cells were cultured in SILAC DMEM supplemented with heavy isotope-
substituted lysine and arginine (see 3.1.5.2). Introduction of ‘heavy’ lysine results in a mass shift 
of 8Da compared to the light amino acid, whereas the chosen ‘heavy’ arginine leads to a 
specific mass shift of 10Da. To avoid arginine to proline conversion, 2mM proline was added to 
the medium [62, 63]. 
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Figure 7: Stable isotope labelling of amino acids in cell culture (SILAC)  
For metabolic labell ing of amino acids in cell culture, mammalian cells are cultured in 
SILAC medium containing isotopically labelled lysine and arginine. To ensure a complete 
incorporation of both labelled amino acids, at least f ive cell cycles are necessary. 
Combining cells with two different labels enables the quantitative comparison of two 
condit ions based on the introduced and def ined mass shift which can be distinguished 
using mass spectrometry. E.g. the mass shift of 8Da is based on the incorporat ion of one 
‘heavy’- labelled lysine in the analysed tryptic peptide. 
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3.2.2.4 Transfection of mammalian cell lines 
Transfection of mammalian cell lines is a powerful analytical method to study protein function, 
generating genetically modified cells by the introduction of foreign nucleic acids into the 
mammalian cells either in a transient or a stable way. In transiently transfected cells, a 
transgene is only expressed for a limited time period, whereas in stably transfected cells the 
transgene is integrated into the genome [64]. 
To enable transfection of mammalian cell lines, 50-80% confluency of cells was achieved by 
seeding the cells one day before transfection. For the amount of cells of one 14cm culture dish, 
8µg DNA was diluted in 1ml PEI transfection reagent (1mg/ml) (see 3.1.5.2). Complex formation 
of DNA and PEI was initiated by mixing and incubating the solution for 10min at RT. Afterwards, 
DNA-PEI mixture was added dropwise to the cells. After transient transfection, cells were 
cultured for another two days before they were harvested. 
3.2.2.5 Generation and maintenance of stable expression cell lines (Flp-In) 
Using the Flp-InTM system of Invitrogen for the generation of stably transfected cell lines allows 
the integration and expression of a gene of interest (GOI) at a specific genomic location. After 
introducing a Flp Recombination Target (FRT) site into the genome of the chosen mammalian 
cell line, the GOI, inserted in an expression vector, is integrated via Flp recombinase-mediated 
DNA recombination [65]. 
For the generation of isogenic stable cell lines using the Flp-InTM system, three different vectors 
were used. First, the pFRT/lacZeo target site vector was used to generate a Flp-InTM host cell 
line. In the FRT/lacZeo construct, the ATG initiation codon is followed by the FRT site which 
serves as binding and cleavage site for the recombinase (see Figure 8). To verify a successful 
integration of the pFRT/lacZeo plasmid, mammalian cells are selected for zeocin resistance and 
expression of lacZ can be assayed by western blot followed by immunostaining. To integrate 
the gene of interest into the parental Flp-InTM host cell line, the chosen GOI has to be cloned 
into a pcDNA5/FRT expression vector. This vector additionally contains a hygromycin 
resistance gene with an implemented FRT site. After cotransfection of this expression vector 
and pOG44, which expresses the Flp recombinase, a homologous recombination between the 
FRT sites takes place. This leads to a Flp-InTM expressions cell line which can be selected for 
hygromycin resistance, zeocin sensitivity or lack of β-galactosidase activity. An inserted human 
CMV promoter is responsible to control and drive the expression of the GOI. 
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Figure 8: Generation of stable cell lines using the Flp-In system 
First, mammalian cel l lines were transfected with a FRT/lacZ-Zeocin target site vector to 
generate the Flp-In host cell l ine which is characterized by zeocin resistance. To introduce 
the gene of interest into the genome of the generated Flp-In host cell line, co-transfect ion 
with pOG44 (recombinase) and pc/DNA5/FRT/GOI was performed. Generated Flp-In 
expression cell l ines are characterized by zeocin sensit ivity, hygromycin B resistance as 
well as by the lack of β-galactosidase expression.  
Flp-In 293 host cells were transfected in 10cm culture dishes using 0.8µg of either 
pcDNA5/FRT/(N)-SF-IFT122, pcDNA5/FRT/(N)-SF-TULP3 or pcDNA5/FRT/(N)-SF-LCA5 and 
7.2µg of pOG44 (FLP recombinase) by means of lipofection (lipofectamin2000) according to 
manufacturing recommendation. Control transfections were done with 0.8µg of expression 
vector but without pOG44. Medium was changed after 24h post transfection. After two days, 
cells were split in a ratio of 1:4 on 10cm dishes using growth medium supplemented with 
100µg/ml hygromycin for selecting only cells carrying the plasmid which contains the 
hygromycin resistance gene. Two weeks later, single clones were picked. Each clone was 
transferred to one well of a 24-well plate containing 1ml growth medium supplemented with 
100µg/ml hygromycin. Cells were expanded stepwise to 6-wells and 10cm culture dishes. 
Stable expression level of the transgene was tested by western blot analysis (see 3.2.3.4). 
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3.2.2.6 Gene editing using the CRISPR/Cas9 system 
A new technology for gene editing is the innovative CRISPR/Cas9 system. This technique uses 
a targeted nuclease which facilitates genome alterations at a defined site. 
 
Figure 9: Gene editing using the CRISPR/Cas9 system  
Specif ic sgRNA, containing a 20-nucleot ide guide sequence, targets the nuclease Cas9 
(NUC) to a specif ic DNA sequence. After the guide sequence has paired with the DNA 
target, Cas9 generates a double-stranded break 3bp upstream of the protospacer adjacent 
motif (PAM). After a nuclease-induced double-stranded break occurs, two types of DNA 
damage repair mechanisms can follow: The error-prone non-homologous end joining 
(NHEJ) or the high-f idelity homology-directed repair (HDR) pathway. In the NHEJ pathway, 
DNA repair is processed and re-joined by endogenous DNA repair machinery. This method 
can lead to random mutat ions which can result for example in gene knockout. To achieve 
a precise edit ing of the genomic DNA, a repair template (plasmid or ssODN) can be 
supplied to induce HDR. 
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In this system, Cas9 nuclease is guided by a short RNA molecule (sgRNA) to generate a 
precise double-stranded break at a target DNA locus. As shown in Figure 9, DNA damage 
repair can occur through two different pathways: First, error-prone non-homologous end joining 
(NHEJ) which leads to random mutations (e.g. knock-out, non-mediated decay) or second, high-
fidelity homology-directed repair (HDR) [60]. 
Flp-In cells expressing (N)-SF-TAP-tagged TULP3 (see 3.2.2.5) were transfected with an 
bicistronic vector expressing a specifically designed sgRNA sequence as well as Cas9 alone or 
together with an additional HDR construct. As a control, an additional transfection was done 
with the ‘empty’ vector (Cas9 gene only). For transfection, 500ng DNA was mixed with 66µl PEI 
and added dropwise to the cells. After 48h, selection was initiated adding DMEM supplemented 
with 8µg/ml Puromycin and cells were cultivated for additional 48h. Subsequently, cells were 
grown for some days in DMEM and transferred to 10cm culture dishes as well as seeded at 
very-low density (1:400) into a 14cm culture dish for single-clone selection. For single-clone 
selection, cells were washed and trypsinated using 20ml trypsin-solution (1:20 in PBS). After 
some minutes, cells started to detach and could be soaked and transferred to 24-well plates. 
Some weeks later, single clones were characterized by PCR. 
3.2.3 Protein chemistry 
3.2.3.1 Protein extraction 
To extract proteins from a 14cm dish of cultured cells, growth medium was removed and cells 
were washed with dPBS. Plates were placed on ice and 1ml lysis buffer (see 3.1.5.6) was 
added. Cells were detached using a cell scraper and the suspension was transferred to reaction 
tubes followed by incubation for 20-30min at 4°C under constant agitation. To separate cell 
debris from clear protein extract, lysates were centrifuged at 10,000xg for 10min at 4°C. The 
supernatant, containing the clear protein extracts, was transferred to fresh tubes. Protein 
concentration was determined using a Bradford assay (for more detail see below in 3.2.3.2) and 
lysates stored at -80°C for long-term storage or directly used for further experiments. 
3.2.3.2 Quantification of protein concentration 
The total amount of protein was determined using a Bradford assay. This colorimetric assay is 
based on an absorbance shift of the dye Coomassie brilliant blue G250. The absorbance 
maximum of the pure dye is at 465nm. After complex formation with proteins, this maximum is 
shifted to 595nm [44]. In this work, the commercial Bio-Rad protein assay kit was used. The 
Dye Reagent Concentrate was diluted 1:5 with ddH2O and 1ml of the diluted reagent was added 
to an appropriate amount of protein sample. For determination, a standard curve with known 
concentrations of BSA was generated. Therefore, standards of 2-8µg BSA were prepared, 
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diluted in the corresponding cell lysis buffer and the absorption was subsequently measured at 
595nm using the diluted dye as reference. 
3.2.3.3 SDS-PAGE 
SDS-PAGE is a widely used technique to separate proteins according to their molecular weight. 
SDS represents an anionic detergent which binds with a ratio of 1.4g SDS per gram protein. As 
a result, the intrinsic charge of the protein is effectively masked by the negative charge of the 
detergent. Due to this nearly constant charge-to-mass ratio of the SDS-protein complexes these 
complexes can be separated according to their molecular masses by electrophoreses in a SDS-
containing polyacrylamide gel. In the SDS-PAGE approach, small proteins are moving faster 
and farther through the gel than larger molecules. 
Gels were casted using the Mini-Protein 3 system chambers with 0.75mm spacers. Solutions for 
the stacking as well as the separation gel were prepared as given in 3.1.5.4. The separation gel 
solution was filled between the glass plates first and covered immediately with isopropanol. 
Polymerisation of acrylamide/bisacrylamide is initiated by ammonium persulfate (APS) and 
catalysed by N,N,N’,N’-tetramethylethylenediamine (TEMED). After 30min, isopropanol was 
removed and stacking gel solution was casted on top. For sample separation, a comb with the 
desired well number was inserted before polymerization. Gels were placed into gel chambers, 
filled with running buffer and combs were removed. Defined protein amount (5-10µg) was mixed 
with 5x Laemmli buffer (see 3.1.5.4) and denatured for 2min at 96°C and cooled down. The 
sample as well as 7µl of a size standard (PageRuler 170kDa/ 250kDa) was loaded on the 
stacking gel. Electrophoresis was initiated by applying 80V until all proteins entered the 
separation gel. After that, voltage was increased to 120V and separation was performed until 
the bromophenol blue dye reached the bottom of the separation gel. For subsequent staining, 
proteins were fixed using EtOH/HAc/ddH2O mixtures. 
Coomassie Staining of SDS-gels 
As far as sufficient amounts of protein (200-400ng per lane) are used, Coomassie staining is the 
method of choice because it is simple and cheap. Nevertheless, the time-consuming destaining 
of Coomassie stained gels is a big disadvantage [44]. 
After fixation of the proteins by incubating the gel three times for 10min in Fixer-Solution, 
staining was performed for less than 10min in Coomassie solution (see 3.1.5.4). To lower down 
background staining, the gel was washed for three times with Fixer-Solution for 10min each.  
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Silver staining of SDS-gels 
Silver staining enables the detection of low amounts of protein (1-10ng per lane) [44]. Thereby, 
Ag+-ions are forming complexes with Glu, Asp and Cys-residues which, after incubation with 
alkaline formaldehyde, are reduced to elementary Ag [44]. 
For silver staining of proteins, SDS-PAGE gels were fixed two times using Fixer-Solution for 
30min each. Subsequently, gels were transferred to 50% EtOH and incubated two times for 
20min followed by some minutes in Na2S2O3-Solution. After briefly washing the gel two times in 
ddH2O, the gels were incubated for 20min in AgNO3-Solution. Gels were washed again in 
ddH2O before proceeding to the developing step (2-5min incubation in Developer-Solution). To 
stop the reaction, Coomassie-Fixer was added and the gel fixed for 10min under constant 
agitation. For long-term storage and preservation, gels were finally incubated two times for 
10min in Preserver-Solution. Recipes of all buffers and solutions are listed in 3.1.5.5. 
3.2.3.4 Western blot analysis and immunostaining 
To immobilize proteins after SDS-PAGE separation, they can be transferred to nitrocellulose or 
polyvinylidene fluoride (PVDF) membranes. Subsequently, antibodies can be used to bind 
appropriate antigens immobilized on the membrane and enable the detection through enzymatic 
activities coupled to the primary or the secondary antibody [66]. 
After SDS-PAGE, proteins were immobilized onto PVDF membranes using tank blotting. First, 
the black side of the holder cassette was covered with one soaked (in western buffer, see 
3.1.5.4) sponge followed by two soaked whatman papers. Subsequently, the SDS-
polyacrylamide gel was placed on top of the two whatman papers. The PVDF membrane was 
activated for at least 30sec in methanol before it was placed on the gel. Two additional soaked 
whatman papers, followed by one soaked sponge, were put on top. To remove air bubbles, a 
blot roller was used in between every step. After closing and placing the cassette into the 
blotting chamber, the chamber was filled with western buffer. Western blotting was performed at 
90V for 90min at 4°C. To visualize immobilization of proteins on the PVDF membrane, proteins 
can be stained using Ponceau-Solution (see 3.1.5.4) and destained again by incubation for 
10min in TBST. After blocking the membrane for at least 30min using Blocking solution 
(3.1.5.4), membrane was incubated either over night with a protein specific primary antibody or 
for 1.5h with a HRP-coupled primary antibody recognizing the FLAG-epitope. Afterwards, the 
membrane was washed three times with TBST. Once a protein specific primary antibody was 
used, the blot was further incubated for 1h with a HRP-coupled secondary antibody which 
recognises the specific Fc portion of the primary antibody. Before the detection was carried out 
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using ECL or ECLplus system according to the manufacturer’s instructions, the membrane was 
washed again for three times with TBST. The ECL and ECLplus systems are based on 
chemiluminescence which is generated by the reaction of horseradish peroxidase (HRP) with 
luminol, present in ECL reagent, and was detected on light-sensitive films (hyperfilm, GE 
Healthcare). 
3.2.4 Analysis of protein-protein interactions 
3.2.4.1 Tandem Affinity Purification (TAP) 
To study protein interactions, Strep FLAG tandem affinity purification (SF-TAP) is a common 
and well described method [67]. Overexpressed proteins are fused to a SF-TAP tag with a 
molecular weight of 4.6kDa. As shown in Figure 10, this SF-TAP tag consists of a Strep-tag II 
as well as a FLAG tag. While the N-terminal SF-TAP tag starts with FLAG tag followed by two 
StrepII tags, the C-terminal (C)-SF-TAP tag starts with the tandem StrepII tag followed by the 
FLAG tag fused to the C-terminus of the POI [68]. 
 
Figure 10: Protein sequence of (N)/(C)-SF-TAP tag  
For tandem affinity purif ication (TAP), so called Strep-FLAG tags are fused to the protein 
of interest (POI) by means of fusion the open reading frame of the POI with the nucleot ide 
sequence encoding the SF-TAP tag. Through these tags the molecular weight of the fusion 
protein increases by 4.6kDa. The structure of the N-terminal SF-TAP tag starts with FLAG 
tag followed by two StrepII tags, whereas the (C)-SF-TAP tag starts with the tandem 
StrepII tag fol lowed by the FLAG tag fused to the C-terminus of the POI. 
For affinity purification of proteins using the Strep-tag II, Strep Tactin sepharose beads can be 
used and the bound proteins can be eluted with D-Desthiobiotin. In contrast, FLAG-tagged 
proteins bind to anti-FLAG-M2 agarose and elution can be done using FLAG peptide (see 
Figure 11). 
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Figure 11: Tandem Affinity Purification (SF-TAP) 
To purify protein complexes of interest and to study protein-protein interactions, tandem 
affinity purif ication (TAP) can be performed. Thereby, overexpressed proteins that are 
fused to a Strep-FLAG TAP tag either on the N-terminus or the C-terminus of the protein 
of interest (POI) and their interaction partners can be purif ied. In the TAP approach two 
purif ication steps are performed sequentially. First, Strep-Tactin sepharose beads are 
used to purify the POI (1). After washing and elut ing bound proteins using D-Desthiobiotin 
(2) a second purif ication step is performed using FLAG-M2-agarose beads (3), recognizing 
the FLAG tag of the POI. To elute bound proteins, a FLAG peptide with a higher aff inity to 
the FLAG tag is added to the reaction (4). 
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Cell lysates were incubated with a corresponding volume of packed Strep-Tactin sepharose 
beads (25µl pure beads per 14cm culture dish) for 1.5h at 4°C on an end-over-end shaker. 
Before use, Strep-Tactin sepharose beads were washed once using 500µl Lysis Buffer followed 
by two washing steps using 500µl Washing Buffer, each. Subsequently, beads were centrifuged 
for 30sec with 5,000xg at 4°C and two thirds of the supernatant were discarded before beads 
were transferred to 1.5ml reaction tubes comprising the cell lysates. After the incubation step, 
beads and bound proteins were transferred to microspin columns and washed three times using 
500µl Washing Buffer (see 3.1.5.6) by pushing through all remaining liquid. To elute bound 
proteins, spin columns were closed with a plug. 100µl Strep-Elution Buffer per cells of one 14cm 
culture dish were added to the beads (still remaining in the microspin columns) and incubation 
was done for 10min at 4°C. During this elution step, beads were manually mixed every two 
minutes. For elution of bound proteins, the plug of the spin columns was removed and columns 
were transferred to fresh 2.0ml reaction tubes before centrifugation was performed for 1min at 
1,000xg at 4°C. Afterwards, a corresponding volume (12.5µl pure beads per 14cm culture dish) 
of washed anti-FLAG-M2-agarose beads (washing procedure similar to Strep-Tactin sepharose 
beads described above) was transferred to Strep-Tactin eluates and incubated for 1.5h at 4°C 
on a shaker. Then, beads were washed for three times using 500µl Washing Buffer and bound 
proteins were eluted by incubating the FLAG-M2-agarose beads with 200µl Flag peptide for 
10min at 4°C followed with constant agitation followed by centrifugation at 1,000xg for 1min at 
4°C. 
3.2.4.2 One-step FLAG affinity purification 
This one-step affinity purification protocol using anti-FLAG-M2-agarose beads (which is also a 
part of the SF-TAP approach described in 3.2.4.1) was published previously by our group [69]. 
This approach is based on the pulldown of proteins tagged with a FLAG-tag using anti-FLAG-
M2 agarose followed by elution of the bound proteins using FLAG peptide.  
After protein extraction from cell cultures of two confluent 14cm culture dishes per sample, the 
cleared cell lysate was incubated with washed (see 3.2.4.1) anti-FLAG-M2-agarose beads 
(12.5µl pure beads per 14cm dish) for 2h at 4°C on a shaker. Beads were then centrifuged for 
1min at 5,000xg, transferred to micro spin columns and washed three times with 500µl Washing 
Buffer each. To elute bound proteins, spin columns were closed and beads were incubated 
using 200µl FLAG peptide per sample for 10min at 4°C. After centrifugation (1,000xg, 1min, 
4°C), eluates were used for protein precipitation (described in 3.2.4.3) followed by an in-solution 
digestion (see 3.2.4.4) and targeted mass spectrometry (described in chapter 3.2.6.2). 
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3.2.4.3 Methanol-chloroform precipitation 
To precipitate purified proteins, a methanol-chloroform precipitation was performed according to 
a protocol developed by Wessel and Flugge in 1984 [70]. This method allows an efficient 
protein precipitation even in presence of detergents and salts. For this approach, the ratio of 
methanol (MeOH), chloroform (CHCl3) and water (H2O) is crucial. 
In this work 200µl volumes of protein containing solution were used for protein precipitation. 
Thereby, 800µl MeOH were added to 200µl aqueous sample and mixed by vortexing. After 
centrifugation at 9,000xg for 30sec at RT, 200µl CHCl3 were added and the solution was 
vortexed and centrifuged again. Subsequently, the solution was mixed with 600µl HPLC H2O, 
vortexed and centrifuged at 16,000xg for 1min to collect precipitated proteins in the interphase. 
The upper phase was discarded. After the addition of 600µl MeOH and vortexing, proteins were 
pelleted via centrifugation for 2min at 16,000xg at RT. Protein pellet was dried for further 
sample preparation. 
3.2.4.4 In-solution tryptic proteolysis 
To perform mass spectrometric-based proteomics, small peptides instead of large proteins are 
necessary. Therefore, enzymatic digestion of precipitated proteins was carried out as described 
previously [69]. A commonly used enzyme for proteolysis is trypsin which is a pancreatic serine 
protease that hydrolyses peptide bonds at the carboxyl group of arginine and lysine except for 
the presence of a proline residue linked to this very carboxyl group. Prior to the tryptic digestion, 
samples are treated with dithiotreitol (DTT) to cleave disulfide bridges of cysteine-containing 
peptides and resulting cysteine residues are alkylated by 2-iodacetamide (IAA). 
Precipitated proteins (10-20µg) were dissolved in 30µl 50mM ammonium bicarbonate (ABC) 
and 4µl RapiGest, a surfactant that improves solubility of the precipitated proteins, by vortexing 
harshly. Subsequently, 1µl DTT (100mM) was added and the solution was mixed and incubated 
for 10min under constant agitation at 60°C. After the sample was cooled down, 1µl IAA 
(300mM) was added and incubation was carried out for 30min at RT in complete darkness. For 
enzymatic digestion of proteins, 2µl trypsin solution (1µg/µl in 1mM HCl) was added and 
proteins were digested overnight at 37°C. The day after, enzymatic cleavage was stopped by 
adding 1.7µl TFA (100%). The whole solution was transferred to polypropylene inserts and 
incubated for 10min at RT. To obtain a clear peptide solution, centrifugation was performed for 
15min at 16,000xg and the supernatant was used for further experiments. 
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3.2.4.5 Desalting via stop-and-go extraction tips 
To prepare peptide mixtures for mass spectrometry analysis, it is necessary to remove 
interfering agents like detergents and salts. For this step, stop-and-go extraction tips 
(StageTips) can be used according to the protocol reported by Rappsilber and colleagues [71]. 
These tips are filled with C18 matrix with a binding capacity of 10µg of peptides. While peptides 
adsorb to the C18 material, salts and detergents pass through. For the elution of bound 
peptides, organic solvents can be used. 
StageTips were equilibrated with 20µl 80/5 solution (80% ACN, 5% TFA) followed by a washing 
step with 20µl 0/5 solution (5% TFA). After loading the acidified sample onto the C18 material, 
the tip was washed again with 20µl 0/5 solution. Peptides were eluted using two sequential 
elution steps. First, with 20µl 50/5 solution (50% ACN, 5% TFA) followed by 20µl 80/5 solution. 
To remove organic solvents and to concentrate purified peptides, the sample was evaporated to 
2-5µl using a vacuum centrifuge. Prior to LC-MS/MS analysis, sample was filled up to 15µl 
using 0.5% TFA. 
3.2.4.6 In-gel digestion of silver stained proteins 
In-gel tryptic proteolysis was performed to prefractionate samples before LC-MS/MS analysis as 
described before [69]. 
After silver staining of SDS-PAGE-separated proteins (3.1.5.4), stained protein bands were cut 
out and sliced into 2-4 small pieces. Pieces were transferred to a 96 well plate and wells filled 
with HPLC H2O. To destain gel pieces, 100µl of a 1:1 ratio of potassium hexacyanoferrat II 
(30mM) and sodium thiosulfate (100mM) were added to each well and incubation was 
performed for 5min at RT on a shaker. The destaining solution was discarded and each well 
was washed three times for a few seconds with 100µl HPLC H2O to remove remaining 
destaining solution. For enzymatic digestion of proteins, gel pieces were incubated with 100µl 
DTT (5mM) per well for 30min at 60°C under agitation before solution was discarded. Then 
100µl IAA (25mM) were added. After incubation for 45min at RT in darkness, IAA solution was 
removed and gel slices were washed for 5min using 100µl ACN (40%) per well. This step was 
repeated once and subsequently 100µl ACN (100%) were added for 2min. After gel slices were 
dried under laminar flow, 40µl trypsin solution (0.01µg/µl in 50mM ABC) were added to each 
well and tryptic cleavage was performed overnight at 37°C. The next day, enzymatic cleavage 
was quenched by adding 10µl TFA solution (2.5%) for 15min. The supernatant was transferred 
to reaction tubes. Gel slices were further incubated for 15min with 80µl 50/0.5 solution (50% 
ACN, 0.5% TFA) and the supernatant was added to the supernatant of the previous step. After 
adding 80µl 100/0.5 solution (100ACN, 0.5% TFA) to the gel pieces for additional 15min, the 
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supernatant was added to the pooled sample. To remove organic solvent, the volume of the 
samples were reduced to 2-5µl using a vacuum centrifuge. For LC-MS/MS analysis, samples 
were resuspended in 0.5% TFA and filled up to a total volume of 15µl. Afterwards, half of the 
sample was injected per MS run. 
3.2.5 Stoichiometric and structural investigations of IFT-A 
3.2.5.1 Absolute quantification of purified IFT-A 
In disease state, protein complexes may change their composition as well as the ratio of the 
components within the protein complex. To understand the underlying mechanism of diseases, 
alterations in protein complex stoichiometry must be taken into consideration. To properly 
address these alterations, relative quantification of proteins and protein complexes is 
insufficient. In contrast, absolute quantification enables the determination of the absolute 
amount of a protein of interest in a complex sample instead of comparing different protein 
amounts in different samples or under different conditions. Performing absolute quantification is 
more demanding than relative quantification in both the sample preparation and in the data 
analysis. To achieve an accurate quantification, which is necessary for applications like 
stoichiometry determination or absolute quantification a targeted mass spectrometry approach 
is highly beneficial (for more detail see 3.2.6.2). Therefore, the combination of an internal 
standard mixture with targeted mass spectrometry is the chosen method for the absolute 
quantification of the ciliopathy-related protein complex IFT-A. No matter what type of targeted 
mass spectrometry technique is used, it always starts with the selection of a target protein set 
based on the objective. Tryptic digestion of the chosen target proteins leads to multiple 
peptides. At least two representative peptides per protein are chosen to generate reliable data 
for the absolute quantification [72]. A careful selection of representative peptides is essential: 
The peptides must be proteotypic, which means that they are specific for only one protein and 
ideally between 8-15 amino acid residues large. Additionally, it is useful to select peptides which 
are most likely being observed in further shotgun experiments analysed on the same mass 
spectrometer instrument. Peptides containing residues which are prone to modification like 
oxidation, deamidation or phoshporylation should also be avoided. To choose target proteins as 
well as precursor ions, a data-dependent shotgun analysis which is commonly performed in 
mass spectrometry based proteomic studies, is used [45]. Selected representative peptides are 
then synthesized and combined to create a standard mix of known peptide concentration. After 
spiking in a known amount of the standard mix into an isotopically coded biological sample 
containing the purified protein complex of interest, targeted mass spectrometry is performed to 
quantify each of the chosen peptides as shown in Figure 12. Calculating the ratio of analysed 
peak-areas of isotopically coded and non-coded peptide leads to the absolute amount of each 
66  Material and Methods 
 
peptide in the biological sample. Hence, the stoichiometry of the protein complex of interest can 
be determined by normalising the ratios to the least abundant protein, which is set to 1. 
 
Figure 12: Workflow for absolute quantification 
To calculate the absolute amount of a protein complex, mammalian cell l ines were 
cultivated in SILAC media to introduce an isotopic label. After aff inity purif ication of the 
protein complex of interest and further tryptic digestion, a known amount of non-coded 
synthetic peptides was spiked into the biological sample. Af ter targeted mass 
spectrometry analysis, the ratio of ‘l ight’ to ‘heavy’ peptide was calculated and then used 
to determine the absolute amounts of the selected proteins and the stoichiometry of the 
protein complex of interest.  
Generating the standard peptide mix 
For the absolute quantification of IFT-A, an internal standard mixture containing at least three 
proteotypic peptides for each of the six complex components was generated. These peptides 
need to be specific for the given protein (proteotypic), they should not contain amino acids 
which are prone to post-translational modification and they need to be identifiable by mass 
spectrometry. To see which peptides are feasible to mass spectrometry analysis, shotgun 
experiments of affinity purified IFT-A were performed as described in 3.2.6.1 (for sample 
preparation see 3.2.4.2). The obtained peptides were evaluated with respect to their specificity 
as well as to their amino acid composition. 
Equimolar peptide mix 
To generate an internal standard mix for the use of absolute quantification, it is necessary that 
the absolute amount of each peptide within the mix is known. Since the determination of peptide 
amount using amino acids analysis is quite expensive, a standard mix was generated applying 
the economic “Equimolarity through Equalizer Peptide” protocol which was published by 
Holzmann et al. [59]. 
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Figure 13: Generating equimolar standard mixture performing EtEP 
To generate an equimolar mixture of standard peptides, the economic “Equimolarity 
through Equalizer Peptide” (EtEP) was used. Selected proteotypic peptides were 
synthesized containing an “Equalizer Peptide” (EP) sequence (FYYR) at the N-terminus. 
Addit ionally,  the sole EP was also ordered in an isotopically coded manner (FYYR*) and 
its amount was analysed via amino acid analysis. Due to the introduced and artif ic ial 
trypt ic cleavage site, enzymatic digestion using trypsin leads to a release of equimolar 
amounts of the EP and of the corresponding standard peptide. A known amount of the 
isotopically coded EP was spiked into each peptide solut ion. Afterwards, the rat io of 
labelled to unlabelled EP was used to quantify the absolute amount of each representative 
peptide. Finally, a standard mixture comprising equimolar amounts of each peptide was 
generated. 
As shown in Figure 13, selected peptides were ordered containing an “Equalizer Peptide 
Sequence” (FYYR-) at the N-terminus of each peptide. Additionally, the sole “Equalizer Peptide” 
(EP) was ordered in an isotopically coded manner with a known absolute amount (determined 
via amino acid analysis). An artificial tryptic cleavage site was introduced between the 
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“Equalizer Peptide Sequence” (FYYR-) and the proteotypic peptide sequence. After tryptic 
proteolysis, this tryptic cleavage site leads to a release of an equimolar amount of the EP and 
the corresponding proteotypic peptide. Then, a known amount of the isotopically coded EP was 
spiked into each individual peptide solution. After targeted mass spectrometry was performed, 
the amount of each proteotypic peptide was determined by the ratio of isotopically labelled to 
unlabelled EP. This ratio was used to quantify the absolute amount of each proteotypic peptide 
in the corresponding stock solution. Finally, a standard mixture comprising equimolar amounts 
of each proteotypic peptide was generated. 
Adjusted peptide mix 
To avoid differences in the dynamic range of quantification upon targeted mass spectrometry, 
another standard mix containing adjusted amounts of standard peptides was generated. The 
amount of each peptide was adjusted to the amount of biological peptide present in the purified 
sample. Therefore, a known amount of synthetic peptides was spiked into a purified IFT-A 
sample (see 3.2.4.2). After targeted mass spectrometry followed by data analysis was 
performed, the ratio of isotopically coded to non-coded peptides was determined to adjust the 
amount of each peptide present in the adjusted standard mix. 
3.2.5.2 Chemical crosslinking of purified protein complex 
Chemical crosslinking of purified proteins is an effective method to study protein-protein 
interactions and to get structural information of a protein complex of interest. After tandem 
affinity purification (TAP) of IFT-A, the purified protein complex is chemically cross-linked using 
the bifunctional crosslinker disuccinimidyl suberate (DSS). This chemical crosslinker contains 
two lysine-reactive N-hydroxysuccinimide (NHS)-esters. To facilitate the following computational 
analysis (see 1.2.1.2) a 1:1 ratio of isotopically-coded and non-coded crosslinker is used. After 
tryptic digestion of cross-linked proteins, the complex sample is prefractionated either using size 
exclusion chromatography (SEC) as described in 3.2.5.3 or performing 3kDa Cut-Off spin 
column filtration (see 3.2.5.4). Only early eluting fractions of SEC or the retarded fraction of spin 
columns, containing large cross-linked peptides, are used for LC-MS/MS analysis. This 
workflow is shown in Figure 14. 
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Figure 14: Workflow of chemical crosslinking of purified IFT-A  
For chemical crosslinking, the purif ied protein or protein complex of interest was 
incubated with a defined amount of the chemical crosslinker disuccinimidyl suberate 
(DSS). After quenching the reaction, cross-linked proteins were precipitated using a 
general MeOH/CHCl3 protocol. Subsequently enzymatic cleavage was performed using 
trypsin. To enr ich cross-linked peptides, two different methods were used. Either peptides 
were fractionated performing size exclusion chromatography (SEC) on a FPLC or sample 
complexity was reduced using conventional 3kDa Cut-Off spin column. Fractions 
containing large, cross-linked molecules were used for further LC-MS/MS analysis. 
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Cells from six 14cm culture dishes were harvested and pooled for one analysis. Cells were 
washed with 5ml dPBS and proteins were extracted using 1ml amine-free Lysis Buffer (see 
3.1.5.7 ) per culture dish. In situ lysis was done for 30min at 4°C on an end-over-end shaker 
followed by centrifugation at 10,000xg for 10min to remove cell-debris. The supernatant, 
containing the cleared cell lysate, was first incubated with washed anti-FLAG-M2-agarose 
beads (12.5µl pure beads per 14cm culture dish) for 1.5h at 4°C under constant agitation. Then, 
beads were centrifuged for 1min at 5,000xg and transferred to micro spin columns. After 
washing the beads three times with Washing Buffer, the beads were incubated with 200µl 
amine-free FLAG-peptide for 10min at 4°C to elute bound proteins. The eluate was then 
incubated with washed Strep-Tactin sepharose beads (25µl pure beads per culture dish) for 
1.5h at 4°C under constant agitation. Afterwards, centrifugation and washing was performed as 
described before and beads were incubated with 4-fold bead volume of amine-free Strep-
Elution Buffer for 10min at 4°C and centrifuged for 1min at 1,000xg. To reduce sample volume, 
solutions were transferred to 30kDa Cut-Off spin columns and centrifuged for 13min at 
13,000xg at 4°C. The supernatant was collected and protein concentration was determined 
performing Bradford Assay (see 3.2.3.2).  
Purified protein complexes were chemically cross-linked using a defined amount of 
disuccinimidyl suberate (DSS) (either 5-, 25-, 40-, 50- or 90-fold excess of protein to chemical 
crosslinker) under constant agitation for 1h at RT. The reaction was quenched through the 
addition of Tris/HCl pH 7.5 to a final concentration of 100mM. Cross-linked proteins were 
precipitated using MeOH/CHCl3 protocol (see 3.2.4.2) and in-solution digestion using trypsin 
was performed as described in 3.2.4.4. To prefractionate cross-linked peptides, either size 
exclusion chromatography (SEC) as described in see 3.2.5.3 or 3kDa CutOff spin column 
filtration was performed (see 3.2.5.4) to reduce sample complexity. After LC-MS/MS analysis, 
the free-available software pipeline xQuest/xProphet was used for data processing. To visualize 
identified crosslinks afterwards, the free available software tool Xinet was applied. Thereby, a 
csv-file extracted from the data file generated by xQuest/xProphet and containing protein ID as 
well as the crosslinking position within the linked peptides is uploaded. Additionally, a fasta 
sequence containing each of the proteins of interest has to be uploaded. To annotate known 
domains within the proteins, described domain localisations within a protein can be uploaded 
using an additional csv file. 
3.2.5.3 Size exclusion chromatography of chemically cross-linked peptides 
Size exclusion chromatography (SEC) is a well described method [51] for the prefractionation of 
a peptide mix after chemical crosslinking. Thereby, molecules are separated due to their 
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molecular size. While small peptides are retained in the pores of the column material, larger 
molecules can pass and elute in the early fractions.  
Cross-linked peptides were resuspended in 12µl SEC Buffer (30%ACN, 0.1%TFA) and 
separated using a Superdex Peptide PC 3.2/30’’ column at a flow-rate of 50µl/min on an Ettan 
FPLC. Fractions of 100µl were collected and UV traces were recorded at 214nm, 254nm and 
280nm. Only early eluting fractions, containing large cross-linked peptides, were used for further 
LC-MS/MS analysis and volumes were reduced using a vacuum centrifuge. For LC-MS/MS 
analysis samples were filled up to 7.5µl with 0.5% TFA and whole sample concentration was 
injected. 
3.2.5.4 Prefractionation using 3kDa CutOff spin column filtration 
To simplify the prefractionation of chemically cross-linked peptides, 3kDa Cut-Off spin columns 
were used to reduce the sample complexity. The cross-linked peptide mix was filled up to 100µl 
using ABC solution (50mM) and transferred to spin columns. Centrifugation was performed 
twice at 4°C: first at 10,000xg for 40min followed by 10min at 13,000xg. The volume of retained 
sample was reduced using a vacuum centrifuge. For LC-MS/MS analysis, 0.5% TFA was added 
to a volume of 7.5µl to the sample and whole sample was injected as one shot. 
3.2.6 LC-MS/MS analysis 
LC-MS/MS analysis was performed on an Ultimate3000 nano-HPLC coupled by a nanospray 
ion source to either an OrbitrapVelos for interaction study, to a QExactive Plus for the absolute 
quantification approach or to an OrbitrapFusion mass spectrometer for the analysis of cross-
linked peptides. 
Peptide mixtures were injected and loaded onto a nano trap column (µ-Precolumn 300µm i.d. x 
5mm, packed with Acclaim PepMap100 C18, 5µm, 100Å; Dionex) at a flow rate of 30µl/min in 
98% buffer C (0.1% trifluoroacetic acid in HPLC-grade water) and 2% buffer B (80% acetonitrile 
(ACN), 0.08% formic acid (FA) in HPLC-grade water). After 3min, peptides were eluted and 
separated on an analytical column (75µm x 25cm, packed with Acclaim PepMap RSLC, 2µm, 
100Å; Dionex) at a flow rate of 300 nl/min by a linear gradient from 2% up to 30% of buffer B in 
buffer A (2% acetonitrile, 0.1% formic acid) for either 82min for interaction study as well as for 
the absolute quantification, 147min for the single fraction after crosslinking using 3kDa Cut-Off 
spin columns or 35min for each fraction collected after crosslinking performing SEC. Afterwards, 
a short steep gradient from 30% to 95% buffer B was performed to elute remaining peptides. 
Eluting peptides were analysed in a LTQ OrbitrapVelos, QExactive Plus or OrbitrapFusion mass 
spectrometer. A LC gradient profile is depicted in Figure 15. 
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Figure 15: LC gradient profile 
This f igure shows the solvent composit ion of the nano pump over t ime. The concentrat ion 
of solvent A is shown in yellow, while the concentration of buffer B is shown in blue. A LC 
gradient of 120min run time in total is depicted here. This gradient starts with 2% of 
solvent B for 5min. Then the concentration of B slowly increases up to 35% during a 
period of 80min followed by a strong increase of buffer B in 5min starting from 35% up to 
95%. After 5min, concentration of %B rapidly decreases to 2% and stays at 2% solver B 
for the last 20min. 
3.2.6.1 Data-dependent analysis 
For data-dependent analysis, full scan MS spectra measured on an OrbitrapVelos were 
acquired in a mass range from m/z 300-1500 with a resolution of 30,000. The ten most intense 
precursor ions were selected, if they exceeded an intensity threshold of 200 and if they were at 
least doubly charged. Selected precursor ions were subsequently fragmented using collision-
induced dissociation (CID) with the CID collision energy set to a value of 35. These parent ions 
were excluded from further isolation for 20sec. Resulting fragment ions were detected in the 
linear ion trap. Lock mass option was activated and set to a background signal with a m/z value 
of 445.12003 [73]. 
For the data-dependent analysis of cross-linked peptides measured on an Orbitrap Fusion, a 
pre-scan was performed in a mass range from m/z 500-2000 with a resolution of 120,000. The 
ten most intense precursor ions were selected if they were at least triply charged and 
sequentially fragmented using collision-induced dissociation (CID) with the CID collision energy 
set to 35%. Resulting fragment ions were detected in the linear ion trap and selected precursor 
ions were excluded from further isolation for 20sec. Target value for MS scan was set to 5x105 
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and for MS/MS fragmentation a target value of 1x104 was chosen. Maximum injection times for 
MS scan as well as MS/MS fragmentation was 100msec. Lock mass option was activated and 
set to a background signal with m/z = 593.15761. 
3.2.6.2 Targeted mass spectrometry 
Selected Reaction Monitoring – SRM 
Selected Reaction Monitoring (SRM) or also called Multiple Reaction Monitoring (MRM) is a 
reliable approach for the quantification of low abundant analytes within a complex sample 
mixture and is generally performed on a triple-quadrupole mass spectrometer. In this method, a 
predefined precursor ion is filtered. After fragmentation of the filtered precursors, a specific 
fragment ion is collected and analysed. As shown in Figure 16, quadrupole 1 (Q1) and 
quadrupole 3 (Q3) serve as mass filters, while the second quadrupole (q2) acts as collision cell 
where the selected precursor ions are fragmented. This set of predefined precursor and 
fragment ions is called a transition. Several of those transitions are monitored over time. The 
addition of retention time windows to the SRM assay achieves a high-selective MS-based 
proteomic approach. In general the 2-4 most intense fragment ions are chosen as transitions for 
each peptide [74]. 
 
Figure 16: Selected Reaction Monitoring – SRM 
Selected Reaction monitor ing, short SRM, is a targeted mass spectrometry approach 
performed on a tr iple quadrupole instrument. Whereas quadrupole 1 (Q1) and quadrupole 
3 (Q3) serve as mass fi lters, quadrupole 2 (q2) represents a coll ision cell. After select ing 
a predefined precursor ion in Q1 and fragmentation of it in q2, predefined fragment ions 
are f iltered and analysed in Q3. The combination of predefined precursor and fragment ion 
is called a transit ion. In SRM approaches, transit ion can only be measured sequentially.  
Parallel Reaction Monitoring – PRM 
Another approach of targeted mass spectrometry is Parallel Reaction Monitoring (PRM) which is 
a common approach performed on quadrupole and Orbitrap containing hybrid mass 
spectrometers. Like in SRM, quadrupole 1 (Q1) acts as mass filter where predefined precursor 
ions are selected. After fragmentation in quadrupole 2 (q2), the collision cell, all corresponding 
fragment ions can be measured in an Orbitrap mass analyser in parallel (see Figure 17). 
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Figure 17: Parallel Reaction Monitoring – PRM 
Parallel Reaction Monitoring (PRM) is a targeted mass spectrometry method performed on 
hybrid mass spectrometers containing a quadrupole as mass filter and an Orbitrap as 
mass analyser. After f il tering a defined precursor ion in quadrupole 1 (Q1) and 
fragmenting it in the col lision cell (quadrupole q2) all result ing fragment ions are analysed 
in parallel using an Orbitrap mass analyser. 
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3.2.7 Data processing 
3.2.7.1 Data-dependent analysis 
Raw data were processed using Proteome Discoverer Daemon (Thermo Scientific; version 2.0) 
and Scaffold (Proteome Software Inc.; version 4.0) for qualitative analysis. All MS/MS spectra 
were analysed using Proteome Discoverer Daemon. Proteome Discoverer Daemon parameters 
were set to search the SwissProt_2014_04 database pre-selected for homo sapiens (2014_04, 
20,199 entries) using Trypsin/P as digestion enzyme. Searches were performed with a fragment 
ion mass tolerance of 0.5Da, permitted precursor charge states of two, three or four and an ion 
tolerance of 10ppm. Carbamidomethylation of cysteine was specified in Mascot as fixed 
modification, whereas deamidation of asparagine and glutamine as well as oxidation of 
methionine were specified as variable modifications. To evaluate MS/MS based peptide and 
protein identification, the software Scaffold was used. Peptide identifications were accepted with 
a probability > 95.0% by the Peptide Prophet algorithm [75] with a Scaffold delta-mass 
correction. Protein identifications were accepted with at least two identified peptides per protein 
and a probability > 99.0% by the Protein Prophet algorithm [76]. Proteins were only considered 
as interaction partners of the used bait, if they were not detected in the control experiments.  
For label-free quantification (LFQ), MS raw data were analysed using MaxQuant software 
(1.5.3.30). Trypsin/P was set as cleaving enzyme. Carbamidomethylation of cysteine was 
selected as fixed modification, protein acetylation and oxidation of methionine were set as 
variable modifications. A maximum of two missed cleavages per peptide were allowed. False 
discovery rates (FDR) for proteins and peptides were both set to 1%. The first search tolerance 
for precursor ions was set to 20ppm following the main search option which was enabled with 
4.5ppm. Fragment ion match tolerance was set to 20ppm. The human sub-set of the human 
proteome reference set provided by SwissProt (Release 2014_04, 544,996 entries) was used 
for peptide and protein identification. For automated detection of contaminants like keratins, the 
MaxQuant contaminant database search was enabled. A minimum of two unique and razor 
peptides with a minimum length of seven amino acids had to be detected for protein 
quantification The option “match between runs” was enabled with a match time window of 
0.7min and an alignment time window of 20 min. 
For the analysis of chemically cross-linked peptides, the previously described open-source 
xQuest/xProphet software pipeline was used. Thereby, cross-linked peptides were identified by 
xQuest search and validated afterwards by xProphet [51, 52, 77]. 
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3.2.7.2 Targeted mass spectrometry 
For data analysis of targeted mass spectrometry, obtained raw data were processed using the 
open source software tool Skyline. This application was developed to generate methods for 
targeted proteomics and to evaluate resulting data [78].  
For data analysis using Skyline, it is essential to adjust parameter settings before raw files are 
uploaded. Peptide settings were set as follows: Trypsin [KR I P] was chosen as enzyme and no 
missed cleavage was allowed. Only peptides with a sequence length between 8 and 25 amino 
acids were considered. Introduced ‘heavy’ isotopic label of peptides was defined as well 
[(13C(6)15N(2)/ (C-term K) and (13C(6)15N(4)/ C-term R)]. For transition settings, allowed 
charges of precursor ions were set to 2 and only resulting y-ions were chosen for the 
quantification. After raw data processing, Skyline depicts identified peptides as shown in Figure 
18. After evaluating automated integration of the software, some refinements were performed 
manually. For the quantification of each peptide, the ratio of labelled to non-labelled peptide was 
calculated by Skyline. 
 
Figure 18: Data analysis using Skyline 
Skyline can be used to visualise raw data, generated by targeted mass spectrometry. 
Before rawfiles are analysed using Skyline, peptide as well as transit ion parameters must 
be set. Uploading rawfiles containing data of isotopical ly coded (biological peptides) and 
non-coded peptides (synthetic peptides) facil itates the il lustration of corresponding peaks. 
On peptide level the ratio of labelled to unlabelled peptide is shown (A). To get more 
information about analysed transit ions, peak areas as well as mass spectra of product 
ions of SILAC-labelled peptide (C) and of synthetic peptide (B) are depicted. 
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4 Results 
4.1 Experimental workflow 
Stoichiometric and structural investigations of the protein complex IFT-A are crucial for the 
understanding of the underlying mechanisms of IFT-A-related ciliopathies. 
 
Figure 19: Experimental workflow 
In order to obtain stoichiometric as well as structural information of IFT-A, the basis of this 
study was the generat ion of stable cell l ines using the Flp-In system. Determination of the 
stoichiometry of proteins forming IFT-A was enabled by absolute quantif icat ion of pur if ied 
IFT-A. Therefore, targeted mass spectrometry was combined with an internal standard 
mix. Furthermore, potential alterations and perturbations in stoichiometry of the IFT-A 
were analysed by two different strategies: To analyse alterations in IFT-A stoichiometry 
during assembly and disassembly of cil ia, IFT-A was purif ied during different cil iary cell 
stages and used for absolute quantif ication. The second experiment to study 
stoichiometric changes of the protein complex was the introduction of mutations into IFT-A 
components by gene edit ing using the CRISPR/Cas9 system. For the structural 
investigation of purif ied IFT-A, chemical crosslinking was performed using the 
homobifunctional chemical crosslinker disuccinimidyl suberate (DSS). Resulting proximity 
information in combination with determined complex stoichiometry represent the basis for 
the modell ing of IFT-A and to understand its role in ciliopathies. 
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For this study, purification of IFT-A in its naturally occurring composition is crucial. As 
hypothesized in 2013 by Gibson et al., overexpression, especially transient overexpression of 
one single protein, may cause an alteration in the corresponding complex assembly [58]. 
Therefore, stable cell lines with a single copy of the transgene integrated into the genome were 
generated using the Flp-In system. In this work, three Flp-In cell lines that stably express either 
(N)-SF-TAP-tagged IFT122, (N)-SF-TAP-tagged TULP3 or (N)-SF-TAP-tagged LCA5 were 
generated to enable the purification of IFT-A protein complex by the use of interacting as well as 
associated proteins as baits. To gain information about the complex composition of IFT-A, 
absolute quantification of all six described complex components (IFT122, IFT140, IFT43, 
TTC21B, WDR19 and WDR35) was performed. For the investigation of potential alterations 
within the stoichiometry of the IFT-A, the protein complex was analysed during different stages 
of ciliary assembly and disassembly. On top, CRISPR/Cas9 system was used to generate 
mutations based on Flp-In (N)-SF-TULP3 cells to study potential perturbations on complex 
composition introduced by mutations within IFT-A components. 
The second part of this study was the structural investigation of the IFT-A. Therefore, purified 
IFT-A was chemically cross-linked using the homobifunctional crosslinker disuccinimidyl 
suberate (DSS). This crosslinker enables links between lysine residues as well as accessible N-
termini and yields proximity information within the complex of interest [51]. The combination of 
both, stoichiometric and structural information, is the basis for the computational modelling of 
IFT-A and to improve basic knowledge about the function of IFT-A and its role in ciliopathies. 
4.2 Generating Flp-In monoclonal cell lines 
For the purification of the protein complex IFT-A, cell lines stably expressing either (N)-SF-
IFT122, (N)-SF-TULP3 or (N)-SF-LCA5 were produced using the Flp-In system. The three 
chosen baits are known to be either a part of the IFT-A (IFT122), associated with IFT-A without 
being an integral part (TULP3) or like LCA5, a labile and rather transiently bound interaction 
partner of the protein complex. Flp-In monoclonal lines were successfully generated for all three 
baits using HEK293 cells as described in 3.2.2.5. 
4.2.1 Behaviour of generated Flp-In monoclonal cell lines in cell culture 
In comparison to non-transfected HEK293 cells, generated Flp-In monoclonal lines were 
relatively slow growing, whereas the morphology of the cells stayed the same. Also the reaction 
to trypsination showed no difference to normal cells independent of the bait. 
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4.2.2 Validation of integration 
To ensure a proper integration and expression of the gene of interest (GOI) into the Flp-In 293 
host cell line (see 3.2.2.5), several validation experiments were performed: 1) PCR-amplification 
of specific regions characterizing the expression vector and its integration site and 2) analysis of 
the protein expression level through SDS-PAGE followed by western blotting. 
4.2.2.1 PCR-based validation of the proper integration of the transgene 
 
Figure 20: Validation of generated Flp-In monoclonal lines via PCR 
PCR was performed to validate a proper integration of the GOI into the Flp-In host cell 
l ine. A: Different primer sets were used to amplify either the 5’-FRT and 3’FRT-region (P-
13-066/P-13-067; P-13-074/P-13-075) or the “f lanking” region (P-13-066/P-13-075; P-13-
070/P-13-079). After integration of the GOI construct into the Flp-In host l ine, the 
sequence length between the SV40 promotor and lacZ-Zeocin gene is too big for a 
successful PCR. Therefore, no PCR fragment of 349/494bp is expected for monoclonal 
cel l l ines that underwent integration of the GOI construct. After the integration of the GOI 
construct into the Flp-In host cells, recombinant Flp-In l ines contain an addit ional 
hygromycin resistance gene sequence as well as a BGHpolyA site which al lows PCR at 5’-
FRT and 3’-FRT with PCR products of 510bp and 602bp, respectively. B: Posit ive Flp-In 
monoclonal lines, highlighted in red, showed a proper integration of the GOI construct into 
the Flp-In host cell l ine. Whereas the 5’-FRT and 3’-FRT sites were amplif ied, the 
“f lanking” regions were not. Those three clones were used for further experiments. 
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Polymerase chain reaction (PCR) was performed to validate a successful and proper integration 
of the GOI construct into the genome of the Flp-In host cell line. As shown in Figure 20A, few 
PCRs with different primer sets allowed the identification of recombined clones. In the parental 
Flp-In host cell line, the “flanking” region between the SV40 promotor and the lacZ-Zeocin gene 
is short and can be amplified. Yielding PCR fragments with a length of either 349bp or 494bp 
(based on the chosen primer combination) are shown in Figure 20B (lanes of Flp-In 293). Based 
on the elongation of the flanking region by an integration of the GOI construct at the Flp-In site, 
this “flanking” region cannot be amplified anymore. In contrast, recombinant Flp-In clones 
possessing an additional hygromycin resistance gene sequence as well as a BGHpolyA site 
enable an amplification of the 5’- and the 3’- FRT sites with fragment sizes of 510bp or 602bp, 
respectively (see Figure 20A). As highlighted in Figure 20B, one clone per each GOI construct 
was chosen for further experiments (red boxes). 
4.2.2.2 Validation using western blotting in combination with immunostaining 
For the validation of a successful expression of the Strep-FLAG-tagged bait protein, protein 
extracts (20µg protein) of the generated cell lines were separated performing SDS-PAGE 
followed by western blotting with further immunostaining (see 3.2.3.3 and 3.2.3.4). 
 
Figure 21: Validation of bait protein expression of Flp-In monoclonal cell lines 
Western blot analysis was performed to validate a successful integration of the gene of 
interest (GOI) into the genome of a mammalian cell l ine, using the Flp-In system of 
Invitrogen. For SDS-PAGE, 20µg extracted proteins of generated Flp-In monoclonal lines 
containing SF-TAP-tagged IFT122, TULP3 or LCA5 as bait as well as of Flp-In 293 host 
cel ls were used. After transferring separated proteins on a PVDF membrane via western 
blot, the FLAG tag of integrated GOI’s was detected using anti-FLAG-HRP antibodies. 
After integrat ion of the GOI into Flp-In 293 host cel l l ine, protein expression of β-
galactosidase was not detectable. 
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An anti-FLAG-HRP antibody was used for the detection of the expression of the chosen bait 
proteins. As shown in Figure 21, all tested monoclonal cell lines expressed a bait protein of the 
appropriate size ((N)-SF-IFT122: 147kDa; (N)-SF-LCA5: 55kDa; (N)-SF-TULP3: 86kDa). 
Successful integration of the GOI construct into the Flp-In host cell line eliminates expression of 
the β-galactosidase gene. Therefore, a second immunostaining was performed using an anti-β-
galactosidase antibody. Whereas a β-galactosidase expression was detectable in Flp-In host 
cell lysates, no β-galactosidase expression was detected in the recombinant Flp-In lines. 
4.3 Establishing targeted mass spectrometry for absolute 
quantification of IFT-A 
4.3.1 Selection of representative peptides of IFT-A 
Absolute quantification of proteins combines the application of representative and proteotypic 
standard peptides of defined quantity with targeted mass spectrometry. As outlined in 3.2.5.1, 
the selection of representative peptides for this elaborative technology is a crucial step. To 
eliminate ambiguous calls, only tryptic peptides which are exclusively present in the target 
protein were identified by Basic Local Alignment SEARCH Tools (BLAST). Length of the amino 
acid sequence as well as amino acid composition of chosen peptides were also filtered to avoid 
amino acids which are prone to post-translational modifications. Figure 22 lists at least three 
representative standard peptides for each complex component which were chosen for absolute 
quantification of purified IFT-A. In Figure 22A, the localisation of the chosen peptides within the 
corresponding protein is given by the position of the amino acid residue (highlighted in blue), 
whereas the distribution of the representative peptides on the protein sequence is depicted by 
red bars in Figure 22B. To determine the absolute amount of each of the peptides performing 
the economic “Equimolarity through Equalizer Peptide” (EtEP), all of the peptides were 
synthesized with an artificial tryptic peptide at the N-terminus. 
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Figure 22: Proteotypic peptides of IFT-A 
To determine the complex stoichiometry using absolute quantif ication, the combination of 
a targeted mass spectrometry approach with an internal standard of proteotypic peptides 
is essential. A: At least three proteotypic peptides were selected as representatives for 
each IFT-A complex component. The peptide sequence of the chosen representat ive 
peptides is highlighted in red while the posit ion of the peptide within the protein sequence 
is depicted in blue. B: The distr ibution of the representative peptides (red bars) on the 
protein sequence is given. 
4.3.2 Generation of an equimolar standard mix performing EtEP 
A standard mix with a known amount of each standard peptide is the basis for the absolute 
quantification of a protein complex of interest. However, the determination of the absolute 
amount of each peptide by amino acid analysis is very expensive. Therefore, quantification of 
the absolute amount was done by a cost-efficient method called “Equimolarity through Equalizer 
Peptide” (EtEP), previously described by Holzmann et al. in 2009 [59] (see 3.2.5.19). In EtEP, 
the absolute amount of only one peptide, the equalizer peptide (EP), is determined by amino 
acid analysis. Furthermore, this EP needed to be synthesized in an isotopically labelled form 
(FYYR*). All representative peptides were synthesized with an attached equalizer peptide 
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sequence (FYYR-) at the N-terminus. This artificial peptide introduces an additional tryptic 
cleavage site which is essential for this EtEP method. 
4.3.2.1 Validating tryptic proteolysis 
Proteolysis of each EP-fused representative peptide using trypsin results in an equimolar 
quantity of released EP and synthetic standard peptide. An efficient tryptic digestion was 
validated performing LC-MS/MS analysis on a QExactive Plus instrument, as shown in Figure 
23. Therefore, generated rawfiles were analysed by the software Skyline to validate the tryptic 
digestion by evaluating the release of the artificial equalizer peptide FYYR. In contrast, an 
unsuccessful tryptic cleavage of the synthesized peptides would result in no release of the 
artificial tryptic peptide FYYR. 
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4.3.2.2 Quantification of standard peptides using isotopically labelled EP 
After a successful proteolysis, the amount of each standard peptide was determined by direct 
in-sample comparison of the released equalizer peptide (EP) with a known amount (8.7µg) of 
the isotopically labelled EP spiked into the trypsin-treated peptide samples. After targeted mass 
spectrometry was performed, rawfiles were analyzed by Skyline again to determine the ratio of 
unlabelled EP (FYYR), released by proteolysis, to the spiked in and isotopically labelled EP 
FYYR*). Figure 24 shows the elution profiles of the spiked-in labelled EP (depicted in blue) and 
of the released EP of each standard peptide (highlighted in red). The analysis showed that the 
amount of released equalizer peptide varied considerably. Differences in synthesis yield and 
solubility (depending on the amino acid composition of the synthetic peptide) may be 
responsible for this variation. To eliminate error-prone quantifications, based on differences in 
abundance of the EP’s and to consider the dynamic range of the mass spectrometer, the 
amount of spiked labelled equalizer peptide was adjusted to the individual amounts of released 
EP. Results are shown in Figure 25. 
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The ratio of unlabelled versus isotopically labelled equalizer peptide, as calculated by Skyline, 
was used for the determination of the concentration of each representative peptide. Therefore, 
the following formula was used: 
ctordilutionfad
l/µl661,396pmoc
ionconcentrat :c
areapeak  :A
with
A
Acc
c
c
A
A
EP
EP
EP
PeptideEP
Peptide
EP
Peptide
EP
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
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EP
EP
d
d
 
The known concentration of the isotopically labelled EP of 661.4 pmol/µL together with the 
dilution factor (see Table 10) was used to calculate the concentration of each standard peptide. 
Table 10 also lists the volume of each peptide sample to generate the equimolar standard mix 
containing 550pmol of each representative peptide. 
Table 10: Calculation for an equimolar standard mixture 
Protein Peptide Mean A(Pep)/A(EP) %CV Dilution factor cPeptide / [pmol/µL] VPeptide / [µl]
WDEAFALGEK 0.9130 12.2 2.5 241.5 2.3
ILFTLAK 0.9415 2.8 2.5 249.1 2.2
GEYILLGGSDK 0.7826 3.3 2 258.8 2.1
DSIGDEDPFTAK 0.9049 6.0 1 598.5 0.9
YLELISSIEER 1.7207 19.2 12.5 91.0 6.0
DTPSGISK 0.5255 14.9 1.6 217.2 2.5
FWDIER 0.7564 8.0 2 250.2 2.2
AHGALTEAYK 0.8787 22.3 2 290.6 1.9
SHLFVDEGLK 1.1666 7.4 10 77.2 7.1
YSLATSR 0.8799 11.0 2.5 232.8 2.4
VLAPEHEVR 0.8532 4.5 2 282.2 1.9
ASEEIEDFR 0.9707 15.0 3 214.0 3
EAILESDAR 0.8781 11.8 3 193.6 2.8
LEDVPR 0.7365 8.2 1.5 324.7 1.7
YGSDPVFR 0.7916 4.9 2 261.8 2.1
AASVYIR 0.6822 11.0 5 90.2 6.1
IFSLLEK 0.7371 7.9 2 243.7 2.3
VGSFLAVGTVK 0.7949 15.4 20 26.3 20.9
LVFIDEK 0.8887 16.6 4 147.0 3.7
VGDLLPHVSSPK 0.7794 5.1 2 257.8 2.1
DGDVLAVIAEK 0.8810 13.7 2 291.3 1.9
YASHLLEK 0.4942 7.7 4 81.7 6.7
THVIAASK 0.8046 2.4 1.5 354.8 1.6
EIGSLLAR 0.8871 4.3 4 146.7 3.7
%CV: percent coefficient of variation 
IFT122
IFT140
IFT43
TTC21B
WDR35
WDR19
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4.3.3 Adjusted standard mix for absolute quantification 
For a most-reliable quantification of peptides, the dynamic range of the used mass spectrometer 
must be considered. This parameter gives the range in which accurate measurements of 
masses can be made [79], depending on the linearity of ion signal to analyte concentration in 
this range. To reliably quantify labelled and its corresponding non-labelled peptide, similar 
amounts of spiked isotopically labelled standard peptide and biological peptide within one 
sample is important. Therefore, previous data of absolute quantification of IFT-A using an 
equimolar standard mix (for more details see 4.4.2.2) was used to determine the amount of 
each peptide within purified IFT-A. Based on this knowledge, a mixture consisting of adjusted 
amounts of each synthetic peptide was created. Table 11 shows the composition of this 
adapted standard mix. In most cases, representative peptides for one protein are present in the 
same amount and therefore adjusted the same way. In contrast, for some proteins (IFT122 and 
WDR19), representative peptides showed different abundances. In this case, each 
representative peptide was adjusted separately. 
Table 11: Calculation for a standard mixture with adjusted amount of synthetic peptides 
Protein Peptide Mean A(Pep)/A(EP) %CV Dilution factor cPeptide / [pmol/µl] VPeptide / [µl] nPeptide / [pmol]
WDEAFALGEK 0.9130 12.2 2.5 241.5 17.6 4250
ILFTLAK 0.9415 2.8 2.5 249.1 9.0 2250
GEYILLGGSDK 0.7826 3.3 2 258.8 3.2 825
DSIGDEDPFTAK 0.9049 6.0 1 598.5 1.4 825
YLELISSIEER 1.7207 19.2 12.5 91.0 46.7 4250
DTPSGISK 0.5255 14.9 1.6 217.2 2.3 500
FWDIER 0.7564 8.0 2 250.2 7.0 1750
AHGALTEAYK 0.8787 22.3 2 290.6 6.0 1750
SHLFVDEGLK 1.1666 7.4 10 77.2 22.7 1750
YSLATSR 0.8799 11.0 2.5 232.8 1.1 250
VLAPEHEVR 0.8532 4.5 2 282.2 0.9 250
ASEEIEDFR 0.9707 15.0 3 214.0 1.2 250
EAILESDAR 0.8781 11.8 3 193.6 2.2 425
LEDVPR 0.7365 8.2 1.5 324.7 1.3 425
YGSDPVFR 0.7916 4.9 2 261.8 1.6 425
AASVYIR 0.6822 11.0 5 90.2 5.5 500
IFSLLEK 0.7371 7.9 2 243.7 19.5 4750
VGSFLAVGTVK 0.7949 15.4 20 26.3 95.1 2500
LVFIDEK 0.8887 16.6 4 147.0 7.3 1075
VGDLLPHVSSPK 0.7794 5.1 2 257.8 8.7 2250
DGDVLAVIAEK 0.8810 13.7 2 291.3 3.7 1075
YASHLLEK 0.4942 7.7 4 81.7 10.1 825
THVIAASK 0.8046 2.4 1.5 354.8 2.3 825
EIGSLLAR 0.8871 4.3 4 146.7 5.6 825
%CV: percent coefficient of variation 
IFT122
IFT140
IFT43
TTC21B
WDR35
WDR19
 
Although it is a good idea to eliminate error-prone concentration differences, the coefficient of 
variance obtained in experiments with the adjusted standard mix were much higher than for 
absolute quantification using an equimolar standard mix (data not shown). This worse 
performance is most likely due to the additional steps in sample handling. Because of that, the 
90  Results 
 
Flp-In (N)-SF-TULP3 monoclonal line in combination with the equimolar standard mix was used 
for further investigations. 
4.3.4 Parameter settings for targeted mass spectrometry 
To set up a method for targeted mass spectrometry, the MS profiles of the representative 
peptides, present in the generated standard mix, were characterized by a data-dependent 
shotgun run. Therefore, the equimolar standard mix was diluted 1:10 in 0.5% TFA (injected 
amount of 55fmol of each standard peptide) and used for MS analysis. The obtained rawfile was 
analyzed using Skyline to evaluate transitions as well as to determine the retention time of each 
eluting peptide.  
4.3.4.1 SRM assay performed on a triple quadrupole 
At the beginning of this study, no mass spectrometer with an option for targeted mass 
spectrometry was available in our lab. Therefore, the analysis based on the Selected Reaction 
Monitoring (SRM) protocol was done on a QTrap5500 instrument in the group of Karl Mechtler 
(Institute of Molecular Pathology, Vienna). For SRM, performed on a triple quadruple mass 
spectrometer, the choice of significant transitions (a precursor ion with one corresponding 
product ion) is essential. The chosen transitions are representatives for the quantification of the 
peptides. To achieve optimal sensitivity, the collision energy (CE) was optimised for each 
transition by selecting the most efficient CE value for every ion pair. CE optimisation was 
performed by measuring each transition with different collision energies. To locate the CE range 
of each transition, different CE values (10, 20, 30) were tested first. Afterwards, best CE value 
of the previous experiment was chosen to refine the CE by testing the chosen CE ± 5 with a 
step size of ± 1. Results were visualized in Skyline to identify ideal conditions. As an example, 
shown in Figure 26, peak areas were analyzed to identify the CE optimum for the ion y4 of the 
peptide FWDIER. The optimal CE for this transition was identified by the chosen value – 4. 
Once optimal CE values were identified for each representative peptide (14 peptides in total as 
shown in Table 12), a transition list was generated to set parameters for the SRM approach. 
This list is shown in Table 12 and includes chosen isotopically coded and non-coded peptides 
(‘light’: L, ‘heavy’: H) with corresponding precursor masses as well as chosen product ions. 
Additionally, optimised CE values are given. To increase speed and selectivity of this approach, 
the retention time was added. For the analysis a retention time window of ± 1.5min was 
selected. 
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Figure 26: Determination of the CE optimum for transitions using Skyline 
Ideal fragmentation condit ions are essential for a robust and reliable quantif ication. 
Therefore, the coll ision energy value was optimized for each peptide and each transition 
separately. To identify the optimum of CE, peak areas of each transition, generated using 
different CE values, were analysed and compared. Therefore, a set of different CE values 
was tested (10, 20, 30). To refine this optimization the range of tested CE values in the 
next experiment was defined by the best CE value of the previous experiment ± 5 with a 
step size of ± 1. Skyline depicts the result ing peak areas to identify the best CE value. As 
highlighted in red, for the product ion y4 of the double charged precursor of the peptide 
FWDIER, ten different CE values were tested. Highest peak area was obtained at -4 below 
the preset CE and used for this very transit ion. 
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Table 12: Transition list for SRM with optimised CE values 
Protein Peptide L/H Precursor [m/z] L/H Product [m/z] L/H Transition RT CE
864.446159/872.460358 +2y8 43.97 26.9
735.403566/743.417765 +2y7 43.97 28.9
664.366452/672.380651 +2y6 43.97 27.9
333.176861/341.19106 +2y3 43.97 34.9
692.434138/700.448337 +2y6 41.30 19.4
579.350074/587.364273 +2y5 41.30 18.4
432.28166/440.295859 +2y4 41.30 24.4
331.233982/339.248181 +2y3 41.30 27.4
718.351865/728.360134 +2y5 40.53 20.5
532.272552/542.280821 +2y4 40.53 20.5
417.245609/427.253878 +2y3 40.53 28.5
852.446159/860.460358 +2y8 16.47 26.0
795.424696/803.438895 +2y7 16.47 27.0
724.387582/732.401781 +2y6 16.47 31.0
381.213246/389.227445 +2y3 16.47 33.0
634.351865/644.360134 +2y6 20.45 21.2
547.319837/557.328106 +2y5 20.45 21.2
434.235772/444.244041 +2y4 20.45 20.2
363.198659/373.206928 +2y3 20.45 20.2
808.383559/818.391828 +2y6 30.52 23.6
679.340966/689.349235 +2y5 30.52 25.6
566.256902/576.265171 +2y4 30.52 24.6
437.214309/447.222578 +2y3 30.52 27.6
837.421342/847.429611 +2y7 16.38 25.8
766.384228/776.392497 +2y6 16.38 26.8
669.331464/679.339733 +2y5 16.38 32.8
540.288871/550.29714 +2y4 16.38 32.8
777.388979/787.397248 +2y7 28.44 21.8
720.367515/730.375784 +2y6 28.44 21.8
633.335487/643.343756 +2y5 28.44 21.8
518.308544/528.316813 +2y4 28.44 28.8
803.425758/813.434027 +2y7 23.56 24.9
690.341694/700.349963 +2y6 23.56 23.9
577.25763/587.265899 +2y5 23.56 23.9
448.215037/458.223306 +2y4 23.56 21.9
615.309666/625.317935 +2y5 18.61 19.0
486.267073/496.275342 +2y4 18.61 18.0
371.24013/381.248399 +2y3 18.61 25.0
457.22929/457.22929 +2b4 18.61 17.0
736.423967/744.438166 +2y6 42.39 20.2
589.355553/597.369752 +2y5 42.39 20.2
502.323525/510.337724 +2y4 42.39 26.2
389.239461/397.25366 +2y3 42.39 28.2
708.403901/718.41217 +2y6 21.65 19.9
637.366787/647.375056 +2y5 21.65 19.9
550.334758/560.343027 +2y4 21.65 20.9
451.266344/461.274613 +2y3 21.65 20.9
588.371538/596.385737 +2y6 8.93 22.8
489.303124/497.317323 +2y5 8.93 21.8
376.21906/384.233259 +2y4 8.93 23.8
305.181946/313.196145 +2y3 8.93 23.8
797.451579/805.465778 +2y7 18.88 24.2
726.414465/734.428664 +2y6 18.88 24.2
502.323525/510.337724 +2y4 18.88 29.2
389.239461/397.25366 +2y3 18.88 31.2
YASHLLEK/K
548.251285/553.25542
525.290548/530.294682
470.729792/475.733926
502.256371/507.260505
480.761092/484.768191
364.700503/369.704637
425.257654/429.264753
VLAPEHEVR/R
390.224145/395.22828
LEDVPR/R
IFSLLEK/K
AASVYIR/R
413.742702/417.749802
WDR35
YGSDPVFR/R
EAILESDAR/R
IFT122
IFT140
IFT43
TTC21B
THVIAASK/K
WDEAFALGEK/K
ILFTLAK/K
583.279846/587.286945
403.262739/407.269839
433.213777/438.217912
530.774731/534.78183
399.211235/404.215369
WDR19
FWDIER/R
AHGALTEAYK/K
YSLATSR/R
ASEEIEDFR/R
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4.3.4.2 PRM assay performed on an Orbitrap instrument 
Later in this study, an Orbitrap hybrid mass spectrometer (QExactive Plus) was available in our 
lab to perform targeted mass spectrometry. In comparison to the SRM approach with predefined 
transitions and transition parameters, parameter setting for a Parallel Reaction Monitoring 
(PRM) approach which can be performed on an Orbitrap hybrid mass spectrometer, is much 
less laborious. As depicted in Table 13, only precursor masses for isotopically labelled 
(highlighted in red) and non-labelled parent ions are predefined. Instead of quantifying only 
predefined product ions like in SRM, all resulting fragment ions are analyzed and detected in 
parallel in the Orbitrap. All chosen precursors are 2-fold positively charged and CE values which 
are essential for a proper fragmentation were universally set to 26. For optimising speed and 
selectivity, the method was set up in a scheduled manner including a retention time range 
(RT±5min). For the qualitative identification of the proteins of interest, not only product ions 
were analysed, but also a targeted MS1 scan of all included precursor masses was generated. 
Table 13: Parameter settings for PRM  
IFT-A component Peptide L/H Precursor [m/z] L/H [z] Polarity RTmin RTmax (N)CE
WDEAFALGEK/K 583.27985 / 587.28695 2 + 50.4 60.4 26
ILFTLAK/K 403.26274 / 407.26984 2 + 47.3 57.3 26
GEYILLGGSDK/K 576.30078 / 580.30788 2 + 44.2 54.2 26
DSIGDEDPFTAK/K 647.79351 / 651.80061 2 + 46.4 56.4 26
YLELISSIEER/R 676.3588 / 681.363 2 + 61.2 71.2 26
DTPSGISK/K 402.7085 / 406.7156 2 + 13.2 23.2 26
FWDIER/R 433.21378 / 438.21791 2 + 44.4 54.4 26
AHGALTEAYK/K 530.77473 / 534.78183 2 + 16.6 26.6 26
SHLFVDEGLK/K 572.80349 / 576.81059 2 + 34.6 44.6 26
YSLATSR/R 399.21124 / 404.21537 2 + 20.3 30.3 26
VLAPEHEVR/R 525.29055 / 530.29468 2 + 17.3 27.3 26
ASEEIEDFR/R 548.25129 / 553.25542 2 + 32.4 42.4 26
EAILESDAR/R 502.25637 / 507.26051 2 + 24.7 34.7 26
LEDVPR/R 364.7005 / 369.70464 2 + 18.9 28.9 26
YGSDPVFR/R 470.72979 / 475.73393 2 + 30.1 40.1 26
AASVYIR/R 390.22415 / 395.22828 2 + 21.6 31.6 26
IFSLLEK/K 425.25765 / 429.26475 2 + 48.5 58.5 26
VGSFLAVGTVK/K 539.31877 / 543.32587 2 + 45.5 55.5 26
LVFIDEK/K 432.24729 / 436.25439 2 + 40.9 50.9 26
VGDLLPHVSSPK/K 624.851 / 628.8581 2 + 36.3 46.3 26
DGDVLAVIAEK/K 565.3086 / 569.3157 2 + 56.2 66.2 26
YASHLLEK/K 480.76109 / 484.76819 2 + 19.5 29.5 26
THVIAASK/K 413.7427 / 417.7498 2 + 9.7 19.7 26
EIGSLLAR/R 429.75581 / 434.75994 2 + 38.3 48.3 26
IFT122
IFT140
IFT43
TTC21B
WDR19
WDR35
 
4.4 Absolute quantification of purified IFT-A 
Absolute quantification of a protein complex of interest consists of different steps including an 
entire purification of the protein complex, the addition of an internal standard mix and targeted 
mass spectrometry of each representative peptide (24 peptides in total as shown in Table 13) 
and its corresponding isotopically labelled peptide. Finally, data analysis is performed to 
quantify the absolute amount of each representative peptide within the sample. 
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4.4.1 Validation of entire purification of IFT-A 
For the stoichiometry determination of a protein complex of interest, it is necessary to purify the 
whole complex in its native state without any loss of compounds [58]. Therefore, purification of 
IFT-A was performed using three different bait proteins. Generated stable cell lines express one 
of three SF-TAP-tagged baits: IFT122, an internal component of the protein complex of interest; 
TULP3 which is known to be associated with IFT-A or LCA5 which is described to interact with 
the complex of interest in a labile and rather transient way (see Figure 27). 
 
Figure 27: Chosen baits for the purification of IFT-A 
To purify IFT-A, three different baits were chosen for the generation of Flp-In monoclonal 
l ines. Either IFT122, TULP3 or LCA5 were chosen. These three baits are all related to the 
IFT-A. IFT122 is an integral part of the IFT-A, TULP3 is associated with it without being an 
integral part of IFT-A and LCA5 is a described interaction partner of IFT-A. All of the 
chosen baits are containing a SF-TAP tag for aff inity purif ication.  
4.4.1.1 One-step affinity purification of IFT-A 
To validate a proper and complete purification of IFT-A performing one-step affinity purification 
using different baits, purified proteins were precipitated and enzymatically cleaved and analysed 
by LC-MS/MS analysis for the identification of each complex component. As shown in Table 14, 
no matter which bait was chosen, all six complex components of IFT-A as well as the introduced 
bait were identified. In this table, the mean of exclusive unique peptide count and the percent of 
coefficient of variation of three biological replicates were depicted. 
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Table 14: One-step affinity purification of generated Flp-In monoclonal lines 
Identified IFT-A complex component Gene name mean %CV mean %CV mean %CV
Tubby-related protein 3 TULP3 0 - 23 4.9 8 25.0
Lebercilin LCA5 0 - 0 - 46 14.3
Intraflagellar transport protein 122 homolog IFT122 71 2.1 38 9.2 22 14.8
Intraflagellar transport protein 140 homolog IFT140 29 38.4 42 10.4 28 20.1
Intraflagellar transport protein 43 homolog IFT43 10 5.6 8 33.1 5 32.7
Tetratricopeptide repeat protein 21B TTC21B 48 15.0 33 8.0 23 19.9
WD repeat-containing protein 19 WDR19 40 34.2 50 9.1 32 25.6
WD repeat-containing protein 35 WDR35 52 9.9 37 19.2 28 3.6
%CV: percent coefficient of variation
Exclusive Unique Peptide Count
Flp-In (N)-SF-IFT122 Flp-In (N)-SF-TULP3 Flp-In (N)-SF-LCA5
 
4.4.1.2 Silver staining and MS analysis of TAP eluates 
A second technique for the validation of an entire purification of the IFT-A was performed by 
SDS-PAGE of TAP-purified IFT-A of monoclonal Flp-In (N)-SF-IFT122, Flp-In (N)-SF-TULP3 
and Flp-In (N)-SF-LCA5 cells (as described in 3.2.3.3). After SDS-PAGE, silver staining with 
further in-gel digestion and MS analysis was performed to identify the six described complex 
components of the protein complex IFT-A (see 3.2.4.6). 
 
Figure 28: Validation of an entire purification of IFT-A using silver staining  
Purif ied IFT-A was separated by SDS-PAGE for further silver staining and in-gel digestion 
followed by MS analysis. As depicted, TAP eluates of Flp-In monoclonal lines, stably 
expressing either (N)-SF-TAP-tagged IFT122, TULP3 or LCA5 were used to validate the 
entire purif ication of all IFT-A complex components. Considering Flp-In (N)-SF-TULP3 and 
Flp-In (N)-SF-LCA5, the protein patterns of purif ied IFT-A were comparable although the 
expression level varied. In comparison, the protein pattern of the cell l ine Flp-In (N)-SF-
IFT122, stably expressing an internal part of the IFT-A, differed signif icantly. MS analysis 
identif ied all IFT-A components (highlighted in red). 
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As depicted in Figure 28, protein patterns of tested Flp-In monoclonal lines varied. While Flp-In 
(N)-SF-TULP3 and Flp-In (N)-SF-LCA5 showed same patterns of purified IFT-A, the expression 
level of all IFT-A components was much weaker using LCA5 as bait. In comparison, an integral 
part of the IFT-A as bait (IFT122) resulted in an alteration within this protein pattern as depicted 
for Flp-In (N)-SF-IFT122. Additionally, all six complex components of the IFT-A were identified 
using MS analysis (highlighted with red arrows). This successful purification of the whole IFT-A 
complex, validated in this study, enables an accurate stoichiometry determination of the IFT-A 
protein complex by absolute quantification. 
4.4.2 Differences in complex stoichiometry of IFT-A according to chosen baits 
To achieve a robust and reliable determination of IFT-A composition, the complex stoichiometry 
from all three generated Flp-In monoclonal cell lines were investigated and compared. 
4.4.2.1 SRM assay using an equimolar standard mix of 14 standard peptides 
As an example for the analysis applying the SRM approach, the results of one biological 
replicate of IFT-A, purified from Flp-In (N)-SF-LCA5 cells, are depicted in Table 15. This sample 
was measured in three technical replicates. Four transitions of at least two representative 
peptides were quantified per complex component. Ratios of labelled to unlabelled peptide were 
calculated using Skyline. As shown in Table 15, median of all representative peptides of one 
protein was calculated and used for the determination of complex stoichiometry by normalising 
all values to the value of the lowest abundant protein (TTC21B). As depicted, the generated 
equimolar standard mix used for this SRM approach consists of 14 standard peptides although 
three representative peptides per complex component were ordered and synthesized. The poor 
solubility of four purchased peptides limited the number of available standard peptides to 14: 
Three representative peptides for the components IFT43 and TTC21B and two representative 
peptides for IFT122, IFT140, WDR19 and WDR35. For further details like standard deviation 
(SD) and coefficient of variation (CV), see Table 17 in the annex.  
The determined median ratios (H/L) of IFT122, IFT43 and WDR19 showed huge variances 
within the chosen representative peptides. For WDR19, the representative peptides IFSLLEK 
and AASVYIR were chosen. While the median ratio (H/L) of all transitions for IFSLLEK was 
determined with 0.4635, the median ratio (H/L) of all transitions for AASVYIR was 0.2430.  A 
look at two described isoforms of WDR19 (as depicted schematically in Figure 48 and in more 
detail in Figure 53), identified the presence of the representative peptide IFSLLEK in both 
known isoforms of WDR19, while the peptide AASVYIR is only present in the larger isoform of 
WDR19. For IFT43, four different isoforms are already described (see Figure 48 and Figure 51). 
While two of the chosen representative peptides (YSLATSR and VLAPEHEVR) are existing in 
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all four known isoforms of IFT43, the third chosen peptide (ASEEIDEFR) is only existing in two 
of the described isoforms. Appropriately, determined median ratios (H/L) of all transitions for  
YSLATSR and VLAPEHEVR were virtually identical (0.1734 for YSLATSR and 0.1664 for 
VLAPEHEVR), while the determined value for ASEEIDEFR differed (0.0694). In contrast, both 
analysed peptides for IFT122 (WDEAFALGEK and ILFTLAK) are existing in all ten described 
isoforms of IFT122 (for more details see Figure 48 and Figure 49), however the determined 
median of ratios (H/L) of all transitions for both representative peptides unveiled huge 
differences (0.3246 for WDEAFALGEK and 1.8846 for ILFTLAK). This significant variety leads 
to the hypothesis of other existing isoforms which are not described and characterized so far. 
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Table 15: Absolute quantification of purified IFT-A using Flp-In LCA5 performing SRM 
Protein Peptide Pre. m/z Prod. m/z Trans. RT CE Trans. MedianPep MedianProt Stoich.
864.446159 +2y8 43.97 26.9 0.3212
735.403566 +2y7 43.97 28.9 0.3279
664.366452 +2y6 43.97 27.9 0.3043
333.176861 +2y3 43.97 34.9 0.3506
692.434138 +2y6 41.30 19.4 2.3033
579.350074 +2y5 41.30 18.4 1.8792
432.28166 +2y4 41.30 24.4 1.89
331.233982 +2y3 41.30 27.4 1.7648
718.351865 +2y5 40.53 20.5 0.2319
532.272552 +2y4 40.53 20.5 0.2259
417.245609 +2y3 40.53 28.5 0.2316
852.446159 +2y8 16.47 26.0 0.1683
795.424696 +2y7 16.47 27.0 0.1652
724.387582 +2y6 16.47 31.0 0.2041
381.213246 +2y3 16.47 33.0 0.181
634.351865 +2y6 20.45 21.2 0.2602
547.319837 +2y5 20.45 21.2 0.1663
434.235772 +2y4 20.45 20.2 0.1631
363.198659 +2y3 20.45 20.2 0.1805
808.383559 +2y6 30.52 23.6 0.073
679.340966 +2y5 30.52 25.6 0.0657
566.256902 +2y4 30.52 24.6 0.0652
437.214309 +2y3 30.52 27.6 0.0819
837.421342 +2y7 16.38 25.8 0.1492
766.384228 +2y6 16.38 26.8 0.1638
669.331464 +2y5 16.38 32.8 0.1941
540.288871 +2y4 16.38 32.8 0.1689
777.388979 +2y7 28.44 21.8 0.1701
720.367515 +2y6 28.44 21.8 0.1588
633.335487 +2y5 28.44 21.8 0.1629
518.308544 +2y4 28.44 28.8 0.1634
803.425758 +2y7 23.56 24.9 0.2465
690.341694 +2y6 23.56 23.9 0.177
577.25763 +2y5 23.56 23.9 0.1792
448.215037 +2y4 23.56 21.9 0.1906
615.309666 +2y5 18.61 19.0 0.181
486.267073 +2y4 18.61 18.0 0.1609
371.24013 +2y3 18.61 25.0 0.1549
457.22929 +2b4 18.61 17.0 -
736.423967 +2y6 42.39 20.2 0.4188
589.355553 +2y5 42.39 20.2 0.9484
502.323525 +2y4 42.39 26.2 0.4324
389.239461 +2y3 42.39 28.2 0.4946
708.403901 +2y6 21.65 19.9 0.3227
637.366787 +2y5 21.65 19.9 0.2398
550.334758 +2y4 21.65 20.9 0.2461
451.266344 +2y3 21.65 20.9 0.2302
642.429721 +2y6 38.13 22.5 -
529.345657 +2y5 38.13 18.5 0.2222
458.308544 +2y4 38.13 18.5 0.2337
345.22448 +2y3 38.13 17.5 0.239
797.451579 +2y7 18.88 24.2 0.1976
726.414465 +2y6 18.88 24.2 0.2181
502.323525 +2y4 18.88 29.2 0.2067
389.239461 +2y3 18.88 31.2 0.2607
Pre. m/z: precursor m/z
Prod. m/z: Product m/z
Trans.: Transition
RT: retention time
CE: collision energy
Pep: peptide
Prot: protein
Stoich: stoichiometry
Ratio H/L: Ratio lebelled peptide to unlabelled peptide
0.2231 1.37
0.3532 2.17
6.77
ILFTLAK 403.262739 1.8846
0.2031
IFT122
WDEAFALGEK 583.279846 0.3246
1.1046
Ratio H/L
1.25
AHGALTEAYK 530.774731 0.1747
IFT140
FWDIER 433.213777 0.2316
IFT43
YSLATSR 399.211235 0.1734
525.290548 0.1664
0.1664 1.02ASEEIEDFR 548.251285 0.0694
VLAPEHEVR
TTC21B
YGSDPVFR 470.729792 0.1632
364.700503 0.1609
390.224145 0.2430
0.1632 1.00EAILESDAR 502.256371 0.1849
LEDVPR
DLAIGLR 379.23197 0.2337
YASHLLEK
WDR19
480.761092 0.2124
WDR35
AASVYIR
IFSLLEK 425.257654 0.4635
 
Results  99 
 
 
 
The determined IFT-A stoichiometries using the three different baits are shown in Figure 29. 
This figure shows the data of four biological replicates, measured in three technical replicates, 
each. The complex stoichiometry of IFT-A, purified from Flp-In (N)-SF-TULP3 or Flp-In (N)-SF-
LCA5 cells, leads to virtually identical complex composition. IFT122 represented the most 
abundant protein with 48% followed by WDR19 (16%) and WDR35 (11%). TTC21B and IFT43 
were less abundant with a proportion of approximately 8%. In contrast and supported by the 
statement of Gibson et al. in 2013 [58], an introduced overexpression, even though these are no 
transient overexpressions, of an internal component of the IFT-A (IFT122) leads to a 
significantly altered complex composition. Analogous to IFT-A complexes isolated with TULP3 
and LCA5 as bait, the most abundant protein was as well IFT122 (56%) but with a clearly higher 
abundance. However, in this experiment WDR19 and IFT140 represented the lowest abundant 
proteins (4%, 2%) here and clearly differed from Flp-In (N)-SF-LCA5 and Flp-In (N)-SF-TULP3. 
This demonstrates that even though stable expression was achieved, the artificial expression of 
an integral component of a protein complex can lead to a severely disturbed stoichiometry. 
 
Figure 29: Stoichiometry of purified IFT-A using different baits performing SRM 
To determine the stoichiometry of IFT-A, Flp-In monoclonal l ines expressing either (N)-SF-
TAP-tagged IFT122, TULP3 or LCA5 were used for one-step aff inity purif ication. Then, 
absolute quantif ication was performed using a SRM approach. Using IFT-A-associated 
proteins or interactors of IFT-A as bait resulted in very similar results, whereas the use of 
an internal component of the IFT-A resulted in a signif icantly different composit ion. 
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4.4.2.2 PRM Assay using an equimolar standard mix of 24 standard peptides 
After a QExactive Plus instrument was available in our lab, a Parallel Reaction Monitoring 
(PRM) approach was set up. To have at least three representative peptides available for the 
quantification of each protein, a new equimolar standard mix containing additional 
representatives was generated. As described in 4.3.4.1, representative peptides which are not 
existing in all the described isoforms of the corresponding IFT-A component led to significant 
variances in the determined median ratios (H/L) of the analysed transitions. To circumvent this 
error-prone quantification, additional representative peptides, ideally present on all described 
isoforms of the corresponding IFT-A protein, were chosen. This equimolar standard mix consists 
of three representative peptides for IFT140, IFT43, TTC21B and WDR35 and of six 
representative peptides for IFT122 and WDR19 (see Table 16). Due to the big difference in 
determined ratio of unlabelled to labelled peptide of two different representative peptides of the 
same IFT-A component, shown in further experiments (see Table 15), the number of standard 
peptides for IFT122 and WDR19 was significantly increased. As an example, detailed 
information of the analysis of one biological replicate from Flp-In (N)-SF-TULP3 is depicted in 
Table 16. For further details like standard deviation (SD) and percent coefficient of variation see 
Table 18. Each IFT-A complex component is depicted in a different colour. Colour gradation 
highlights different product ions, included in the calculation. Analysis was performed the same 
way as for the SRM approach. Ratio of labelled to unlabelled transitions was determined using 
Skyline. After calculating the median of all ratios of fragment ions within a representative 
peptide, the median of all representative peptides per protein was determined, to diminish the 
influence of individual representative peptides which are probably not present in all existing 
isoforms (described as well as not yet described isoforms) of the corresponding IFT-A proteins. 
The distribution of the representative peptides on described isoforms of the corresponding IFT-
A components is depicted in Figure 48. For the stoichiometry determination of IFT-A, all ratios 
were normalized to the value of the lowest abundant protein (IFT43). 
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Table 16: Absolute quantification of IFT-A using Flp-In (N)-SF-TULP3 performing PRM 
Protein Peptide Precursor m/z Fragment Ion RT Fragment Ion MedianPeptide MedianProtein Stoich.
y10 0.8024
y6 0.7132
y7 0.7132
y8 0.7434
y9 0.7387
y4 0.3414
y5 0.3019
y6 0.4232
y7 0.6749
y8 0.6761
y9 0.7025
y4 0.9516
y5 1.3372
y6 0.8298
y6 1.1704
y7 0.9332
y8 0.9653
y9 1.0574
y6 0.7501
y7 0.5174
y8 0.5831
y9 0.7258
y5 0.7364
y6 0.6396
y7 0.6606
y8 0.6851
y4 0.7459
y5 0.7327
y6 0.5854
y7 0.4631
y8 0.4969
y4 0.2023
y5 0.1898
y6 0.1918
y7 0.1683
y8 0.1900
y4 0.3371
y5 0.4550
y6 0.3959
y7 0.3723
y8 0.4796
y4 0.5853
y5 0.6253
y6 0.4938
y5 0.5960
y6 0.6870
y7 0.6347
y3 0.4036
y4 0.4977
y5 0.4429
y4 0.6111
y5 0.6012
y6 0.5340
y7 0.5474
y3 0.6282
y4 0.6703
y5 0.7151
y6 0.4904
y6 0.1573
y7 0.1592
y8 0.1408
y4 0.3657
y5 0.3210
y6 0.4165
y4 0.6151
y5 0.8795
y6 0.2704
y10 0.6379
y11 0.4778
y6 0.7080
y7 0.6302
y8 0.5403
y9 0.5115
y10 1.3723
y6 1.0876
y7 0.9379
y8 1.0947
y9 1.2419
y4 0.6749
y5 0.6136
y6 0.5610
y5 0.5268
y6 0.4588
y4 0.4968
y5 0.5081
y6 0.5681
y7 0.5806
RT: retention time
Stoich: stoichiometry
Ratio H/L: Ratio labelled peptide to unlabelled peptide
17.93 0.4928
0.7074
0.6729
0.3959
0.5743
0.6002
0.5381
0.615148.6
VLAPEHEVR 530.294682 26.44 0.3959
FWDIER 438.217912 51.97 0.7393
0.1900553.25542
YASHLLEK 484.768191 28.42 0.5381
VGDLLPHVSSPK 628.858069 44.1 0.5853
THVIAASK 417.749802
AHGALTEAYK 534.78183 25.59 0.6729
YGSDPVFR
AASVYIR
475.733926
395.22828
38.27
30.51
587.286945 57.59 1.0113
YLELISSIEER 681.362959 67.98 0.6544
EIGSLLAR 434.759944 46.17 0.6136
LVFIDEK
569.315703
429.264753
436.254385
63.31
55.7
27.9
0.6347
0.4429
DGDVLAVIAEK
IFSLLEK
0.1573
0.3657
0.5743
0.6492
0.9516
SHLFVDEGLK 576.810587 42.42 0.4969
YSLATSR 404.215369 28.77 0.5853
WDEAFALGEK
0.7387
DTPSGISK 406.715624 21.69 0.3414
GEYILLGGSDK 580.307878 51.66 0.6761
40.56
53.71
VGSFLAVGTVK 543.325873 52.86
ILFTLAK 407.269839 54.63
EAILESDAR 33.09
TTC21B 1.45
WDR19 1.52
WDR35 1.36
1.0947
LEDVPR
507.260505
369.704637
Ratio H/L
IFT122 1.80
IFT140 1.70
IFT43 1.00
DSIGDEDPFTAK 651.800614
ASEEIEDFR
 
102  Results 
 
To validate the result of stoichiometry alterations induced by the use of IFT122 as bait, absolute 
quantification of IFT-A from all three generated Flp-In clones was performed using PRM and the 
equimolar standard mixture consisting of 24 representative peptides in total. Four biological 
replicates were prepared for each cell line and each sample was measured twice (see Figure 
30). 
 
Figure 30: PRM-based stoichiometry of purified IFT-A using three different baits 
Absolute quantif ication performing PRM of purif ied IFT-A from the three Flp-In monoclonal 
cel l l ines revealed differences in IFT-A stoichiometry depending on whether an integral 
part of the protein complex is used as bait (as in case of IFT-A purif ied from (N)-SF-
IFT122) or bait proteins that are associated with the IFT-A ((N)-SF-TULP3) or labile 
interaction partners ((N)-SF-LCA5) of the protein complex. For the calculation of the 
stoichiometry, four biological repl icates, measured as two technical replicates, were 
consulted. 
Comparing the results from all three cell lines, determined stoichiometries of IFT-A from Flp-In 
(N)-SF-TULP3 and Flp-In (N)-SF-LCA5 were again virtually identical, whereas the composition 
of IFT-A using IFT122 as bait protein significantly differed. Considering the coefficient of 
variance (CV) for stoichiometries obtained with IFT122 and TULP3 as baits, CV values were 
below 20%. Analyzing IFT-A composition, purified from Flp-In (N)-SF-LCA5 cells, the variance 
especially for WDR19 and TTC21B is quite high. As mentioned before, LCA5 is a rather labile 
and transiently bound interaction partner of IFT-A, resulting in a lower amount of purified IFT-A 
using Flp-In (N)-SF-LCA5 cells. Due to this low abundance of IFT-A components, the absolute 
quantification of the representative peptides is error-prone. Whereas IFT122 predominated in 
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IFT-A preparations from Flp-In (N)-SF-IFT122 (with a total amount of about 60%), the amount of 
IFT122, IFT140 and TTC21B was similar (around 20%) in Flp-In cell lines with SF-TAP-tagged 
TULP3 or SF-TAP-tagged LCA5 as bait. Thereby, the described core complex of IFT-A, formed 
by IFT122, IFT140 and WDR19 represented the major portion with 59% percent in total. The 
least abundant protein for IFT-A purified from Flp-In (N)-SF-TULP3 and Flp-In (N)-SF-LCA5 was 
IFT43, whereas IFT140 and WDR19 were the least abundant proteins in purified IFT-A from 
Flp-In (N)-SF-IFT122 cells. Considering the determined IFT-A stoichiometry in Flp-In (N)-SF-
TULP3 cells and the molecular masses of the IFT-A components (IFT122: 141.8kDa, IFT140: 
165.2kDa, IFT43: 23.5kDa, TTC21B: 150.9kDa, WDR19: 151.6kDa and WDR35: 133.5kDa), 
the mass of the IFT-A protein complex is a multiple of 1,098kDa.  
4.4.3 Reproducibility 
For the study and understanding of the underlying mechanisms of IFT-A-related ciliopathies, it 
is important to known how reliable the determined protein complex stoichiometry is. Therefore, 
reproducibility of absolute quantification is a crucial point. To evaluate the reproducibility of this 
approach, four biological replicates of purified IFT-A, for each of the generated Flp-In 
monoclonal line, were analysed in duplicates. Results are shown in Figure 31. 
 
 
Figure 31: Reproducibility of absolute quantification using different baits 
An important factor to evaluate the determined complex stoichiometry is the reliabil ity of 
the absolute quantif ication. Therefore, the reproducibil ity of four biological replicates per 
generated cell line, each measured twice, is depicted. Biological replicates of the three 
chosen Flp-in monoclonal cel l l ines are depicted as rhombuses and highlighted in different 
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colours: Flp-In (N)-SF-IFT122 is depicted in blue, Flp-In (N)-SF-TULP3 in red and Flp-In 
(N)-SF-LCA5 is highlighted in green. The mean copy number of each IFT-A component of 
analysed biological replicates is depicted as horizontal line. The error bars represent the 
standard deviation. Biggest variation of biological replicates is apparent in experiments 
using Flp-In (N)-SF-IFT122 cells. In contrast, results of biological replicates using SF-
TAP-tagged TULP3 and SF-TAP-tagged LCA5 are highly reproducible. However, there are 
outl iers for the stoichiometry of TTC21B and WDR19 using Flp-In (N)-SF-LCA5 cells. Flp-
In (N)-SF-TULP3 obtained most reliable data performing absolute quantif icat ion of IFT-A. 
Therefore, this cell line was used for further invest igations. 
4.5 Induced alterations in IFT-A complex stoichiometry  
4.5.1 Gene editing of IFT-A components using the CRISPR/Cas9 system 
The advanced CRISPR/Cas9 system was used to generate targeted mutations in genes 
encoding IFT-A complex components. As shown previously, Flp-In (N)-SF-TULP3 yielded 
comparable stoichiometries of IFT-A compared to Flp-In (N)-SF-LCA5 but achieved better 
results regarding reproducibility. Therefore, previously generated Flp-In (N)-SF-TULP3 
monoclonal cells were used for gene editing as described in 3.2.2.6.  
4.5.1.1 Validation of generated CRISPR clone mixtures using PCR 
Validation of CRISPR/Cas9-induced targeted gene editing was performed by PCR. As depicted 
in Figure 32, different single guide RNAs (sgRNA) were used to target either WDR19 or IFT43. 
To enable homologous directed repair (HDR), HDR constructs were also co-transfected in some 
experiments. Based on expected PCR products of manipulated clones, Flp-In (N)-SF-TULP3 
transfected with Cas9 construct bearing an additional cistron for the expression of 
IFT43_sgRNA1 or IFT43_sgRNA2 or with the combination of IFT43_sgRNA2 and a co-
transfected HDR construct showed promising results (present PCR product for IFT43 (650bp) 
with or without an additional PCR fragment indicating a successful integration of the HDR 
construct (230bp)) and are highlighted in red boxes in Figure 32. These cell mixtures were 
selected for single clone selection. Similarly, transfections of Flp-In (N)-SF-TULP3 with 
constructs bearing WDR19_sgRNA1, WDR19_sgRNA2 as well as transfections with the 
combination of WDR19_sgRNA1 with HDR construct 2 (HDR2) were selected for single clone 
selection. To characterize mutations of single clones, DNA-sequencing was performed (see 
Figure 33 and Figure 34). 
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Figure 32: Validation of generated CRISPPR clone mixtures via PCR 
(N)-SF-TULP3 cells transfected with a Cas9 construct bearing an addit ional cistron for 
various sgRNAs or co-transfected with an addit ional HDR construct were characterized 
performing Polymerase Chain Reaction (PCR). Different primer pairs were used depending 
on applied sgRNA with or without a HDR construct. As expected, PCR fragments for IFT43 
and WDR19 are present in every tested mixture. The clone mixture of Flp-In (N)-SF-
TULP3 treated with IFT43_sgRNA2 and the HDR construct showed an addit ional fragment 
and was chosen with cells transfected only either with IFT43_sgRNA1 or IFT43_sgRNA2 
(highlighted in red (A)) for single clone selection. Tested clone mixture of Flp-In (N)-SF-
TULP3 transfected with WDR19_sgRNA1, WDR19_sgRNA2 and cells transfected with the 
combination of WDR19_sgRNA1 and HDR construct showed expected PCR products for a 
successful edit ing and were selected for single clone selection. As a control, Flp-In cells 
transfected with an “empty” Cas9 vector ( lacking sgRNA) were also chosen for single 
clone selection. 
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4.5.1.2 Validation of CRISPR/Cas9 edited single clones via Sequencing 
Flp-In (N)-SF-TULP3 transfected with Cas9/sgRNA constructs were seeded at low density and 
cultured in DMEM supplemented with puromycin for single clone selection (see 3.2.2.6). 
Individual clones were then characterized by DNA-sequencing. Therefore, genomic DNA was 
extracted and PCR products were analysed. As depicted in Figure 33, two different single 
clones with following mutations in the IFT43 gene were identified: one clone with a single base 
insertion of an adenine (c.541_542insA) and one clone with a single base insertion of a guanine 
(c.582_583insG). The c.541_542insA was observed upon the use of IFT43_sgRNA1 for the 
gene editing experiments. Due to the frame shift, this mutation results in an amino acid 
exchange of threonine (T) to asparagines (N) at amino acid position 181 followed by a 
premature stop (p.T181Nfs*2) in the reading frame for IFT43.  
 
Figure 33: Generated mutations in IFT43 using CRISPR/Cas9 system 
CRISPR/Cas9-based targeted edit ing in Flp-In monoclonal l ine stably expressing SF-TAP-
tagged TULP3 resulted in two different mutants of IFT43: Application of IFT43_sgRNA1 
led to a single base insertion of an adenine (c.541_542insA). This insertion induces a 
frame shift and leads to a truncated IFT43 protein with an amino acid exchange of 
threonine (T) to asparagines (N) and a premature stop (p.T181Nfs*2). In contrast, using 
IFT43_sgRNA2, a mutation (c.582_583insG) that results in a prolonged protein is 
predicted. This protein is characterized by an amino acid exchange from glutamine (Q) to 
alanine (A) fol lowed by 22 addit ional novel amino acids translated from the altered reading 
frame (p.Q195Afs*22). 
The presence of a premature stop codon may provoke a known surveillance pathway present in 
all eukaryotes, the so called nonsense-mediated mRNA decay (NMD). Based on the fact that a 
translation of a protein with an introduced premature stop codon leads in most instances to a 
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non-functional or to a down regulated activity of the resulting protein, this mechanism eliminates 
those altered mRNA constructs preventively [80]. The single base insertion c.582_583insG 
obtained with the IFT43_sgRNA2 results in a frame shift which causes an amino acid exchange 
from a glutamine (Q) to an alanine (A) residue at amino acid position 195 followed by additional 
21 amino acid residues (p.Q195Afs*22) translated from an alternate reading frame. This 
actually resulted in a prolonged protein compared to the wildtype IFT43 (Figure 33).  
 
Figure 34: Generated mutations in WDR19 using CRISPR/Cas9 system 
Performing gene edit ing using CRISPR/Cas9 system resulted in two different mutants of 
WDR19: Application of WDR19_sgRNA1 led to a deletion of two bases 
(c.3107_3108delAT). Based on an induced frame shif t, this leads to an amino acid 
exchange of tyrosine (Y) to phenylalanine (F) fol lowed by a premature stop 
(p.Y1036Ffs*5). The second mutation in WDR19 was obtained applying WDR19_sgRNA2. 
Thereby, eleven basepairs were deleted and five basepairs inserted, afterwards 
(c.3063_3074delinsAGATC). The result ing frame shift leads to an amino acid exchange 
from arginine (R) to aspartate (D) at amino acid posit ion 1022 followed by 21 novel amino 
acid residues (p.R1022Dfs*21). 
Obtained mutations within the WDR19 gene are shown in Figure 34. Again, two mutations 
within single clones were validated by DNA sequencing. One clone, obtained from gene editing 
with WDR19_sgRNA1, had a deletion of two bases (c.3107_3108delAT) and the second clone, 
obtained with the WDR19_sgRNA2, had a complex insertion/ deletion mutation with eleven 
basepairs deleted and five basepairs inserted (c.3063_3074delinsAGATC). The 
c.3107_3108delAT causes a frame shift and results in an amino acid exchange at position 1036 
followed by a premature stop (p.Y1036Ffs*5). The second identified mutations 
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(c.3063_3074delinsAGATC) also introduces a frame shift leading to a protein characterized by 
an amino acid exchange of an arginine (R) to an aspartate (D) followed by 21 novel amino acid 
residues (p.R1022Dfs*21). 
4.5.2 Absolute quantification of IFT-A in CRISPR/Cas9-induced mutant cell 
clones 
To determine the potential effect of mutant IFT43 as well as of mutant WDR19 on the 
composition and stoichiometry of IFT-A, absolute quantification was performed using IFT-A 
purified from single clones carrying mutations either in WDR19 or IFT43 as well as in control 
cells. Results from the first pilot experiment are shown in Figure 35. Most mutant clones did not 
show a significant effect on complex composition of IFT-A, except clones carrying the 
p.T181Nfs*2 mutation in IFT43. Sequencing results of all three tested single clones, containing 
the IFT43_p.T181Nfs*2 mutation, were identical. However, differences on protein level were 
determined. 
 
Figure 35: Effect on IFT-A composition of all identified single clones 
Absolute quantif ication of CRISPR/Cas9-induced mutant clones was performed to identify 
effects on the composit ion and stoichiometry of IFT-A. In comparison to the control (WT), 
mainly the mutant carrying the p.T181Nfs*2 in IFT43 showed clear alterations in the 
stoichiometry of IFT-A components. In comparison to the control, this mutation is 
characterized by an increased portion of the IFT-A components IFT122, IFT140 and 
WDR19 in comparison to IFT43, TTC21B and WDR35. Although no difference in DNA 
sequence of the three tested single clones was identif ied, a slight alteration in 
composit ion of IFT-A can be shown. 
To analyse the effect on IFT-A composition upon introduction of a mutant, four different single 
clones (WT, WDR19_p.R1022Dfs*21, IFT43_p.Q195Afs*22 and IFT43_p.T181Nfs*2) were 
selected and used to prepare four biological replicates per clone. Absolute quantification was 
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performed for four biological replicates per single clone and each was measured twice as 
technical replicate. Results are depicted in Figure 36. 
 
Figure 36: Effect of selected single clones on complex composition of purified IFT-A 
A strong effect on IFT-A complex stoichiometry was observed in the Flp-In (N)-SF-TULP3 
carrying the p.T181Nfs*2 mutation in IFT43. Cells from clones carrying the p.Q195Afs*22 
mutation in IFT43 or the p.R1022Dfs*21 mutation in WDR19 showed no alterat ion in IFT-A 
composit ion compared to WT cells. The determined ratio of labelled to unlabelled protein 
(determined by the representative standard peptides) is depicted in the bar chart. As 
depicted, protein expression level of the IFT-A components of cells carrying the 
IFT43_p.Q195Afs*22 mutation is similar to the expression level in the control cells. For 
cel ls with WDR19_p.R1022Dfs*21 the expression level is reduced while the composit ion of 
the IFT-A stays the same. In contrast,  the overall expression level of IFT-A components in 
Flp-In (N)-SF-TULP3 cells carrying the IFT43_p.T181Nfs*2 mutation is reduced while the 
composit ion is characterized by a loss of IFT43, TTC21B and WDR35. 
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Regarding the bar chart, protein expression level of analysed single clones is depicted. 
Whereas the expression level of all IFT-A components of Flp-In (N)-SF-TULP3 cells carrying the 
IFT43_p.Q195Afs*22 mutation showed no significant alteration in comparison to the control 
cells, the expression level of cells either with WDR19_p.R1022Dfs*21 mutation or 
IFT43_p.T181Nfs*2 was obviously reduced. While composition of IFT-A in Flp-In (N)-SF-TULP3 
with WDR19_p.R1022Dfs*21 stayed unaltered, stoichiometry of IFT-A in cells carrying the 
c.541_542insA mutation that causes a premature stop in IFT43 (p.T181Nfs*2) was changed. 
4.5.3 IFT-A complex composition within fibroblasts 
This approach was adapted to IFT-A purified from human fibroblasts. Therefore, human 
fibroblasts of either control persons or of patients carrying mutations related to the ciliopathy 
Sensenbrenner Syndrome were transfected with TULP3 to pull out the IFT-A complex by one-
step affinity purification using anti-FLAG-M2-agarose beads. The cultivation of human 
fibroblasts as well as the one-step affinity purification was done by Machteld Oud, a PhD 
student at the Radboud university medical center Department of Human Genetics in Nijmegen 
(Netherlands). Afterwards, eluates of one-step affinity purification were sent to our lab for 
protein precipitation and enzymatic cleavage followed by absolute quantification using the 
equimolar standard mix in combination with PRM (see 3.2.5.1). First results of IFT-A 
composition of human fibroblasts are highlighted in Figure 37. In this graph, results of IFT-A 
composition obtained from human fibroblasts are face to face with results obtained with Flp-In 
(N)-SF-TULP3 monoclonal cells. As depicted in Figure 37A, although only one biological 
replicate for the human fibroblasts was available for absolute quantification so far, the 
composition of IFT-A in healthy control fibroblasts was identical to the composition within Flp-In 
(N)-SF-TULP3 cells. Results for IFT-A composition within human fibroblasts carrying a 
homozygous mutation in the gene encoding IFT43 (c.1A>G/p.M1_K21del) were comparable to 
the composition of Flp-In (N)-SF-TULP3 carrying the IFT43_p.T181Nfs*2 mutation. In both 
cases the portion of IFT43, TTC21B and WDR35 was reduced in contrast to the amount of 
IFT122, IFT140 and WDR19. Regarding protein expression levels of the IFT-A components, 
highlighted in Figure 37B, the expression level of the healthy fibroblasts was comparable to the 
expression level of all components within Flp-In (N)-SF-TULP3 cells. Although the expression 
level of IFT122, IFT140 and WDR19 within human fibroblasts carrying the homozygous 
mutation were similar to the control cells, the protein expression level of IFT43, TTC21B and 
WDR35 was significantly reduced. In contrast, the expression level of the IFT-A components 
within Flp-In (N)-SF-TULP3 control line with IFT43_p.T181Nfs*2 was lower than for the 
Sensenbrenner Syndrome-related mutation in human fibroblasts.  
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Figure 37: IFT-A complex composition within human fibroblasts 
To compare complex composit ion of IFT-A purif ied from human fibroblasts with IFT-A 
stoichiometry from Flp-In (N)-SF-TULP3 cells,  results of absolute quantif ication of control 
cel l l ines as well as a cell l ines carrying mutations within IFT43 are depicted. A: Complex 
composit ion of IFT-A in control cell l ines was identical for both, human fibroblasts as well 
as Flp-In cells, although only one biological replicate was available for absolute 
quantif ication. Comparing both cell lines carrying mutations within IFT43, the complex 
composit ion was virtual ly identical. B: Regarding both control lines, the protein expression 
level was similar. For the human fibroblasts carrying the homozygous mutation, 
expression level of three components (IFT122, IFT140 and WDR19) was comparable to 
the one obtained in the control l ines, while the expression level of IFT43, TTC21B and 
WDR35 was reduced. In contrast, the protein expression level of all IFT-A components 
within Flp-In cells carrying the IFT43_p.T181Nfs*2 mutat ion was reduced. 
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4.5.4 Complex composition of IFT-A during ciliary assembly and disassembly 
A biological process which might lead to alterations in the stoichiometry of IFT-A is the 
assembly and disassembly of cilia. As described before (see 1.1.2), IFT-A is involved in 
retrograde intraflagellar transport (IFT) returning protein cargo from the ciliary tip back to the cell 
body. To promote different ciliary stages, hTERT-RPE1 cells were cultured in various conditions 
before absolute quantification of purified IFT-A was performed. To support the assembly of cilia, 
cells were starved whereas restimulation of starved cells results in the disassembly of cilia. 
To compare the alterations within IFT-A complex composition during different ciliary stages, 
composition of purified IFT-A from hTERT-RPE1 cells, starved for 24h, were compared to the 
stoichiometry of IFT-A within cells starved for 24h with following restimulation period of either 2h 
or 4h. As a control, purified IFT-A from hTERT-RPE1 cells, cultured in growth medium, were 
analysed (see Figure 38). This first experiment unveiled alterations within IFT-A composition 
during the assembly and disassembly of cilia. As expected, IFT-A composition purified from 
hTERT-RPE1 cells starved for 24h with following restimulation period showed big differences in 
complex stoichiometry in contrast to control cells as well as to the cells that were starved for 
24h without restimulation. Additionally, control cells showed similar results for IFT-A composition 
like hTERT-RPE1 with induced assembly of the cilia. Regarding the bar chart, protein 
expression level of the IFT-A components in control cells as well as in conditions forcing the 
assembly of cilia is much higher than for IFT-A during ciliary disassembly. Cells, representing 
the control fraction were seeded one day later than cells of different starvation and restimulation 
conditions. The similarity of IFT-A composition of the control cells to the composition within cells 
starved for 24 hours hypothesizes a potential influence of cell confluence on the complex 
composition of purified IFT-A. Therefore, another experiment investigating complex composition 
of IFT-A considering higher cell confluence was performed. Different IFT-A stoichiometries 
considering cell confluence are depicted in Figure 39. Again same growth conditions were 
tested as in the previous experiment to simulate ciliary assembly as well as the disassembly of 
cilia. To simulate higher cell confluence, more cells were seeded per 14cm culture dish. As 
highlighted in Figure 39, no alteration within the complex composition of purified IFT-A was 
identified. The composition of IFT-A within hTERT-RPE1 cells of high cell confluence was 
comparable to the stoichiometry of the ciliary assembly of the previous experiment. These 
results verify the hypothesis that the phenotype of ciliary assembly or disassembly of hTERT-
RPE1 cells is depending on cell confluence. 
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Figure 38: Complex composition of IFT-A during ciliary assembly and disassembly 
To investigate stoichiometric alterations of IFT-A during dif ferent cil iary stages, hTERT-
RPE1 cells of different cult ivat ion condit ions were analysed by absolute quantif ication. 
Control cells were cultured in growth medium, while other ci l iary stages were simulated by 
24h starvation, 24h starvation followed by 2h of restimulation or 24h starvation followed by 
4h of restimulat ion. Cells, starved for 24h, unveiled different composit ion of IFT-A 
condit ions in comparison to hTERT-RPE1 cells starved for 24h with following 
rest imulation. Unexpectedly, control cells showed similar complex composit ion as cells 
starved for 24h. This may be caused by a high confluence of cells in the control 
condit ions, simulating a similar condit ion as for starved cells. Regarding the bar charts, 
protein expression levels of IFT-A components in condit ions forcing ciliary disassembly 
were decreased in comparison to the control cells as well as in the stage of cil iary 
assembly. The composit ion of the control cells hypothesizes a potential inf luence of cell 
confluence on complex stoichiometry of IFT-A. 
114  Results 
 
 
Figure 39: Confluence-related complex composition of IFT-A 
To study the influence of cell confluence on IFT-A complex composit ion, hTERT-RPE1 
cells were cultured under different condit ions while more cells were seeded on each 
culture dish to simulate higher cel l confluence. As depicted, no matter which cell condit ion 
was analysed by absolute quantif ication, the complex composit ion of IFT-A as well as the 
protein expression level of all tested conditions were comparable. This verif ies the 
hypothesis that the assembly or disassembly phenotype of hTERT-RPE1 cells is 
depending on cel l confluence. 
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4.6 Chemical crosslinking of purified IFT-A 
To determine the binding surfaces within the IFT-A and to understand its function, it is 
necessary to gain structural knowledge. For the structural analysis of IFT-A, a huge amount of 
the purified protein complex is crucial. Since yields of purified IFT-A were consistently higher 
using Flp-In (N)-SF-TULP3 cells, this cell line was chosen to investigate the structural 
interaction of IFT-A components by means of chemical crosslinking combined with mass 
spectrometry. After cells were harvested, tandem affinity purification (TAP) of IFT-A was 
performed to purify IFT-A as pure as possible with high and medium affinity interactors only [69, 
81]. After chemical crosslinking and proteolysis of purified proteins, cross-linked peptides were 
enriched before LC-MS/MS analysis to reduce sample complexity and to increase the likelihood 
of identifying true cross-linked peptides (see 3.2.5.2). For an efficient crosslinking of primary 
amines of N-termini and lysine residues of purified IFT-A, reaction conditions like the ratio of 
crosslinker to purified protein and the composition of the reaction buffer had to be chosen 
carefully. 
4.6.1 Optimization of the crosslinking workflow 
The workflow of a chemical crosslinking approach contains a number of critical parameters like 
the amount of purified protein, the selection of a suitable crosslinker, the ratio of chemical 
crosslinker to protein amount, the reaction time and reaction temperature, buffer conditions, the 
enrichment of cross-linked peptides as well as a suitable method for LC-MS/MS analysis. 
4.6.1.1 Presence of dithiotreitol (DTT) during chemical crosslinking 
The presence of dithiotreitol (DTT) in reaction buffers stabilizes the native conformation of 
proteins by preventing cysteine and methionine from oxidation damage [82, 83]. Nevertheless, a 
drawback of DTT is that it reduces disulfide bridges formed by cysteine residues. Thereby, the 
protein structure can be severely altered because the tertiary structure is generally stabilized by 
disulfide bridges [84] and released thiol groups are also accessible to chemical crosslinking with 
succinimidyl esters [85]. However, this may complicate the further data analysis. To explore 
whether the use of DTT improves the data quality, crosslinking either with or without DTT in the 
reaction buffer was performed and identified crosslinks were compared as depicted in Figure 
40. Regarding the average amount of identified crosslinks, the number of inter- and intra-links 
was higher using DTT in the reaction buffer. However, the variance between the biological 
replicates was significantly higher using DTT, except for identified mono-links. Using DTT during 
chemical crosslinking, the biggest portion of identified links was represented by inter-links, while 
mono-links were least abundant. In comparison, without DTT in the reaction buffer, inter-links 
represented the major portion while intra-links were least abundant. 
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Figure 40: Number of identified crosslinks with or without DTT 
To compare the inf luence of dithiotreitol (DTT) on chemical crosslinking, purif ied IFT-A 
was cross-linked using a reaction buffer either with or without 2mM DTT. A: The data of 
six biological repl icates are shown by a rhombus either in blue: with DTT or in red: without 
DTT. The identif ied amount of crosslinks between proteins (inter) or within proteins (intra) 
or single peptides attached to the crosslinker (mono) is used to compare the effect of DTT 
on chemical crosslinking. Mean and standard deviation (SD) of the biological replicates 
are depicted using a horizontal l ine. The average amount of inter- and intra- links was 
higher using DTT in the reaction buffer, although the variance between the biological 
repl icates was much higher using DTT, except for identif ied mono links. B: To identify 
differences between both experiments, the fraction of identif ied crosslink types is 
depicted. Using DTT during chemical crosslinking, the major fraction of identif ied l inks 
were inter-l inks while least abundant l inks were mono-links. In comparison, without DTT in 
the reaction buffer, inter-l inks represented the largest portion, while intra-links were least 
abundant. 
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4.6.1.2 Concentration of the chemical crosslinker DSS 
The ratio of the chemical crosslinker to the protein amount as well as its concentration are 
critical parameters for a successful crosslinking approach. If the amount of chemical crosslinker 
is insufficient, the number of available chemically crosslinked peptides may be too low for mass 
spectrometry analysis. Furthermore, not every accessible lysine residue may be cross-linked 
resulting in an uneven distribution of the cross-linked residues all over the protein complex. In 
contrast, an excess of chemical crosslinker may result in a large fraction of mono-linked 
peptides. As described in previous studies [85, 86], chemical crosslinkers based on succinimidyl 
ester enable crosslinks between primary amines (N-termini, lysine residues) as well as with 
other amino acids like cysteine and tyrosine, although its reactivity with primary amines is 
higher. Certain conditions, like an excess of chemical crosslinker, probably promotes this non-
amine reactivity and thereby enables crosslinking of other residues as well. Furthermore, an 
excess of crosslinker may impede the analysis of low abundant inter- and intra-links due to an 
overrepresentation of mono-linked peptides that will not react with a second residue because 
this is already occupied with another crosslinker molecule. To test different concentrations of 
chemical crosslinker, five different ratios of protein amount to disuccinimidyl suberate (DSS) (5-, 
25-, 40-, 50-, 90-fold) were tested. Evaluation was done comparing the fractions of inter-, intra- 
and mono-links. Results are shown in Figure 41. 
 
Figure 41: Optimization of DSS concentration for chemical crosslinking 
Five ratios of protein amount of purif ied IFT-A to the crosslinker DSS were tested to 
identify best reaction condit ions. As expected, higher amounts of chemical crosslinker 
increased the fraction of mono-links (depicted in green) and reduced the portion of 
identif ied inter-l inks (blue). In contrast, decreasing the amount of DSS led to an increase 
in the fraction of identif ied inter-l inks. Considering the three experiments with 40-, 50- and 
90-fold excess of protein in relation to applied crosslinker, no dramatic increase in intra- 
and inter-l inks was achieved. A 50-fold excess of protein is a good ratio because there is 
enough buffer for technical errors. Therefore, this condit ion (50-fold protein to crosslinker) 
was chosen for further structural investigation of IFT-A. 
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The least amount of identified inter-links (between two different peptides of different proteins) 
was obtained using a 5-fold or 25-fold excess of protein to chemical crosslinker. For this ratio of 
protein to crosslinker, highest amount of mono-links was obtained. With decreasing amount of 
chemical crosslinker the fraction of identified inter-links raised. Considering the three 
experiments with a 40, 50 and 90-fold excess of protein to DSS, no further dramatic increase in 
inter- and intra-links was obtained. Based on these results, a 50-fold excess of protein amount 
in relation to the chemical crosslinker DSS was used for further structural investigation of IFT-A 
because this ratio offers enough buffer for technical errors. 
4.6.1.3 Different methods to enrich cross-linked peptides 
For LC-MS/MS analysis of low abundant peptides, an enrichment step is required. To enrich low 
abundant cross-linked peptides within a complex mixture of inter-, intra-, mono- and non-linked 
peptides, size exclusion chromatography (SEC) is a well-established method. This method is 
based on separation of the peptide mixture by liquid chromatography. Thereby, small molecules 
are restrained in the pores of the column material, while bigger molecules, for example cross-
linked peptides, are able to pass. Thereby, cross-linked peptides are eluting in the first fractions 
which can then be used for further LC-MS/MS analysis. Although SEC is well described and 
established for this application, this approach is labour- and time-consuming as well as 
expensive. Therefore, I tested whether filtration through a 3kDa CutOff spin column is capable 
to replace SEC for this application. The principle is similar: larger molecules are restrained in 
the upper part of the filter while small molecules pass through the filter. The results for the 
comparison of both methods is shown in Figure 42. The amount of each identified crosslink type 
achieved with SEC or using 3kDA CutOff spin columns is illustrated. For this experiment, Flp-In 
(N)-SF-TULP3 cells were used. After purification of IFT-A with following chemical crosslinking, 
cross-linked peptides were either enriched by SEC or 3kDa CutOff spin column filtration to 
reduce sample complexity. As depicted in Figure 42A, the distribution of identified precursor 
ions in lower mass ranges (1500-4500) was similar, whereas precursors with higher molecular 
masses (>4500) were not identified after 3kDa CutOff column filtration. As highlighted in Figure 
42B, the proportion of identified crosslink types differed between both methods. After SEC, 
mono-linked peptides represented the least abundant portion. In contrast, after using CutOff 
spin columns, the fraction of intra molecular crosslinks was least abundant. Regarding the 
number of identified crosslinks, SEC of purified samples yielded in significantly more inter- and 
intra-links than using spin columns. 
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Figure 42: SEC or CutOff spin column filtration for the purification of cross-linked peptides 
Direct comparison of SEC and 3kDa CutOff spin column filtration for the purif ication of 
cross-linked peptide mixture. IFT-A, purif ied from Flp-In (N)-SF-TULP3 was used for 
chemical crosslinking. The sample was prefractionated either by SEC or using spin 
columns followed by LC-MS/MS analysis. A: Comparing the precursor distribution, 
patterns of both methods were similar in the molecular mass range of 1500 to 4500. For 
higher M r , precursor ions were only identif ied in the sample purif ied by SEC. B: The ratio 
of identif ied crosslink types differed between both tested methods. Performing SEC, the 
amount of mono-linked peptides (depicted in green) represented the smallest fraction. 
Using spin columns resulted in less intra-links (red). Also the overall amount of identif ied 
inter- and intra-l inks was notably higher performing SEC. 
120  Results 
 
Another experiment with four biological replicates was performed to compare efficiency and 
robustness of both enrichment methods in more detail. In this experiment, HEK293T cells 
transiently transfected with TULP3 were used to generate biological replicates, because the 
amount of purified IFT-A is higher using overexpression. Again, purification and crosslinking 
was performed. Then, the cross-linked peptide mix was split to perform both enrichment 
methods separately. Detailed results are shown in Figure 43. Comparing the distribution of 
identified precursor ions performing SEC (highlighted in blue) or spin column filtration (depicted 
in red), the distributions were similar with most identified precursors the molecular mass range 
of 1500 to 2000 (see Figure 43A). However, standard deviation was much higher performing 
SEC. Figure 43B gives the average distribution (left) and amount (right) of identified links for 
both enrichment methods. While no difference within the proportions of crosslink types was 
apparent, the average number of identified crosslinks was higher using 3kDa CutOff spin 
columns. Furthermore, this simplified method led to less variations over the four replicates. The 
distribution of the data for the four replicates is depicted in Figure 43C. Each rhombus 
represents one biological replicate either performing SEC (blue) or spin column filtration (red). 
While the identified numbers of crosslinks within the biological replicates using spin columns 
were stable with only one outlier present, values generated performing SEC were highly 
dispersed. 
The number of identified links within IFT-A, purified from HEK293T cells, was higher after spin 
column filtration in contrast to the higher number of identified links after SEC in the previous 
experiment using IFT-A purified from Flp-In (N)-SF-TULP cells (see Figure 42). These variations 
might be explained by a higher sensitivity of SEC. Thereby, 3kDa Cut Off spin columns are less 
sensitive with lower amounts of starting material (in experiments purifying IFT-A from Flp-In (N)-
SF-TULP3 cells) than SEC. In contrast, with an increase in sample amount (in experiments 
using HEKT293T cells for the purification of IFT-A) this sensitivity gain of SEC might be 
compensated. To compare both enrichment methods and to evaluate potential effects of the 
used method on the identification and localisation of crosslinks, identified links for all 
experiments were visualized using the software tool Xinet (see 4.6.2). 
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Figure 43: SEC and spin column filtration of cross-linked peptide mixture from HEK293Ts 
To compare the eff iciency of both enrichment methods, four addit ional biological 
repl icates were generated using HEK293T cells, transient ly transfected with (N)-SF-
TULP3. After purif ication and crosslinking, sample was split and enrichment of cross-
linked peptides was either performed by SEC or using 3kDa CutOff spin columns. A: 
Precursor distr ibution of both tested methods showed no signif icant difference. With both 
methods, precursors of a molecular mass within the range of 1500 to 2500 were most 
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abundant. Variations within analysed replicates were much higher performing SEC. B: The 
average number of identif ied crosslinks was higher using spin columns (red), although the 
distribution of crosslink types was highly similar. Addit ionally, this simplif ied method using 
spin columns led to less variation over the replicates. C: Reproducibility of both 
enrichment methods. The data points for all biological replicates are shown as rhombuses. 
The ones obtained after SEC are depicted in blue and the ones using spin columns are 
highlighted in red. The average number and the standard deviation of identif ied crossl inks 
are il lustrated by horizontal l ines either in blue or red. Identif ied crosslinks performing 
SEC were highly disperse, whereas results obtained using spin columns were much more 
consistent.  
4.6.2 Structural investigation of IFT-A using chemical crosslinking 
For the extraction of identified links within the biological sample, the Software pipeline 
xQuest/xProphet was used. The freely available software tool Xinet was applied for the 
visualization of identified crosslinks. 
4.6.2.1 Identified links within IFT-A after SEC 
Identified crosslinks, obtained from Flp-In (N)-SF TULP3 cells using a 50-fold excess of protein 
to DSS, are depicted in Figure 44. In Figure 44A the number of crosslinks either identified in at 
least two of three biological replicates or in three of three biological replicates are listed. Total 
number of crosslinks, identified in at least three biological replicates, are visualized in Figure 
44B, while crosslinks, identified in all tested biological replicates, are highlighted in Figure 44C. 
A total number of 708 crosslinks was identified considering only links that were present in at 
least two of the three tested samples. Thereby, more than 50 percent (54.5%) of the identified 
crosslinks were inter-links (386 inter-links) followed by 27.7% mono-links (196 mono-links) and 
17.8% of intra-links (126 intra-links). In contrast, 224 crosslinks were identified in all three tested 
biological replicates. Again most portion of identified crosslinks were represented by 103 
identified inter-links (46.0%) followed by 42.0% of mono-links (94 mono-links) and 12.1% intra-
links (27 identified intra-links). As depicted in Figure 44B, considering crosslinks identified in at 
least two of the three tested samples, crosslinks within all of the six protein components of IFT-
A were identified. The smaller graph on top represents a scheme of the identified crosslinks by 
correlating the thickness of the lines to the number of identified inter-links. For example in the 
approach considering only links identified in two of three experiments, only crosslinks between 
IFT43 and four other components (IFT122, TTC21B, IFT140 and WDR35) were identified and 
were least abundant (thin lines) in comparison to high abundant links between IFT140 and 
TTC21B (thick lines). The lower graphs of Figure 44B/C illustrate the identified crosslinks in 
more detail. This closer look into the localisation of identified links unveiled that most identified 
crosslinks between proteins and within a protein are present within described interaction 
domains, like TPR domains (light blue) and WD40 domains (light green). For example, many of 
the identified inter-links between WDR19 and IFT140 were identified between the TPR regions 
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between amino acid position 800 and 950 of WDR19 with the WD40 domains between amino 
acid position 250 and 370 of IFT140 or with the TPR domains localised around amino acid 
position 1200 of IFT140. As depicted, many links were identified on spots which are not 
described so far. This data indicates additional interaction domains which are not described and 
characterized, yet. Similar results were achieved by a more stringent approach, depicting links 
that were identified in three of three analysed biological replicates, shown in Figure 44C. 
However, no links within IFT43 were identified considering only crosslinks identified in all three 
tested replicates. The overall number of identified links was reduced significantly. Nevertheless, 
many of the crosslinks identified in all three experiments were located within described 
interaction domains and again not yet described crosslinking “hotspots” were identified, further 
on. 
For detailed information about amino acid position and peptide sequences of identified 
crosslinks, see Table 19 (for links identified in at least two of three replicates ) and Table 20 ( for 
crosslinks identified in all tested experiments) in the annex.  
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Figure 44: Identified links within IFT-A from Flp-In (N)-SF TULP3 after SEC 
To visualize the extracted information of identif ied crosslinks, Xinet was used to depict 
l inks of Flp-In (N)-SF TULP3 cells cross-linked with DSS in the ratio 50:1 
(protein:crosslinker). A: Links either identif ied in at least two of three or in all three tested 
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samples are listed. Thereby, the overall number of l inks identif ied in at least two of three 
replicates was 708 in contrast to 224 links identif ied in all experiments. For both analysis, 
the port ion of inter-l inks was higher than for intra- as well as for mono-links. The 
generated model on top of f igure B and C il lustrates the amount of identif ied l inks 
schematically, while the graph below visualizes the localizat ion of the identif ied links in 
detail. Thereby, inter-links between two different IFT-A components are depicted by dark 
green lines, intra-links are highlighted by purple semicircles, loop-links identif ied within 
the same peptide are depicted as red loops and mono-l inks are highlighted by purple 
f lags. Known and described interaction domains within IFT-A components are highlighted 
on the protein representation in light green (WD40 domains) and light blue (TPR domains). 
B: Links identif ied in at least two of three biological replicates were depicted. Many of the 
identif ied links were localized within known interaction domains, for example the identif ied 
inter-l inks between TPR regions (amino acid posit ion 800 to 950) of WDR19 with WD40 
domains (amino acid position 250 to 370) or with TPR regions (around amino acid posit ion 
1200) of IFT140. Addit ionally, many links were localized in regions which are not 
described so far, indicating addit ional interaction domains (e.g. at amino acid posit ion 600 
or 1120 of WDR35). C: Only links identif ied in all three biological replicates were 
highlighted. Thereby, the overall amount of identif ied links was reduced in contrast to l inks 
identif ied in at least two of three experiments. For example no link between IFT43 and any 
other component of IFT-A was identif ied in all three experiments. Nevertheless, some links 
between IFT-A components were quite robust and were identif ied in all tested samples. 
Again, some of the robust crossl inks were identif ied in described interacting domains like 
in TPR domains of WDR19, whereas some crosslinks were identif ied in undescr ibed 
regions (e.g. around amino acid posit ion 1150 of WDR19) indicating new interaction 
domains. 
4.6.2.2 Identified links within IFT-A using different enrichment methods 
As described in 3.2.5, two different methods were used to enrich chemically cross-linked 
peptides. This fractionation is essential for the identification of low abundant cross-linked 
peptides via mass spectrometry. To facilitate the enrichment of chemically cross-linked 
peptides, 3kDa CutOff spin columns were used to reduce sample complexity. This approach 
was compared to the well described but time-, labour- and cost-intense size exclusion 
chromatography (SEC). Therefore, a chemically cross-linked sample (as described in 3.2.5.2) 
was split after proteolysis and either SEC or spin column filtration was performed for 
fractionation. After MS rawfiles were evaluated by xQuest/xProphet, identified links were 
visualized using Xinet.  
Chemical crosslinking of IFT-A purified from Flp-In (N)-SF-TULP3 cells 
Results are shown in Figure 45. Total number of identified links of one biological sample 
obtained either after SEC or 3kDa CutOff spin column filtration are listed in Figure 45A. The 
total number of links identified after SEC (864 links) was significantly higher than after CutOff 
column filtration (629 links), although the portion of identified inter-links was higher for both 
approaches (66.1% for SEC and 56.4% for CutOff spin columns) than for the other link types. 
Performing SEC resulted in 18.5% intra-links (160 intra-links) followed by 15.4% mono-linked 
peptides (133 mono-links). In contrast, only 13.5% of identified links using spin columns were 
intra-links (85 intra-links) while 30.0% were represented by mono-links (189 mono-linked 
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peptides). Localisation of identified links obtained after SEC are depicted in Figure 45B, while 
position of identified links obtained using spin columns are highlighted in Figure 45C. 
Considering the schematic models of the identified links (upper graph in figure B and C), links 
within all six complex components were identified using both enrichment methods. The 
abundance of inter-links (depicted by the thickness of the lines) was also similar for both 
methods. Thereby, inter-links between IFT140 and TTC21B were most prevalent while inter-
links of IFT43 with the other IFT-A components were least abundant. Using 3kDa CutOff spin 
column filtration to enrich cross-linked peptides, no inter-links between IFT43 and WDR19 were 
identified in contrast to SEC. The localization of the identified links was similar for both 
enrichment methods although the overall number of identified links was higher performing SEC 
(see Figure 45B/C lower graph). Furthermore, localization of identified links was comparable to 
previous results highlighting described interaction domains as well as identifying new interaction 
regions indicated by crosslink “hot-spots” (see Figure 44). 
Amino acid position and peptide sequence of the links, identified in both enrichment methods, 
are shown in the annex (see Table 21). 
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Figure 45: Identified inks of IFT-A (Flp-In (N)-SF TULP3) after SEC or spin column filtration 
Results of two different methods for the enrichment of cross-l inked peptides are depicted. 
A: Numbers of links identif ied either after SEC or after 3kDa CutOff spin column fi ltration 
are l isted. The overal l amount of identif ied links was higher after SEC (864 links) than 
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after spin column filtration (629 links). However, the major portion of identif ied links was 
represented by inter-l inks (66.1% after SEC and 56.4% after spin column fi ltration) for 
both enrichment methods. B: Visualization of identif ied links obtained after SEC. C: 
Visualization of identif ied links obtained after spin column filtration. Both enrichment 
methods identif ied links within all IFT-A complex components, although no inter-l ink 
between IFT43 and WDR19 was identif ied using spin columns. However, the abundances 
of identif ied links were similar for both approaches (corresponding to the thickness of the 
lines in the upper graph). Although the overall amount of identif ied inter-l inks was higher 
after SEC, the localization patterns within the proteins were quite similar for both 
methods. For example the crosslinking hot-spots all over WDR35 were identif ied no matter 
which enr ichment method was used. 
Chemical crosslinking of IFT-A purified from HEK293T 
For the validation of the facilitated enrichment approach using 3kDa CutOff spin columns, 
biological replicates are crucial. To handle this increase in sample material, Hek293T cells, 
transiently transfected with (N)-SF-TULP3, were used for the generation of the biological 
replicates. Samples were generated as described previously in 3.2.5.2 and split before cross-
linked peptides were either enriched performing SEC or 3kDa CutOff spin column filtration. 
Results of links identified in at least two of four IFT-A samples from HEK293T cells are depicted 
in Figure 46, while links identified in at least three of the four tested replicates are highlighted in 
Figure 47. For detailed information of crosslinked amino acids and positions of identified links 
after SEC, see Table 22 (links identified in at least two of four biological replicates) and Table 
23 (links identified in at least three of four replicates). Information of identified links after spin 
column filtration is depicted in Table 24 (identified links within at least two of four biological 
replicates) and 
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Table 25 (links identified in at least three of four experiments) in the annex. 
Considering the number of links identified in at least two of four tested biological replicates from 
HEK293T cells (Figure 46A), the amount of identified links was significantly higher after spin 
column filtration (1144 links after spin column filtration and 708 links identified after SEC). After 
SEC, major portion of link types was represented by mono-linked peptides (47.7% with 338 
identified mono-links) followed by 281 inter-links (39.7%) and 89 intra-linked peptides (12.6%). 
In contrast, major portion after spin columns filtration was represented by 45.6% inter-links (522 
identified inter-links) followed by 42.0% mono-linked peptides (481 mono-links) and 12.3% intra-
links (141 intra-linked peptides). Although the distribution of crosslink types after both 
enrichment methods varied, crosslinks within all IFT-A components were identified after both 
enrichment methods (results after SEC are depicted in Figure 46B and results after spin column 
filtration are highlighted in Figure 46C). Although the overall amount of links identified in at least 
two of three replicates of HEK293T cells was higher after 3kDa CutOff spin column filtration, 
patterns of crosslink localisations after both enrichment methods were comparable. However, 
some links were only identified either after SEC or after the use of 3kDa CutOff spin columns. 
For example the inter-link between TTC21B (at amino acid position 1304) and WDR35 (at 
amino acid position 1119) was only identified after SEC; while the inter-link between TTC21B 
(at amino acid position 1221) and IFT43 (at amino acid position 21) was only identified after 
spin column filtration. Again, same crosslinking “hotspots” were detected as in previous 
experiments using IFT-A purified from Flp-In (N)-SF-TULP3 cells. 
The number of links, identified in at least three of four biological replicates, is listed in Figure 
47A. Similar to the results obtained considering links identified in at least two of four 
experiments, the overall number of identified links was higher after 3kDa CutOff spin column 
filtration (759 identified links after spin column filtration and 423 links after SEC). However, the 
major portion of link types obtained with both methods was represented by mono-linked 
peptides (57.7% after SEC and 51.5% after spin column filtration), followed by inter-links (34.8% 
after SEC and 36.2% after spin column filtration) and least abundant intra-links (7.6% for SEC 
and 12.3% after spin column filtration). Visualization of identified links is depicted in Figure 47B 
(SEC) and Figure 47C (3kDa CutOff spin column filtration). Considering only links identified in at 
least three of four tested samples, no crosslinks within IFT43 were identified after both 
enrichment methods. However, the abundances of identified links between IFT-A components 
varied (e.g. inter-links between IFT122 and IFT140 were one of the most prevalent inter-links 
after SEC, while these inter-links were low abundant after using spin columns for the 
enrichment of cross-linked peptides). Nevertheless, similar patterns were elucidated considering 
the localisation of the identified links. Again, as seen in previous experiments some of the 
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identified links were located in described interaction domains while others were identified in yet 
undescribed regions. These explored hotspots indicate new interacting regions. 
Concluding the results of structural information of IFT-A after two different enrichment methods 
and keeping in mind that SEC is more time-, and cost-intense then the use of 3kDa CutOff spin 
columns, this facilitated method is a nice alternative to the well described SEC obtaining similar 
results of types and positions of identified crosslinks. 
Results  131 
 
 
 
 
Figure 46: Identified links of IFT-A from HEK293T cells (in at least 2 of 4 replicates) 
Crosslinks within IFT-A (purif ied from HEK293T cells, transiently transfected with (N)-SF-
TULP3) identif ied in at least two of four biological replicates after SEC or spin column 
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f iltration. A: Number of identif ied l inks either after SEC or spin column filtration is l isted. 
Thereby, the number of identif ied links was higher using 3kDa CutOff spin columns for the 
enrichment of crosslinked peptides (1144 identif ied l inks) than after SEC (708 links). After 
SEC, mono-links (47.7%) represented the major portion of crosslink types, while the major 
portion after spin column filtration was represented by inter-l inks (45.6%). B: Visualizat ion 
of identif ied crosslinks after SEC. C: Visualization of identif ied crosslinks after spin 
column filtration. Considering patterns and localisation of identif ied crossl inks, results 
obtained with both enrichment methods were comparable, although the overall amount of 
identif ied links was higher after 3kDa CutOff spin columns were used. Visualizing the 
results of both methods, revealed many links in described interaction domains (WD40 
domains in green and TPR domains in blue) as well as unveiled non-described interact ion 
points within IFT-A components. 
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Figure 47: Identified links of IFT-A from HEK293T cells (in at least 3 of 4 replicates) 
Links identif ied in at least three of four biological replicates of cross-l inked IFT-A, purif ied 
from transiently transfected HEK293T, are depicted. A: Number of  l inks identif ied after 
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SEC or after spin column filtrat ion is listed. The number of identif ied links was higher after 
spin column fi ltration (759 identif ied l inks) in contrast to 423 identif ied links after SEC. 
However, the major portion of l ink types was represented by mono-linked peptides (57.7% 
after SEC and 51.5% after spin column filtration) fol lowed by inter- and intra-links for both 
enrichment methods. B: Visualization of links identif ied in at least three of four replicates 
after SEC. C: Visualization of l inks identif ied in at least three of four replicates after spin 
column filtration. For both enrichment methods, no inter-l inks between IFT43 and other 
IFT-A components were identif ied. Considering the abundances of identif ied links, inter-
l inks between IFT122 and IFT140 were most prevalent in experiments performing SEC, 
while these inter-l inks were one of the least prevalent l inks in experiments performing spin 
column filtration. Although this distr ibution varied, both methods were similar regarding 
localisation of identif ied crosslinks either within described interaction domains or within 
undescr ibed crosslinking “hotspots”. 
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5 Discussion 
5.1 Stoichiometric analysis of IFT-A 
The aim of this study is to unveil the stoichiometry as well as the structural composition of IFT-A 
for the first time which is essential to understand its function in intraflagellar transport as well as 
its role in IFT-A-related ciliopathies. This study includes the stoichiometry determination of IFT-A 
in Flp-In monoclonal cell lines under standard growth conditions as well as the investigation of 
differences in IFT-A composition during different ciliary stages and alterations in stoichiometry 
caused by mutations introduced in genes encoding individual components of IFT-A. To 
circumvent the effect of artificial overexpression which may cause protein misfolding as well as 
complex misassembly [58], this study is based on the generation of Flp-In monoclonal lines 
stably expressing SF-TAP-tagged baits from a defined genomic integration site. For the 
purification of IFT-A in its entire composition, three different baits were used: (N)-SF-IFT122, 
(N)-SF-TULP3 and (N)-SF-LCA5. To eliminate the possible effect of the chosen baits on the 
assembly of IFT-A which could have violated the stoichiometric investigation of this study, the 
three baits represent proteins with different relations to IFT-A. While IFT122 is an integral part of 
the protein complex IFT-A, TULP3 is known to be associated with IFT-A and LCA5 is a labile 
and rather transient interaction partner of this protein complex [87]. Although the expression 
level of LCA5 was considerably lower than for the two other baits (IFT122 and TULP3; Figure 
21), all six protein complex components were identified after performing one-step affinity 
purification of extracted proteins of all three cell lines (Table 14) as well as after silver staining 
with following MS analysis of TAP eluates (Figure 28). For the stoichiometry determination of 
IFT-A in its naturally occurring composition, mass spectrometry based absolute quantification 
was used. Therefore, Flp-In monoclonal cell lines were cultured in SILAC ‘heavy’ medium to 
introduce a stable isotopic label. To calculate the absolute amount of each proteotypic peptide 
within purified IFT-A, a known amount of a synthetic standard mixture, containing non-labelled 
representative peptides, was spiked in. Targeted mass spectrometry was performed to analyse 
the ratio of non-labelled and labelled representative peptide which was then used to determine 
the stoichiometry of IFT-A. Other than in previous studies [46, 59] in which spiked standard 
peptides consisted of corporate stable isotopes, in this study isotopic labels incorporated into 
the protein complex of interest were used which significantly reduced the costs. To further 
reduce the costs for the non-labelled standard mixture, the “Equimolarity through Equalizer 
Peptide” (EtEP) method which was published previously by Holzmann et al. [59] was applied. 
This method enables the generation of an equimolar standard mix based on representative 
peptides containing an equalizer peptide sequence at the N-terminus which introduces an 
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additional tryptic cleavage site. Through tryptic proteolysis, an equimolar release of the 
equalizer peptide and the representative peptide is initiated. Adding a known amount of an 
isotopically labelled equalizer peptide to the representative peptide enables the absolute 
quantification of the released equalizer peptide as well as of the representative peptide (see 
Figure 13). This method also allows the generation of a standard mixture with variable and 
adjusted amounts of each representative peptide. Although the idea of adjusting the internal 
standard mix according to the amount of the identified complex components seemed more 
appropriate regarding the measurement accuracy of mass spectrometer in its dynamic range 
[49], the variability of data using an adjusted standard mix was obviously higher due to a more 
complex preparation procedure. At the beginning of this study, three representative peptides 
were chosen for each complex component. Since four of the synthesized peptides were not 
dissolvable, additional new representative peptides were chosen to create another equimolar 
standard mix. To reduce the high variances between the chosen representative peptides for 
IFT122 as well as for WDR19 (Table 15), more than three representative peptides were used 
for the new equimolar mix. The presence of some variances between different representative 
peptides of the same protein, as unveiled for IFT122 and WDR19 performing SRM with an 
equimolar standard mix of 14 representative peptides (Table 15), may be explained by the 
presence of different isoforms, cleavage products or post-translational modifications of these 
IFT-A proteins. For example, the determined ratio (H/L) of the peptides IFSLLEK and AASVYIR 
which were chosen as representatives for WDR19 showed huge variances. A closer look on 
described isoforms of WDR19 unveiled that IFSLLEK is present in both known isoforms, while 
AASVYIR is only present in the longer isoform of WDR19 (Figure 48 and Figure 53). The 
existence of protein isoforms which may differ in purpose and property enables the functional 
diversity [88]. However, the general task to identify the present isoforms involved in protein 
complexes as well as their effect is still challenging [89]. 
Targeted mass spectrometry is a versatile tool to perform absolute quantification of a protein 
complex of interest. Different targeted mass spectrometry approaches are available for the 
different types of mass spectrometers. The first stoichiometry determination of this study using 
Selected Reaction Monitoring (SRM) was performed with the group of Karl Mechtler at the 
Institute of Molecular Pathology in Vienna on a QTrap5500. SRM is a well-described method to 
perform targeted mass spectrometry using a triple quadrupole instrument. In comparison to 
Parallel Reaction Monitoring (PRM), performed on a hybrid mass spectrometer comprising a 
quadrupole as mass filter and an Orbitrap as mass analyzer, more intense method development 
is necessary for a SRM approach. As described previously by Ronsein et al. in 2015 [90], both 
methods are comparable regarding linearity, dynamic range, precision and reproducibility while 
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the analysis of many product ions using PRM results in a gain in specificity. The comparison of 
the determined complex stoichiometry performing either PRM or SRM is shown in Figure 29 and 
Figure 30. For these data, biological replicates of each of the three bait-expressing monoclonal 
Flp-In cell lines were analysed performing absolute quantification using either SRM or PRM for 
targeted mass spectrometry analysis. However, two different equimolar standard mixtures were 
used. As mentioned before, the first equimolar standard mix, used for the SRM approach in this 
study, was consisting of only 14 representative peptides resulting in highly diverse calculated 
ratios (H/L) of some representative peptides of the same protein (Table 15). Thereby, only the 
percent coefficient of variation (%CV) of the representative peptides for three IFT-A components 
(IFT140, TTC21B and WDR35) was below 20% (Table 17). Further PRM approaches were 
performed using the new equimolar amount containing 24 representative peptides in total. This 
resulted in notably differences of IFT-A stoichiometry determined either by SRM or PRM (Figure 
29 and Figure 30) based on more robust data with %CV value below 20% (Table 18) for all six 
IFT-A complex components. Nevertheless, both methods identified a huge effect on the 
complex composition of IFT-A using an integral component of IFT-A (IFT122) as bait. No matter 
which targeted mass spectrometry method was used, IFT-A composition in Flp-In (N)-SF-
TULP3 and Flp-In (N)-SF-LCA5 were virtually identical, while stoichiometry of IFT-A in Flp-In 
(N)-SF-IFT122 differed. Thereby, not only a predominant overrepresentation of IFT122 (56% by 
SRM; 62% by PRM) was identified, also the portion of IFT140 (2% by SRM; 2% by PRM) and 
WDR19 (4% by SRM; 3% by PRM) were notably reduced (Figure 29 and Figure 30). This leads 
to the conclusion that the selection of an appropriate bait is a crucial point for affinity purification 
of the protein complex of interest without disrupting its complex composition which is in 
agreement with Gibson et al. [58]. Although not much is known about the composition and the 
molecular function of IFT-A, it consists of a core complex which is formed by three IFT-A 
proteins: IFT122, IFT140 and WDR19 as described previously [29, 91]. The mass of IFT-A was 
previously predicted with around 750kDa [91] which conforms an IFT-A stoichiometry of one 
single copy per IFT-A component. In contrast, considering the determined complex composition 
of IFT-A in Flp-In (N)-SF-TULP3 (IFT122:IFT140:IFT43:TTC21B:WDR19:WDR35 – 
1.7:1.6:1.0:1.2:1.5:1.2) (see Figure 30) and keeping in mind that IFT-A consists of repetitive 
units [92] which hampers the determination of an exact mass of the existing protein complex, 
the predicted mass of this protein complex is a multiple of 1,098kDa. Based on the results 
presented here, the major portion of the determined IFT-A composition was represented by the 
IFT-A core complex with an amount of 59% (IFT122: 21%, IFT140: 20% and WDR19: 18%). 
One way to improve the understanding of this IFT subcomplex is to investigate changes in 
complex compositions during ciliary assembly and disassembly as well as to analyse the protein 
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complex of interest if one of the components is lacking or mutated. The formation and 
disassembly of cilia includes many consecutive steps as depicted in Figure 2. It has been 
shown that IFT-A which represents a subcomplex of the intraflagellar transport machinery (IFT) 
is involved in retrograde ciliary transport [1, 13, 28]. This transport of protein cargo from the 
ciliary tip back to the cell body is indispensable for ciliary disassembly and turnover which 
includes many consecutive steps as depicted in Figure 2. This poses the question, if the 
composition of IFT-A and its complex stoichiometry changes during the assembly and the 
disassembly of a cilium. Based on this hypothesis, hTERT-RPE1 cells were cultivated in SILAC 
‘heavy’ medium for absolute quantification of IFT-A during ciliogenesis. Other than HEK293T 
based cell lines, hTERT-RPE1 cells enable a controlled triggering of different ciliary cell stages. 
Starvation of hTERT-RPE1 using growth medium without fetal bovine serum (FBS) as 
supplement induces the formation of a cilium, whereas restimulating the cells using DMEM 
containing FBS promotes the disassembly of cilia [93-95]. For the investigation of stoichiometry 
changes during different ciliary cell stages of IFT-A in hTERT-RPE1 cells, cells were cultured 
under normal growth conditions, under starvation conditions and under starvation conditions 
followed by restimulation periods. In cilia-induced cell stages (starvation of cells), the major 
portion of the IFT-A complex was represented by the core complex (69%) formed by IFT140 
(28%), WDR19 (25%) and IFT122 (16%). In comparison, the portion of IFT-A core increased 
slightly to 71% after 2h of restimulation and to 76% after a restimulation period of 4h. However, 
the portion of two IFT-A components (WDR35 and IFT43) decreased notably (Figure 38). These 
results conclude that the core complex of the IFT-A remains stable, while the amount of the 
other components may vary during ciliary assembly and maintenance. In contrast, the complex 
stoichiometry of IFT-A from hTERT-RPE1 cells cultured under the same conditions but with an 
increased amount of cells per culture dish, was not changed (Figure 39) and further stresses 
the point that cellular conditions are a crucial and sensitive factor for this experimental setup. To 
improve reproducibility of such sensitive experiments, cell counting may be an effective tool for 
future investigations of stoichiometry changes of IFT-A during different ciliary stages [96]. The 
second type of experiments to study induced changes of IFT-A complex stoichiometry applied in 
this work was targeted gene editing of genes encoding IFT-A proteins. The CRIPSR/Cas9 
system is a highly efficient and advanced method to create either repair-induced mutations or 
specific mutations at desired gene loci. In this study, mutations within IFT43 or WDR19 were 
generated using Flp-In (N)-SF-TULP3 cells in combination with different designed single guide 
RNAs (sgRNAs) as well as homology directed repair (HDR) constructs. Sequencing results of 
the mutated single clones identified two repair-induced mutations in IFT43 (Figure 33) and two 
repair-induced mutations in WDR19 (Figure 34). In contrast, the introduction of defined 
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mutations using HDR constructs failed. Although two repair mechanisms occur in dividing cells, 
the error-prone non-homologous end joining (NHEJ) is more prominent than the directed HDR 
[97, 98]. As observed in prior studies, the efficiency of HDR is depending on the concentration 
and length of the HDR construct, on the cell cycle as well as on the activity of the NHEJ within 
this cell line [99, 100]. As a consequence, the introduction of specific and disease-associated 
mutations is very time consuming. Using CRISPR/Cas9-based gene editing, four identified 
single clones including mutations either in IFT43 or WDR19 were characterized and used for 
one-step affinity purification of IFT-A. Only one out of the four mutant lines showed significant 
changes in IFT-A composition in comparison to control cells (Figure 35). This mutation is 
characterized by a single base insertion of an adenine (c.541_542insA) resulting in a frameshift 
and premature termination of the translation of IFT43 (p.T181Nfs*2). Considering the 
composition of IFT-A, purified from Flp-In cells carrying the p.T181Nfs*2 mutation, the overall 
expression level of IFT-A was decreased in comparison to the control cells. Furthermore, the 
amount of three IFT-A components (IFT43, TTC21B and WDR35) was decreased 
tremendously. Although disease-causing mutations in IFT43 are already described [33], none of 
the published ciliopathy-related mutation was identified in or nearby this location. One of the 
CRISPR/Cas9-induced clones which included a mutation in WDR19 carried a deletion of two 
bases (c.3107_3108delAT) and is characterized by an amino acid exchange of tyrosine to 
phenylalanine (Y1036Ffs*5) causing a frame shift. This mutant is only one codon apart from a 
known ciliopathy-related mutation (p.S1037L). This described mutation WDR19_p.S1037L [57] 
causes an amino acid substitution from serine to leucine at position 1037 of the protein. 
Although both variations are within the same region, no significant change in IFT-A complex 
stoichiometry was observed in this CRISPR/Cas9-induced clone. This allows to draw the 
conclusion that the amino acid sequence affected in those mutants is important to bind motor 
proteins or for specific cargo binding, Due to that, mutations within this domain may result in an 
altered binding surface of the IFT-A component WDR19. The ciliopathy-related mutation 
p.S1037L is caused by the exchange of a cytosine with thymine. Two-thirds of all existing 
single-nucleotide polymorphisms (SNPs) represents an exchange of C with T and are based on 
an epigenetic mechanism: Cytosine (C) methylation is performed using the enzyme 
methyltransferase. This enzyme transfers a methyl group from S-adenosyl-L-methionine to 
cytosine. Based on deamination of methylcytosine, thymine (T) is formed. Therefore, this 
mechanism is essential for many different functions. For example to control gene expression as 
well as to protect the genome against selfish DNA [101-103]. To demonstrate the potential of 
this method for medical as well as clinical applications, the stoichiometry of IFT-A from human 
fibroblast cell lines generated from two patients with Sensenbrenner Syndrome in comparison to 
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IFT-A purified from fibroblasts of one healthy donor, was determined in a pilot experiment within 
this study. Thereby, the cultivation of human fibroblasts as well as the one-step affinity 
purification was performed by Machteld Oud, a PhD student at the Radboud University Medical 
Center Department of Human Genetics in Nijmegen (Netherlands). Preliminary data of 
determined IFT-A stoichiometry unveiled obvious effects on IFT-A complex stoichiometry 
induced by both Sensenbrenner Syndrome associated mutations (one fibroblast cell line per 
Sensenbrenner Syndrome associated mutation) in comparison to the control fibroblast cell line. 
The complex composition of IFT-A purified from the control fibroblast cell line was virtually 
identical to the composition of IFT-A purified from Flp-In (N)-SF-TULP3 cells (Figure 37). 
Comparing both cells lines carrying mutations in the gene encoding IFT43, the induced effect on 
the composition of IFT-A was similar: Whereas the amount of WDR35, TTC21B and IFT43 was 
obviously decreased, the portion of the IFT-A core complex (IFT122, IFT140 and WDR19) was 
increased obviously. However, these results were obtained from only one biological replicate 
per cell line. 
5.2 Structural investigations of IFT-A 
Previous studies unveiled the train-like structure of IFT particles. Thereby, two distinct train 
types were identified: A long and narrow train-like structure involved in anterograde IFT and a 
short and compact structure of particles which is important for the retrograde ciliary movement 
[92]. Structural architecture of IFT-B, especially of the core complex of IFT-B was already 
characterized by crystal structure analysis [104, 105] whereas, only little is known about the 
structure and the assembly of IFT-A, so far. To generate structural information of this ciliopathy-
related protein complex for the first time, chemical crosslinking of TAP-purified IFT-A was 
performed. Chemical crosslinking of lysine residues within protein complexes is an efficient tool 
to gain proximity as well as structural information about involved proteins [51, 106, 107]. 
According to the defined length of the used chemical crosslinker disuccinimidyl suberate (DSS) 
of 11.4Å and considering the length of the lysine side chains (6-6.5Å), the distance of 
crosslinked residues is predefined [50]. A 1:1 mixture of isotopically coded and non-coded 
homobifunctional disuccinimidyl suberate (DSS) was used in this study, to facilitate 
computational analysis using the software pipeline xQuest/xProphet, as described previously 
[52, 108]. Chemical crosslinking was performed with IFT-A, purified by tandem affinity 
purification (TAP) to obtain the complex of interest with little contaminants [69, 81]. For a 
successful chemical crosslinking, the ratio of protein to chemical crosslinker is important. 
Therefore, the experimental setup was optimised applying different crosslinker concentrations 
as well as different reaction buffers. Thereby, the presence of dithiotreitol (DTT) in the reaction 
buffer increased the number of identified crosslinks. However, the variance within tested 
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biological replicates was lower using the reaction buffer without DTT (Figure 40). The 
distribution of identified crosslink types differed only slightly. Nevertheless, one needs to 
consider that the presence of dithiotreitol within the reaction buffer reduces disulfide bonds and 
enables thiol groups of cysteines to be linked by DSS as well [85]. Thereby, the amount of 
crosslinker available for chemical crosslinking of lysine residues is effectively reduced. Based 
on these results and considerations, a reaction buffer without DTT was chosen for further 
experiments. To investigate an optimal ratio of chemical crosslinker to protein amount, 5-, 25-, 
40-, 50-, or 90-fold excess of protein to chemical crosslinker were tested. While a decrease of 
chemical crosslinker resulted in an increased proportion of inter-molecular crosslinks and a 
decreased proportion of mono-linked peptides, only a slight further increase in proportion of 
identified inter-links was achieved upon increasing the ratio of purified protein to chemical 
crosslinker from 50-fold to 90-fold excess (Figure 41). Further increase in amount of DSS may 
result in an overrepresentation of mono-linked residues which are not able to react with a 
second residue because this is occupied already by another crosslinker molecule, as well. 
Therefore, a 50-fold excess of protein to DSS was chosen for the following experiments. While 
the number of identified inter-links between TTC21B and IFT140 were most abundant, only few 
inter-links were observed between IFT43 and other IFT-A proteins. Moreover, applying a more 
stringent approach illustrating only links that were identified in all three tested replicates, no 
crosslinks between IFT43 and other IFT-A components were depicted (Figure 44). The low 
number of identified crosslinks with IFT43 supports the results of determined stoichiometry of 
IFTA, where IFT43 is the least abundant protein in the complex. A closer look into the cross-
linked positions within the IFT-A proteins unveiled the presence of crosslinking “hotspots” where 
crosslinks were identified more frequently. These “hotspots” were located in either known and 
described interaction domains like WD40 and TPR regions [109-111] or indicate novel 
interacting domains which are not described yet. As described previously [91], four of the six 
IFT-A components (IFT122, IFT140, WDR19 and WDR35) carry a similar domain distribution 
comprising multiple WD40 domains at the N-terminus. These interaction domains (WD40 and 
TPR) are estimated to stabilize the protein complex on the one hand and to undertake the 
selective transport of ciliary cargoes on the other hand [112]. The WD40 domain within Clathrin, 
a complex involved in the formation of coated vesicles [112] for example is known to selectively 
bind unique cargo [113]. Another example is the protein IFT46 which is a known component of 
the intraflagellar transport protein B (IFT-B). This protein is part of the core complex of IFT-B 
[114]. Its C-terminal domain is important for the complex stability [104, 115], while its N-terminal 
domain is essential for the ciliary transport [116-118]. Many inter-links were detected close to 
the C-terminus of WDR19 and WDR35. These parts of the proteins are not characterized as 
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interaction domains, so far. Regarding intra-links identified within TTC21B, almost every 
detected intra-molecular crosslink links two lysine residues within two described and 
characterized interaction domains (TPR). Illustrating only more reliable links, identified in all 
tested biological replicates of Flp-In (N)-SF-TULP3 cells, the prevalence of identified inter-links 
differed. Thereby, the amount of inter-links between IFT140 and WDR19 was most prevalent. 
No matter which stringency was applied, both indicated the existence of new non-characterized 
interaction domains within IFT-A complex components (Figure 44). Similar to previous 
experiments using IFT-A, purified from Flp-In (N)-SF-TULP3, chemical crosslinking of IFT-A, 
purified from HEK293T cells, identified many already described interaction domains within IFT-A 
components. Most of the depicted links were identified within characterized WD40- and TPR 
domains (Figure 46B/C). However, many crosslinks were identified in “hotspots” which are not 
described so far. For example, only WD40 domains at the N-terminus of WDR35 are described, 
but identified crosslinks were covering the whole WDR35 sequence. The same pattern was 
shown for IFT122. Also many of the intra-links were identified in at least one described 
interaction domain Figure 46B. As previously described by siRNA studies, three IFT-A 
components (IFT122, IFT140 and WDR19) form a core-complex of the protein complex of 
interest [29]. Based on the identified crosslinks, obtained in this study and illustrated using 
Xinet, TTC21B may be another part of this core complex, as well. The amount of identified inter-
links of TTC21B with other complex components was as abundant as for IFT122, IFT140 and 
WDR35 (Figure 44-Figure 47). 
To understand the effect of CRISPR/Cas9-induced mutations in IFT-A proteins, localisation of 
identified crosslinks in IFT-A, purified from wildtype cells, was considered. Some of the 
identified inter-links of IFT43 were close to the C-terminus of this protein (Figure 44B). Two of 
the CRISPR/Cas9-induced mutant clones cover mutations at the C-terminus of IFT43. One 
clone with a single base insertion of an adenine (c.541_542insA/ p.T181Nfs*2) resulted in an 
amino acid exchange of threonine (T) to asparagines (N) at amino acid position 181 with a 
further premature stop in the translation of IFT43. This mutant reduces the size of the protein 
IFT43 notably. In contrast, the second mutation caused by a single base insertion 
(c.582_583insG/ p.Q195Afs*22) resulted in a slightly prolonged form of IFT43 (Figure 33). As 
depicted in Figure 35, a tremendous effect on the complex composition of IFT-A was only 
obtained in IFT-A purified from the clone carrying the mutation resulting in a shortened IFT43 
(IFT43_ c.541_542insA/ p.T181Nfs*2). The loss in binding of IFT43, TTC21B and WDR35 can 
be explained considering the identified crosslinks of IFT43. Most of the inter-links, identified 
close to the C-terminus of IFT43, were linked to TTC21B. A loss of the C-terminal half of IFT43, 
caused by the c.541_542insA/ p.T181Nfs*2 mutation, resulted in a reduction of TTC21B and 
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proteins linked to TTC21B like WDR35, although there were still many other cross-links present. 
This allows to draw the conclusion that IFT43 may function as a stabilizer of the repetitive 
structure of IFT-A. Regarding the second mutation c.582_583insG/ p.Q195Afs*22, the 
extension of IFT43 did not cause an apparent effect on complex composition of IFT-A. This 
allows to draw the conclusion that the amino acid sequence around the mutation site of the 
clone is crucial to stabilize IFT-A. Both generated CRISPR/Cas9-induced clones mutated in 
genes encoding WDR19 (p.Y1036Ffs*5 and p.R1022Dfs*22), resulted in an alteration within a 
described TPR domain. Analysing the complex stoichiometry of both mutations identified no 
alteration in comparison to the control (Figure 35). Regarding identified inter-links within the 
TPR domain of WDR19 (around amino acid position 1020), only one inter-link within this domain 
of WDR19 with the N-terminal half of IFT140 was identified. This refers to the conclusion that 
this identified linkage between the identified domains of IFT140 and WDR19 is not essential to 
keep the composition of IFT-A in its naturally occurring state, however it might be important for 
binding of external proteins like specific cargoes.  
As described previously [51], for LC-MS/MS analysis of low abundant cross-linked peptides a 
previous enrichment step of these molecules is crucial. Size exclusion chromatography (SEC) is 
a well-described and commonly performed prefractionation method to enrich cross-linked 
peptides, although SEC is time-, labour- and cost-intense. To facilitate this prefractionation, an 
economic method for the reduction of sample complexity is described in this study. This easy-
to-handle method is characterized by the use of 3kDa CutOff spin columns. This part of the 
study includes the comparison of both prefractionation methods with regard to the amount and 
the localisation of identified crosslinks as well as the applicability of this innovative enrichment 
method for the following LC-MS/MS analysis of cross-linked peptides. Therefore, purified IFT-A 
was chemically cross-linked using DSS. After proteolysis of cross-linked proteins, sample was 
split and prefractionation was performed either by SEC or spin column filtration. The precursor 
distribution of all identified precursor ions showed same patterns for both methods considering 
lower mass ranges (1500-4500). Using spin columns, however no precursor ions with relative 
molecular mass (Mr) higher than 5500 were detected, although 3kDa CutOff spin columns 
should restrain peptides with a molecular mass >3kDa. The overall amount of crosslinks was 
higher performing SEC, except the amount of mono-links. Considering the proportion of 
identified link types, the fractions of identified crosslinks varied between both enrichment 
methods (Figure 42). Since the available amount of IFT-A purified from Flp-In (N)-SF-TULP3 
cells is limited, following experiment was performed using transiently transfected HEK293T cells 
to compare SEC with spin column filtration. Again, sample was split after proteolysis and either 
spin column filtration or SEC was performed to enrich cross-linked peptides. Using HEK293T 
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cells, transiently transfected with (N)-SF-TULP3, precursor distribution patterns of both 
prefractionation methods were comparable (Figure 43). In contrast to previous experiments 
using IFT-A purified from Flp-In cells, the overall amount of identified precursors was higher 
using 3kDa CutOff spin columns except in the relative molecular mass range of 1500-2000. 
Furthermore, the obtained standard deviation of the four tested biological replicates was 
significantly higher performing SEC, especially for the amount of identified inter-links. While the 
overall amount of identified crosslinks (no matter which crosslink type) was higher using 3kDa 
CutOff spin columns, the portion of mono-links was higher after SEC (Figure 43). One needs to 
consider that the amount of IFT-A, purified from Flp-In cells is lower than purified from 
transiently transfected HEK293T cells which may explain the differences in both experiments 
regarding different cell types. For example the material of spin columns may bind a certain 
amount of peptides irreversibly which may be irrelevant if the amount of starting material 
exceeds a certain amount of applied peptides. In contrast to SEC, spin column filtration is an 
easy-to-handle and much faster approach which does not require a lot of LC experience. Due to 
this facilitated method, every lab without the required equipment for SEC can easily perform 
chemical crosslinking with further mass spectrometric analysis. 
5.3 Modelling IFT-A 
As validated in previous studies, chemical crosslinking together with mass spectrometry 
analysis enables structural modelling of a protein complex of interest comparable with 
investigated crystal structures [119-121]. This combination of chemical crosslinking with mass 
spectrometry provides great potential in elucidating and characterizing structural information of 
a protein complex of interest [122]. Thereby, generated mass spectrometry data has to be 
incorporated into modelling algorithms as constraint for potential models. Until now, this data 
integration constitutes a big bottleneck [50]. The combination of determined complex 
stoichiometry of IFT-A with crosslinking positions, identified in this study, can be used to 
generate a structural model of the protein complex IFT-A which may facilitate the understanding 
of its function during ciliary assembly and disassembly as well as its role in ciliopathies. 
Complex composition of IFT-A identified three IFT-A proteins (IFT122, WDR19 and IFT140) as 
most prevalent complex components (Figure 30). This promotes the presence of a core-
complex of IFT-A [29]. TTC21B was more prevalent in the determined IFT-A composition than 
WDR35 and IFT43 which was furthermore indicated by the amount of identified crosslinks 
between TTC21B and other IFT-A components (Figure 44). However, chemical crosslinking has 
a great disadvantage: The irregular distribution of lysine residues all over the proteins leads to a 
patchy data generation [50] using a lysine-reactive crosslinker like DSS for chemical 
crosslinking. Thereby, only positive crosslinking results can be recognised for the structural 
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modelling of IFT-A because the absence of crosslinks may be due to sterical as well as 
chemical reasons [41]. Prior studies unveiled two different train-like IFT particles using electron-
tomographic analysis of the IFT trains. These train-like IFT particles consist of repetitive units: 
The long and narrow trains for the anterograde transport as well as the short and compact 
particle trains involved in retrograde IFT [92]. Putting all these outcomes together, a detailed 
and meaningful model of the IFT-A can be generated to create the foundation for further studies 
of IFT-A-related ciliopathies. Nevertheless, a less complex assembly and stoichiometry of IFT-A 
was expected. Considering the obtained information of IFT-A, modelling of this protein complex 
represents a massive task because so many combinations of the structural composition of IFT-
A are possible. Additionally, the intra-links can be inter-links between two copies of a protein. 
This makes it even more complex. 
5.4 Perspectives 
The stoichiometric and structural investigations of the protein complex IFT-A, unveiled in this 
study, provided new insight into the composition and the stoichiometry alterations of IFT-A 
during different ciliary stages. However, these obtained results allow to draw new conclusions 
and propose new questions. For example, the influence of cell confluence on the complex 
composition of IFT-A unveiled the complex stoichiometry as sensitive and flexible at least during 
ciliogenesis or ciliary disassembly. To study stoichiometry alterations induced by targeted 
CRISPR/Cas9 mutants, further optimisation of this approach are crucial to promote the 
homology directed repair (HDR) mechanism. Based on the designed HDR constructs, there is 
an opportunity to simulate the IFT-A composition present in identified IFT-A-related ciliopathies 
like Sensenbrenner Syndrome. The attempt to introduce the described amino acid exchange of 
serine to leucine at amino acid position 1037 in WDR19 (p.S1037L) using a designed single 
guide RNA (sgRNA) only resulted in a repair-induced mutation (WDR19_p.Y1036F). Although 
non-homologous end joining (NHEJ) is the predominate DNA repair mechanism, the homology 
directed repair (HDR) mechanism can be encouraged by selected reaction conditions like cell 
cycle or the concentration and length of the designed HDR construct [99, 100]. The comparison 
of the IFT-A stoichiometry from a targeted ciliopathy-related mutant within an IFT-A protein with 
the complex composition of IFT-A from control cells might shed light upon the underlying 
molecular mechanisms of ciliopathies by identifying the role of IFT-A within the intraflagellar 
transport. Although, generated Flp-In cells are of human origin, the study of stoichiometry 
alterations of IFT-A in human fibroblasts of patients suffering from ciliopathy diseases as well as 
from healthy donors would be a great benefit for medical and clinical applications. The first pilot 
experiment with one replicate per fibroblast cell line showed virtually identical results compared 
to IFT- A from Flp-In cell lines (Figure 37). However, more biological replicates have to be 
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analysed to promote this conclusion. To find out if there is a common underlying mechanism of 
IFT-A-related ciliopathies, IFT-A composition within more patients has to be analysed. The 
approach of absolute quantification of IFT-A, presented in this study, is a robust tool that 
enables the exact determination of alterations in complex composition and also to distinguish 
between alternative mechanisms. 
Chemical crosslinking of CRISPR/Cas9-induced mutant Flp-In (N)-SF-TULP3 monoclonal cells 
could be the basis for further investigations of disease-related structural changes in IFT-A 
composition. Thereby, the structural investigation can shed light on the function and role of each 
IFT-A complex component. For this task it would be great to have tools at hand that allow the 
quantification of identified crosslinks. However, available software tools are limited to 
identification of crosslinks, so far. To circumvent the patchy nature of chemical crosslinking 
considering the irregular distribution of lysine residues all over the surface of purified IFT-A, the 
use of other crosslinker types (varying in reactive site or spacer length) represents a promising 
tool to gain additional structural information about the protein complex of interest [50]. For the 
evaluation of the facilitated enrichment method of cross-linked peptides, portrayed in this study, 
another approach using other protein complexes to unveil its efficiency may be set up. 
However, this includes much optimization effort to enable an efficient chemical crosslinking of 
the purified protein complex of interest. 
This study presented an effective and cost-efficient approach to study the stoichiometric as well 
as the structural composition of IFT-A. Based on the novel results, obtained in this study, other 
protein complexes of interest can be studied the same way to identify their role and molecular 
function. 
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7 Annex 
7.1 Additional Figures and Tables 
Table 17: Absolute quantification of IFT-A using Flp-In (N)-SF-LCA5 performing SRM 
Protein Peptide Pre. m/z Prod. m/z Trans. RT CE Trans. SDTrans %CVTrans MedianPep SDPep %CVPep MedianProt SDProt %CVProt Stoich.
864.446159 +2y8 43.97 26.9 0.3212 0.0058 1.8
735.403566 +2y7 43.97 28.9 0.3279 0.0263 8.0
664.366452 +2y6 43.97 27.9 0.3043 0.0110 3.6
333.176861 +2y3 43.97 34.9 0.3506 0.0199 5.7
692.434138 +2y6 41.30 19.4 2.3033 0.0637 2.8
579.350074 +2y5 41.30 18.4 1.8792 0.0436 2.3
432.28166 +2y4 41.30 24.4 1.89 0.1177 6.2
331.233982 +2y3 41.30 27.4 1.7648 0.0995 5.6
718.351865 +2y5 40.53 20.5 0.2319 0.0082 3.6
532.272552 +2y4 40.53 20.5 0.2259 0.0046 2.0
417.245609 +2y3 40.53 28.5 0.2316 0.0073 3.1
852.446159 +2y8 16.47 26.0 0.1683 0.0062 3.7
795.424696 +2y7 16.47 27.0 0.1652 0.0256 15.5
724.387582 +2y6 16.47 31.0 0.2041 0.0265 13.0
381.213246 +2y3 16.47 33.0 0.181 0.0120 6.6
634.351865 +2y6 20.45 21.2 0.2602 0.0086 3.3
547.319837 +2y5 20.45 21.2 0.1663 0.0054 3.2
434.235772 +2y4 20.45 20.2 0.1631 0.0026 1.6
363.198659 +2y3 20.45 20.2 0.1805 0.0050 2.8
808.383559 +2y6 30.52 23.6 0.073 0.0038 5.2
679.340966 +2y5 30.52 25.6 0.0657 0.0016 2.5
566.256902 +2y4 30.52 24.6 0.0652 0.0038 5.8
437.214309 +2y3 30.52 27.6 0.0819 0.0050 6.1
837.421342 +2y7 16.38 25.8 0.1492 0.0052 3.5
766.384228 +2y6 16.38 26.8 0.1638 0.0030 1.8
669.331464 +2y5 16.38 32.8 0.1941 0.0066 3.4
540.288871 +2y4 16.38 32.8 0.1689 0.0091 5.4
777.388979 +2y7 28.44 21.8 0.1701 0.0090 5.3
720.367515 +2y6 28.44 21.8 0.1588 0.0009 0.6
633.335487 +2y5 28.44 21.8 0.1629 0.0179 11.0
518.308544 +2y4 28.44 28.8 0.1634 0.0025 1.5
803.425758 +2y7 23.56 24.9 0.2465 0.0310 12.6
690.341694 +2y6 23.56 23.9 0.177 0.0026 1.5
577.25763 +2y5 23.56 23.9 0.1792 0.0020 1.1
448.215037 +2y4 23.56 21.9 0.1906 0.0008 0.4
615.309666 +2y5 18.61 19.0 0.181 0.0175 9.7
486.267073 +2y4 18.61 18.0 0.1609 0.0029 1.8
371.24013 +2y3 18.61 25.0 0.1549 0.0044 2.9
457.22929 +2b4 18.61 17.0 - - -
736.423967 +2y6 42.39 20.2 0.4188 0.0087 2.1
589.355553 +2y5 42.39 20.2 0.9484 0.0827 8.7
502.323525 +2y4 42.39 26.2 0.4324 0.0905 20.9
389.239461 +2y3 42.39 28.2 0.4946 0.0245 4.9
708.403901 +2y6 21.65 19.9 0.3227 0.0388 12.0
637.366787 +2y5 21.65 19.9 0.2398 0.0088 3.7
550.334758 +2y4 21.65 20.9 0.2461 0.0032 1.3
451.266344 +2y3 21.65 20.9 0.2302 0.0059 2.6
642.429721 +2y6 38.13 22.5 - - -
529.345657 +2y5 38.13 18.5 0.2222 0.0118 5.3
458.308544 +2y4 38.13 18.5 0.2337 0.0067 2.9
345.22448 +2y3 38.13 17.5 0.239 0.0064 2.7
797.451579 +2y7 18.88 24.2 0.1976 0.0297 15.0
726.414465 +2y6 18.88 24.2 0.2181 0.0065 3.0
502.323525 +2y4 18.88 29.2 0.2067 0.0348 16.8
389.239461 +2y3 18.88 31.2 0.2607 0.0038 1.4
WDR19 0.353225 0.1560 44.2 2.165032
WDR35
525.290548
470.729792
502.256371
480.761092
364.700503
425.257654
390.224145
379.23197
583.279846
403.262739
433.213777
530.774731
399.211235
548.251285
IFSLLEK
AASVYIR
DLAIGLR
YASHLLEK
YSLATSR
ASEEIEDFR
VLAPEHEVR
YGSDPVFR
EAILESDAR
LEDVPR
0.3246
1.8846
0.1747
0.1734
0.0694
WDEAFALGEK
ILFTLAK
FWDIER
AHGALTEAYK
0.1632
0.1849
0.1609
0.4635
IFT122
IFT140
IFT43
TTC21B
0.2430
0.2337
0.2124 0.0279
0.0086
13.1
3.7
0.0425 17.5
0.2521 54.4
0.0137 8.5
0.0327 17.7
0.0047 2.9
0.0187 11.2
1.1046 1.1031
0.0078 11.3
0.0457 26.4
0.0192 5.9
0.2362 12.5
0.0581 35.0
10.1
0.2316 0.0034 1.5
0.0177
0.1664
0.0133 8.1
99.9
0.2031 0.0403 19.8
0.1664
6.77
1.02
1.00
1.25
0.1632
Ratio H/L
0.22305 0.0151 6.8 1.367147
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Table 18: Absolute quantification of IFT-A using Flp-in (N)-SF-TULP3 performing PRM 
Protein Peptide Precursor m/z Fragment Ion RT Fragment Ion MedianPep SDPep %CVPep MedianProt SDProt %CVProt Stoich.
y10 0.8024
y6 0.7132
y7 0.7132
y8 0.7434
y9 0.7387
y4 0.3414
y5 0.3019
y6 0.4232
y7 0.6749
y8 0.6761
y9 0.7025
y4 0.9516
y5 1.3372
y6 0.8298
y6 1.1704
y7 0.9332
y8 0.9653
y9 1.0574
y6 0.7501
y7 0.5174
y8 0.5831
y9 0.7258
y5 0.7364
y6 0.6396
y7 0.6606
y8 0.6851
y4 0.7459
y5 0.7327
y6 0.5854
y7 0.4631
y8 0.4969
y4 0.2023
y5 0.1898
y6 0.1918
y7 0.1683
y8 0.1900
y4 0.3371
y5 0.4550
y6 0.3959
y7 0.3723
y8 0.4796
y4 0.5853
y5 0.6253
y6 0.4938
y5 0.5960
y6 0.6870
y7 0.6347
y3 0.4036
y4 0.4977
y5 0.4429
y4 0.6111
y5 0.6012
y6 0.5340
y7 0.5474
y3 0.6282
y4 0.6703
y5 0.7151
y6 0.4904
y6 0.1573
y7 0.1592
y8 0.1408
y4 0.3657
y5 0.3210
y6 0.4165
y4 0.6151
y5 0.8795
y6 0.2704
y10 0.6379
y11 0.4778
y6 0.7080
y7 0.6302
y8 0.5403
y9 0.5115
y10 1.3723
y6 1.0876
y7 0.9379
y8 1.0947
y9 1.2419
y4 0.6749
y5 0.6136
y6 0.5610
y5 0.5268
y6 0.4588
y4 0.4968
y5 0.5081
y6 0.5681
y7 0.5806
0.0570 9.3
0.0481 9.8
0.0421 7.8
0.3054 49.7
0.0901 15.4
0.1656 15.1
0.0971 15.0
0.0101 6.4
0.0478 13.1
0.0456 7.2
0.0473 10.7
0.0384 6.7
0.0124 6.5
0.0587 14.8
0.0674 11.5
0.0417 6.2
0.0093 1.3
0.0632 12.7
0.2649 27.8
0.1065 10.5
0.1121 17.1
0.0365 4.9
0.0618 18.1
0.0156 2.3
0.0047 0.8
0.1050 17.5
0.0075 1.4
0.0894 12.6
0.0271 4.0
0.0296 7.5
Ratio H/L
IFT122 1.80
IFT140 1.70
IFT43 1.00
DSIGDEDPFTAK 651.800614
ASEEIEDFR
TTC21B 1.45
WDR19 1.52
WDR35 1.36
1.0947
LEDVPR
507.260505
369.704637
40.56
53.71
VGSFLAVGTVK 543.325873 52.86
ILFTLAK 407.269839 54.63
EAILESDAR 33.09
0.7387
DTPSGISK 406.715624 21.69 0.3414
GEYILLGGSDK 580.307878 51.66 0.6761
0.9516
SHLFVDEGLK 576.810587 42.42 0.4969
YSLATSR 404.215369 28.77 0.5853
WDEAFALGEK
27.9
0.6347
0.4429
DGDVLAVIAEK
IFSLLEK
0.1573
0.3657
0.5743
0.6492
EIGSLLAR 434.759944 46.17 0.6136
LVFIDEK
569.315703
429.264753
436.254385
63.31
55.7
587.286945 57.59 1.0113
YLELISSIEER 681.362959 67.98 0.6544
AHGALTEAYK 534.78183 25.59 0.6729
YGSDPVFR
AASVYIR
475.733926
395.22828
38.27
30.51
YASHLLEK 484.768191 28.42 0.5381
VGDLLPHVSSPK 628.858069 44.1 0.5853
THVIAASK 417.749802
VLAPEHEVR 530.294682 26.44 0.3959
FWDIER 438.217912 51.97 0.7393
0.1900553.25542
17.93 0.4928
0.7074
0.6729
0.3959
0.5743
0.6002
0.5381
0.615148.6
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Figure 48: Scheme of known isoforms of IFT-A components 
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Figure 49: Alignment of IFT122 isoforms and chosen representative peptides 
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Figure 50: Alignment of IFT140 isoforms and chosen representative peptides 
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Figure 51: Alignment of IFT43 isoforms and chosen representative peptides 
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Figure 52: Alignment of TTC21B isoforms and chosen representative peptides 
162  Annex 
 
 
Figure 53: Alignment of WDR19 isoforms and chosen representative peptides 
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Figure 54: Alignment of WDR35 isoforms and chosen representative peptides 
164  Annex 
 
Table 19: Identified links of IFT-A from Flp-In (N)-SF-TULP3 cells after SEC (in at least 2of3) 
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Table 20: Identified links of IFT-A from Flp-In (N)-SF-TULP3 cells after SEC (in at least 3of3) 
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Table 21: Links of IFT-A (Flp-In (N)-SF-TULP3) identified after both enrichment methods 
Id Protein1 Protein2 XLType Method(s) AbsPos1 AbsPos2 Mr
CLDMSASRKK-NKNGEEK-a9-b2 IF122 IF122 intra-protein xl SEC/CutOff 527 161 2150.05
DTPSGISKVK-HAYDKLR-a8-b5 IF122 IF122 intra-protein xl SEC/CutOff 995 1021 2070.111
FLLHSLPKDTPSGISK-HAYDKLR-a8-b5 IF122 IF122 intra-protein xl SEC/CutOff 987 1021 2778.506
LDSPGYAAETYLKXGDLK-QGGWAGDSVKASK-a13-b10 IF122 IFT43 inter-protein xl SEC/CutOff 830 69 3414.633
ELAXEALEGLDFETAKK-K16-156 IF122 monolink SEC/CutOff 663 n/a 2066.003
ELAXEALEGLDFETAKK-K17-155 IF122 monolink SEC/CutOff 664 n/a 2065.019
ELAXEALEGLDFETAKK-K17-156 IF122 monolink SEC/CutOff 664 n/a 2066.003
LVETKDSIGDEDPFTAK-K17-155 IF122 monolink SEC/CutOff 1153 n/a 2019.014
AEEVMKVK-SVSKHK-a6-b4 IF140 IF122 inter-protein xl SEC/CutOff 270 128 1754.95
FGFEKGENXNCVCYCK-ALLKSGDTEK-a5-b4 IF140 IF140 intra-protein xl SEC/CutOff 323 1227 3256.458
AAVSGDEKALDXFNWK-CGKLEDVPR-a8-b3 IF140 TT21B inter-protein xl SEC/CutOff 179 1001 3007.419
NIIGFYTKGR-RCGKLEDVPR-a8-b4 IF140 TT21B inter-protein xl SEC/CutOff 1275 1001 2534.318
YYEEKGVQMDR-YDXAEDLLKR-a5-b9 IF140 TT21B inter-protein xl SEC/CutOff 1077 1221 2823.303
FGFEKGENMNCVCYCK-IHVKNGDHXKGAR-a5-b10 IF140 WDR19 inter-protein xl SEC/CutOff 323 1171 3657.637
YYEEKGVQMDR-KKIEGMVR-a5-b2 IF140 WDR19 inter-protein xl SEC/CutOff 1077 1233 2514.274
AAVSGDEKALDMFNWKK-K16-156 IF140 monolink SEC/CutOff 187 n/a 2065.035
AAVSGDEKALDMFNWKK-K17-155 IF140 monolink SEC/CutOff 188 n/a 2064.036
AAVSGDEKALDMFNWKK-K17-156 IF140 monolink SEC/CutOff 188 n/a 2065.029
AAVSGDEKALDMFNWKK-K8-155 IF140 monolink SEC/CutOff 179 n/a 2064.036
AAVSGDEKALDMFNWKK-K8-156 IF140 monolink SEC/CutOff 179 n/a 2065.019
ALSYYEKSDTHR-K7-155 IF140 monolink SEC/CutOff 926 n/a 1623.793
GENMNCVCYCKVKGLLAAGTDR-K11-155 IF140 monolink SEC/CutOff 334 n/a 2670.249
GVQMDRAVMLYHKAGHFSK-K13-156 IF140 monolink SEC/CutOff 1090 n/a 2330.176
KYQEALQLCLGQNMSITEEMAEKXTVAK-K1-155 IF140 monolink SEC/CutOff 1151 n/a 3414.664
RIGASTKSK-HAYDKLR-a7-b5 TT21B IF122 inter-protein xl SEC/CutOff 603 1021 1986.085
IMENYCLMATKQK-YYEEKGVQXDR-a11-b5 TT21B IF140 inter-protein xl SEC/CutOff 1134 1077 3199.441
FFSMAEKRNSR-GKEPYTK-a7-b2 TT21B TT21B intra-protein xl SEC/CutOff 1014 157 2331.16
AKLEPGFQYCK-LGKLLSESMK-a2-b3 TT21B WDR35 inter-protein xl SEC/CutOff 1020 736 2582.343
YDMAEDLLKR-MFFYLSKK-a9-b7 TT21B WDR35 inter-protein xl SEC/CutOff 1221 7 2469.216
EALVHCETDNKIXLELAR-K11-155 TT21B monolink SEC/CutOff 919 n/a 2312.168
EALVHCETDNKIXLELAR-K11-156 TT21B monolink SEC/CutOff 919 n/a 2313.144
FFSMAEKRNSR-K7-156 TT21B monolink SEC/CutOff 1014 n/a 1527.762
IAKMNWNAIDAEEFEK-K3-156 TT21B monolink SEC/CutOff 1185 n/a 2063.972
XDSQELKTLINYYCQER-K7-155 TT21B monolink SEC/CutOff 7 n/a 2361.091
IDAKYK-NIKEPK-a4-b3 WDR19 IF122 inter-protein xl SEC/CutOff 1229 762 1601.912
TSAAESXISVVLGKK-KYTQAGNK-a14-b1 WDR19 IF140 inter-protein xl SEC/CutOff 208 1211 2582.339
YKEAVVAYENAK-MKDKTLWR-a2-b2 WDR19 IF140 inter-protein xl SEC/CutOff 912 953 2598.34
ETQSLDGAKXVAR-K9-155 WDR19 monolink SEC/CutOff 955 n/a 1575.78
GVLWENWPMDKGVFIAYDDDK-K21-156 WDR19 monolink SEC/CutOff 580 n/a 2653.251
SEINLPGNCVAMDWDKDGDVLAVIAEK-K16-156 WDR19 monolink SEC/CutOff 64 n/a 3114.472
VATCGDNCIKIQDLVDLK-K10-156 WDR19 monolink SEC/CutOff 299 n/a 2217.103
KPELDSLMEGGEGK-LSGKTGR-a1-b4 WDR35 IF140 inter-protein xl SEC/CutOff 1123 276 2344.189
RDVWDXKWAK-KPEEADR-a7-b1 WDR35 IF140 inter-protein xl SEC/CutOff 600 733 2331.155
DNPDLFAMMEKTR-FFSXAEKR-a11-b7 WDR35 TT21B inter-protein xl SEC/CutOff 614 1014 2735.266
VLKLETQTDDAK-AKEADGRYK-a3-b2 WDR35 WDR19 inter-protein xl SEC/CutOff 42 905 2534.312
DVWDMKWAKDNPDLFAXMEK-DVWDMKWAK-a6-b6 WDR35 WDR35 intra-protein xl SEC/CutOff 600 600 3800.704
VGXCEQAVTAFLKCSQPK-K18-156 WDR35 monolink SEC/CutOff 886 n/a 2225.033  
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Table 22: Identified links of IFT-A from HEK293T cells after SEC (in at least 2of3) 
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Table 23: Crosslinks of IFT-A from HEK293T cells after SEC (in at least 3of3) 
Id Protein1 Protein2 XLType Biological Replicates AbsPos1 AbsPos2 Mr
EALVHCETDNKIXLELAR-K11-156 TT21B monolink SEC_BR1/2/4 919 n/a 2313.12
EKMADIYLKHR-K9-155 TT21B monolink SEC_BR1/2/4 700 n/a 1557.825
XIKISDGSKQGHVLK-K9-155 TT21B monolink SEC_BR1/2/3/4 142 n/a 1810.989
EPYTKKALK-HFNKAR-a5-b4 TT21B TT21B intra-protein xl SEC_BR1/3/4 162 1048 1986.089
GKEPYTK-AQSQKK-a2-b5 TT21B TT21B intra-protein xl SEC_BR2/3/4 157 574 1647.894
EQRKGAGEK-NGDHMKGAR-a4-b6 TT21B WDR19 inter-protein xl SEC_BR1/2/3/4 104 1171 2124.061
FFSMAEKRNSR-SIKLIK-a7-b3 TT21B IF140 inter-protein xl SEC_BR1/2/3 1014 796 2210.213
DKMLYITCFR-CKDDPGP-a2-b2 TT21B IF122 inter-protein xl SEC_BR1/2/3/4 705 1236 2271.03
EQRKGAGEK-NKNGEEK-a4-b2 TT21B IF122 inter-protein xl SEC_BR1/2/3/4 104 161 1956.982
HFNKARK-KEGRER-a4-b1 TT21B WDR35 inter-protein xl SEC_BR1/2/3/4 1048 473 1810.992
YDMAEDLLKR-XFFYLSKK-a9-b7 TT21B WDR35 inter-protein xl SEC_BR1/2/3 1221 7 2469.218
DCGAILENXKQFSEAAQLYEK-K10-155 WDR19 monolink SEC_BR1/2/3 854 n/a 2615.247
GLYYDKAASVYIR-K6-155 WDR19 monolink SEC_BR1/2/3/4 871 n/a 1672.882
IHLQYAKAKEADGR-K9-155 WDR19 monolink SEC_BR2/3/4 905 n/a 1753.947
RGVNQALKHPSR-K8-156 WDR19 monolink SEC_BR1/2/4 836 n/a 1517.833
NGDHMKGAR-XADIYLKHR-a6-b7 WDR19 TT21B inter-protein xl SEC_BR2/3/4 1171 700 2284.1
ALKHFLK-CKDDPGP-a3-b2 WDR19 IF122 inter-protein xl SEC_BR1/2/3 1041 1236 1780.903
ETQSLDGAKXVAR-CKDDPGP-a9-b2 WDR19 IF122 inter-protein xl SEC_BR1/2/3/4 955 1236 2346.061
AAVSGDEKALDMFNWKK-K16-156 IF140 monolink SEC_BR1/2/3/4 187 n/a 2065.017
AAVSGDEKALDMFNWKK-K17-156 IF140 monolink SEC_BR1/2/3 188 n/a 2065.022
AAVSGDEKALDMFNWKK-K8-156 IF140 monolink SEC_BR1/2/3/4 179 n/a 2065.017
AAVSGDEKALDXFNWKK-K16-155 IF140 monolink SEC_BR1/2/3 187 n/a 2080.019
AAVSGDEKALDXFNWKK-K17-155 IF140 monolink SEC_BR1/2/3/4 188 n/a 2080.019
ALSYYEKSDTHR-K7-156 IF140 monolink SEC_BR1/3/4 926 n/a 1624.771
AQAFKNAIRLCK-K5-156 IF140 monolink SEC_BR1/2/3 1040 n/a 1574.852
GENXNCVCYCKVKGLLAAGTDR-K11-155 IF140 monolink SEC_BR1/2/4 334 n/a 2686.221
GVQMDRAVMLYHKAGHFSK-K13-156 IF140 monolink SEC_BR1/2/3/4 1090 n/a 2330.173
GVQMDRAVXLYHKAGHFSK-K13-155 IF140 monolink SEC_BR1/2/4 1090 n/a 2345.178
XCVKTQRLDVAK-K4-156 IF140 monolink SEC_BR1/3/4 813 n/a 1619.851
AEEVMKVK-SVSKHK-a6-b4 IF140 IF122 inter-protein xl SEC_BR1/2/3/4 270 128 1754.952
AVXLYHKAGHFSK-RCKDDPGP-a7-b3 IF140 IF122 inter-protein xl SEC_BR1/2/3 1090 1236 2585.23
NIIGFYTKGR-RCKDDPGP-a8-b3 IF140 IF122 inter-protein xl SEC_BR1/2/4 1275 1236 2249.131
YYEEKGVQMDR-LDKAER-a5-b3 IF140 IF122 inter-protein xl SEC_BR1/3/4 1077 802 2285.082
GENXNCVCYCKVK-KEGRER-a11-b1 IF140 WDR35 inter-protein xl SEC_BR1/2/4 334 473 2588.15
DTXLGKFYHFQR-K6-155 IF122 monolink SEC_BR2/3/4 941 n/a 1712.821
DTXLGKFYHFQR-K6-156 IF122 monolink SEC_BR1/2/3/4 941 n/a 1713.818
ELAXEALEGLDFETAKK-K16-156 IF122 monolink SEC_BR1/2/3/4 663 n/a 2066
ELAXEALEGLDFETAKK-K17-156 IF122 monolink SEC_BR1/2/3/4 664 n/a 2066
LQCLSFSGVKER-K10-156 IF122 monolink SEC_BR1/3/4 463 n/a 1578.804
WDEAFALGEKHPEFK-K10-156 IF122 monolink SEC_BR1/3/4 856 n/a 1958.947
XLITKQADWAR-K5-155 IF122 monolink SEC_BR1/2/3 753 n/a 1502.805
XLITKQADWAR-K5-156 IF122 monolink SEC_BR2/3/4 753 n/a 1503.763
CKELVKK-WYDKAEK-a2-b4 IF122 TT21B inter-protein xl SEC_BR1/2/3 388 807 1980.04
DTPSGISKVK-AQSQKK-a8-b5 IF122 TT21B inter-protein xl SEC_BR1/2/4 995 574 1857.03
NKNGEEKVK-VKEQRK-a2-b2 IF122 TT21B inter-protein xl SEC_BR1/2/4 161 100 1969.099
CLDXSASRKK-KYTQAGNK-a9-b1 IF122 IF140 inter-protein xl SEC_BR2/3/4 527 1211 2257.108
AFHKAGRQR-CKDDPGP-a4-b2 IF122 IF122 intra-protein xl SEC_BR1/2/3/4 887 1236 1994.979
CLDXSASRKK-QIGKDR-a9-b4 IF122 IF122 intra-protein xl SEC_BR2/3/4 527 275 2064.034
QSKALGAYR-NIKEPK-a3-b3 IF122 IF122 intra-protein xl SEC_BR2/3/4 1007 762 1858.03
ANYFFDAAKLXFK-K9-155 WDR35 monolink SEC_BR1/3/4 948 n/a 1735.875
DNPDLFAMMEKTR-K11-156 WDR35 monolink SEC_BR1/3/4 614 n/a 1722.81
KANYFFDAAKLMFK-K1-156 WDR35 monolink SEC_BR1/3/4 939 n/a 1848.938
RDVWDXKWAK-K7-155 WDR35 monolink SEC_BR1/2/3/4 600 n/a 1504.753
WAKDNPDLFAMMEKTR-K3-155 WDR35 monolink SEC_BR1/2/4 603 n/a 2107.038
KPELDSLXEGGEGK-AQSQKK-a1-b5 WDR35 TT21B inter-protein xl SEC_BR1/2/3 1123 574 2331.158
KPELDSLXEGGEGK-IGASTKSK-a1-b6 WDR35 TT21B inter-protein xl SEC_BR2/3/4 1123 603 2433.237
WAKDNPDLFAXMEK-IDAKYK-a3-b4 WDR35 WDR19 inter-protein xl SEC_BR1/2/4 603 1229 2585.235
RDVWDMKWAK-MALVKR-a7-b5 WDR35 IF140 inter-protein xl SEC_BR1/3/4 600 1340 2188.151
DNPDLFAMMEKTR-CKDDPGP-a11-b2 WDR35 IF122 inter-protein xl SEC_BR1/2/3/4 614 1236 2492.11
LMFKIADEEAK-LDKAER-a4-b3 WDR35 IF122 inter-protein xl SEC_BR1/2/4 952 802 2162.111
DVWDMKWAK-GSKPLR-a6-b3 WDR35 WDR35 intra-protein xl SEC_BR1/2/3/4 600 963 1972.011
DVWDMKWAK-KGSKPLR-a6-b4 WDR35 WDR35 intra-protein xl SEC_BR1/2/3/4 600 963 2100.103  
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Table 24: Crosslinks of IFT-A (HEK293T) cells after spin column filtration (in at least 2of3) 
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Table 25: Crosslinks of IFT-A (HEK293T) cells after spin column filtration (in at least 3of3) 
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